QUARTERLY REPORT

Q1 2025 — Quarterly report (Form 10-Q)

Q1 2025PDF · 155 pages1.7 MB
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 10-Q
☒ 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2025
OR
☐ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission file number: 001-38855
___________________________________
Nasdaq, Inc.
(Exact name of registrant as specified in its charter)
Delaware 	52-1165937
(State or Other Jurisdiction of Incorporation or Organization) 	(I.R.S. Employer Identification No.)
151 W. 42nd Street, 	New York, 	New York 	10036
(Address of Principal Executive Offices) 	(Zip Code)
Registrant’s telephone number, including area code: +1 212 401 8700
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $0.01 par value per share 	NDAQ 	The Nasdaq Stock Market
4.500% Senior Notes due 2032 	NDAQ32 	The Nasdaq Stock Market
0.900% Senior Notes due 2033 	NDAQ33 	The Nasdaq Stock Market
0.875% Senior Notes due 2030 	NDAQ30 	The Nasdaq Stock Market
1.75% Senior Notes due 2029 	NDAQ29 	The Nasdaq Stock Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer 	☒ 	Accelerated filer 	☐
Non-accelerated filer 	☐ 	Smaller reporting company 	☐
Emerging growth company 	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Class 	Outstanding at April 22, 2025
Common Stock, $0.01 par value per share 	574,121,620 shares

-- 1 of 155 --

Nasdaq, Inc.
Page
Part I. FINANCIAL INFORMATION
Item 1. 	Financial Statements 	1
Condensed Consolidated Balance Sheets 	1
Condensed Consolidated Statements of Income 	2
Condensed Consolidated Statements of Comprehensive Income 	3
Condensed Consolidated Statements of Changes in Stockholders' Equity 	4
Condensed Consolidated Statements of Cash Flows 	5
Notes to Condensed Consolidated Financial Statements 	6
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	26
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	38
Item 4. 	Controls and Procedures 	41
Part II. OTHER INFORMATION
Item 1. 	Legal Proceedings 	41
Item 1A. 	Risk Factors 	41
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds 	41
Item 3. 	Defaults Upon Senior Securities 	42
Item 4. 	Mine Safety Disclosures 	42
Item 5. 	Other Information 	42
Item 6. 	Exhibits 	42
SIGNATURES 	43
i

-- 2 of 155 --

About this Form 10-Q
Throughout this Form 10-Q, unless otherwise specified:
• “Nasdaq,” “we,” “us” and “our” refer to Nasdaq, Inc.
• “Nasdaq Baltic” refers to collectively, Nasdaq Tallinn AS, Nasdaq Riga,
AS, and AB Nasdaq Vilnius.
• “Nasdaq BX” refers to the cash equity exchange operated by Nasdaq BX,
Inc.
• “Nasdaq BX Options” refers to the options exchange operated by Nasdaq
BX, Inc.
• “Nasdaq Clearing” refers to the clearing operations conducted by Nasdaq
Clearing AB.
• “Nasdaq CXC” and “Nasdaq CX2” refer to the Canadian cash equity
trading books operated by Nasdaq CXC Limited.
• “Nasdaq First North” refers to our alternative marketplaces for smaller
companies and growth companies in the Nordic and Baltic regions.
• “Nasdaq GEMX” refers to the options exchange operated by Nasdaq
GEMX, LLC.
• “Nasdaq ISE” refers to the options exchange operated by Nasdaq ISE,
LLC.
• “Nasdaq MRX” refers to the options exchange operated by Nasdaq MRX,
LLC.
• “Nasdaq Nordic” refers to collectively, Nasdaq Clearing AB, Nasdaq
Stockholm AB, Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd, and
Nasdaq Iceland hf.
• “Nasdaq PHLX” refers to the options exchange operated by Nasdaq
PHLX LLC.
• “Nasdaq PSX” refers to the cash equity exchange operated by Nasdaq
PHLX LLC.
• “The Nasdaq Options Market” refers to the options exchange operated by
The Nasdaq Stock Market LLC.
• “The Nasdaq Stock Market” refers to the cash equity exchange and listing
venue operated by The Nasdaq Stock Market LLC.
Nasdaq also provides the following list of abbreviations and acronyms used
throughout this Quarterly Report on Form 10-Q as a tool for the reader.
2022 Revolving Credit Facility: $1.25 billion senior unsecured revolving
credit facility, which matures on December 16, 2027
2025 Notes: $500 million aggregate principal amount issued of 5.650% senior
unsecured notes due June 28, 2025
2026 Notes: $500 million aggregate principal amount issued of 3.850% senior
unsecured notes due June 30, 2026
2028 Notes: $1 billion aggregate principal amount issued of 5.350% senior
unsecured notes due June 28, 2028
2029 Notes: €600 million aggregate principal amount issued of 1.75% senior
unsecured notes due March 28, 2029
2030 Notes: €600 million aggregate principal amount issued of 0.875% senior
unsecured notes due February 13, 2030
2031 Notes: $650 million aggregate principal amount issued of 1.650% senior
unsecured notes due January 15, 2031
2032 Notes: €750 million aggregate principal amount issued of 4.500% senior
unsecured notes due February 15, 2032
2033 Notes: €615 million aggregate principal amount issued of 0.900% senior
unsecured notes due July 30, 2033
2034 Notes: $1.25 billion aggregate principal amount issued of 5.550% senior
unsecured notes due February 15, 2034
2040 Notes: $650 million aggregate principal amount issued of 2.500% senior
unsecured notes due December 21, 2040
2050 Notes: $500 million aggregate principal amount issued of 3.250% senior
unsecured notes due April 28, 2050
2052 Notes: $550 million aggregate principal amount issued of 3.950% senior
unsecured notes due March 7, 2052
2053 Notes: $750 million aggregate principal amount issued of 5.950% senior
unsecured notes due August 15, 2053
2063 Notes: $750 million aggregate principal amount issued of 6.100% senior
unsecured notes due June 28, 2063
Adenza: Adenza Holdings, Inc.
AI: Artificial Intelligence
ARR: Annualized Recurring Revenue
AUM: Assets Under Management
CCP: Central Counterparty
CFTC: U.S. Commodity Futures Trading Commission
CAT: A market-wide consolidated audit trail established under an SEC
approved plan by Nasdaq and other exchanges
EMIR: European Market Infrastructure Regulation
Equity Plan: Nasdaq Equity Incentive Plan
ESPP: Nasdaq Employee Stock Purchase Plan
ETP: Exchange Traded Product
Euro Notes: The 2029, 2030, 2032 and 2033 Notes
Exchange Act: Securities Exchange Act of 1934, as amended
FINRA: Financial Industry Regulatory Authority
GICS: Global Industry Classification Standard
IPO: Initial Public Offering
Nasdaq eligible IPO win rate: Eligible IPO win rate includes only companies
that meet quantitative Nasdaq listing standards.
NSCC: National Securities Clearing Corporation
OCC: The Options Clearing Corporation
OTC: Over-the-Counter
ii

-- 3 of 155 --

PSU: Performance Share Unit
SaaS: Software as a Service
SEC: U.S. Securities and Exchange Commission
SERP: Supplemental Executive Retirement Plan
SFSA: Swedish Financial Supervisory Authority
SOFR: Secured Overnight Financing Rate
SPAC: Special Purpose Acquisition Company
S&P: Standard & Poor's
S&P 500: S&P 500 Stock Index
TSR: Total Shareholder Return
U.S. GAAP: U.S. Generally Accepted Accounting Principles
U.S. Tape plans: U.S. cash equity and U.S. options industry data
NASDAQ, the NASDAQ logos, and other brand, service or product names or
marks referred to in this report are trademarks or service marks, registered or
otherwise, of Nasdaq, Inc. and/or its subsidiaries. FINRA and Trade Reporting
Facility are registered trademarks of FINRA.
This Quarterly Report on Form 10-Q includes market share and industry data
that we obtained from industry publications and surveys, reports of
governmental agencies and internal company surveys. Industry publications
and surveys generally state that the information they contain has been
obtained from sources believed to be reliable, but we cannot assure you that
this information is accurate or complete. We have not independently verified
any of the data from third-party sources nor have we ascertained the
underlying economic assumptions relied upon therein. Statements as to our
market position are based on the most currently available market data. For
market comparison purposes, The Nasdaq Stock Market data in this Quarterly
Report on Form 10-Q for IPOs and new listings of equity securities (including
issuers that switched from other listings venues, closed-end funds and ETPs)
is based on data generated internally by us; therefore, the data may not be
comparable to other publicly-available IPO data. Data in this Quarterly Report
on Form 10-Q for IPOs and new listings of equity securities on the Nasdaq
Nordic and Nasdaq Baltic exchanges and Nasdaq First North also is based on
data generated internally by us. IPOs and new listings data is presented as of
period end. While we are not aware of any misstatements regarding industry
data presented herein, our estimates involve risks and uncertainties and are
subject to change based on various factors. We refer you to the “Risk Factors”
section in our Form 10-K for the fiscal year ended December 31, 2024 that
was filed with the SEC on February 21, 2025.
Nasdaq intends to use its website, ir.nasdaq.com, as a means for disclosing
material non-public information and for complying with SEC Regulation FD
and other disclosure obligations.
iii

-- 4 of 155 --

Forward-Looking Statements
The SEC encourages companies to disclose forward-looking information so
that investors can better understand a company’s future prospects and make
informed investment decisions. This Quarterly Report on Form 10-Q contains
these types of statements. Words such as “may,” “will,” “could,” “should,”
“anticipates,” “estimates,” “expects,” “projects,” “intends,” “plans,”
“believes” and words or terms of similar substance used in connection with
any discussion of future expectations as to industry and regulatory
developments or business initiatives and strategies, future operating results or
financial performance, and other future developments are intended to identify
forward-looking statements. These include, among others, statements relating
to:
• our strategic direction;
• the integration of acquired businesses, including accounting decisions
relating thereto;
• the scope, nature or impact of acquisitions, divestitures, investments, joint
ventures or other transactional activities;
• the effective dates for, and expected benefits of, ongoing initiatives,
including transactional activities and other strategic, restructuring,
technology, de-leveraging and capital return initiatives;
• our products and services;
• the impact of pricing changes;
• tax matters;
• the cost and availability of liquidity and capital; and
• any litigation, or any regulatory or government investigation or action, to
which we are or could become a party or which may affect us and any
potential settlements of litigation, regulatory or governmental investigations
or actions.
Forward-looking statements involve risks and uncertainties. Factors that
could cause actual results to differ materially from those contemplated by the
forward-looking statements include, among others, the following:
• our operating results may be lower than expected;
• our ability to successfully integrate acquired businesses or divest sold
businesses or assets, including the fact that any integration or transition
may be more difficult, time consuming or costly than expected, and we may
be unable to realize synergies from business combinations, acquisitions,
divestitures or other transactional activities;
• loss of significant trading and clearing volumes or values, fees, market
share, listed companies, market data customers or other customers;
• our ability to develop and grow our non-trading businesses;
• our ability to keep up with rapid technological advances, including our
ability to effectively manage the development and use of AI in certain of our
products and offerings, and adequately address cybersecurity risks;
• economic, political, regulatory and market conditions and fluctuations,
including inflation, tariffs, interest rate and foreign currency risk inherent in
U.S. and international operations, and geopolitical instability;
• the performance and reliability of our technology and technology of third
parties on which we rely;
• any significant systems failures or errors in our operational processes;
• our ability to continue to generate cash and manage our indebtedness; and
• adverse changes that may occur in the litigation or regulatory areas, or in
the securities markets generally, or increased regulatory oversight
domestically or internationally.
Most of these factors are difficult to predict accurately and are generally
beyond our control. You should consider the uncertainty and any risk related
to forward-looking statements that we make. These risk factors are more fully
described in the “Risk Factors” section in our Form 10-K filed with the SEC
on February 21, 2025. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this report. You
should carefully read this entire Quarterly Report on Form 10-Q, including
“Part I. Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and the condensed consolidated
financial statements and the related notes. Except as required by the federal
securities laws, we undertake no obligation to update any forward-looking
statement, release publicly any revisions to any forward-looking statements or
report the occurrence of unanticipated events. For any forward-looking
statements contained in any document, we claim the protection of the safe
harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995.
iv

-- 5 of 155 --

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Nasdaq, Inc.
Condensed Consolidated Balance Sheets
(in millions, except share and par value amounts)
March 31, 2025 	December 31, 2024
Assets 	(unaudited)
Current assets:
Cash and cash equivalents 	$ 	690 $ 	592
Restricted cash and cash equivalents 	18 	31
Default funds and margin deposits (including restricted cash and cash equivalents of $4,023 and $4,383,
respectively) 	5,686 	5,664
Financial investments 	201 	184
Receivables, net 	986 	1,022
Other current assets 	237 	293
Total current assets 	7,818 	7,786
Property and equipment, net 	621 	593
Goodwill 	14,179 	13,957
Intangible assets, net 	6,830 	6,905
Operating lease assets 	381 	375
Other non-current assets 	818 	779
Total assets 	$ 	30,647 $ 	30,395
Liabilities
Current liabilities:
Accounts payable and accrued expenses 	$ 	255 $ 	269
Section 31 fees payable to SEC 	264 	319
Accrued personnel costs 	198 	325
Deferred revenue 	981 	711
Other current liabilities 	187 	215
Default funds and margin deposits 	5,686 	5,664
Short-term debt 	400 	399
Total current liabilities 	7,971 	7,902
Long-term debt 	8,926 	9,081
Deferred tax liabilities, net 	1,586 	1,594
Operating lease liabilities 	393 	388
Other non-current liabilities 	216 	230
Total liabilities 	19,092 	19,195
Commitments and contingencies
Equity
Nasdaq stockholders’ equity:
Common stock, $0.01 par value, 900,000,000 shares authorized, shares issued: 598,118,694 at March 31, 2025 and
598,920,378 at December 31, 2024; shares outstanding: 573,940,099 at March 31, 2025 and 575,062,217 at
December 31, 2024 	6 	6
Additional paid-in capital 	5,450 	5,530
Common stock in treasury, at cost: 24,178,595 shares at March 31, 2025 and 23,858,161 shares at December 31,
2024 	(672) 	(647)
Accumulated other comprehensive loss 	(1,896) 	(2,099)
Retained earnings 	8,658 	8,401
Total Nasdaq stockholders’ equity 	11,546 	11,191
Noncontrolling interests 	9 	9
Total equity 	11,555 	11,200
Total liabilities and equity 	$ 	30,647 $ 	30,395
See accompanying notes to condensed consolidated financial statements.
1

-- 6 of 155 --

Nasdaq, Inc.
Condensed Consolidated Statements of Income
(unaudited)
(in millions, except per share amounts)
Three Months Ended March 31,
2025 	2024
Revenues:
Capital Access Platforms 	$ 	515 $ 	479
Financial Technology 	432 	392
Market Services 	1,134 	794
Other revenues 	9 	9
Total revenues 	2,090 	1,674
Transaction-based expenses:
Transaction rebates 	(579) 	(481)
Brokerage, clearance and exchange fees 	(274) 	(76)
Revenues less transaction-based expenses 	1,237 	1,117
Operating expenses:
Compensation and benefits 	329 	340
Professional and contract services 	36 	34
Technology and communication infrastructure 	77 	67
Occupancy 	28 	28
General, administrative and other 	6 	28
Marketing and advertising 	14 	11
Depreciation and amortization 	156 	155
Regulatory 	15 	9
Merger and strategic initiatives 	24 	9
Restructuring charges 	5 	26
Total operating expenses 	690 	707
Operating income 	547 	410
Interest income 	11 	6
Interest expense 	(96) 	(108)
Other income (loss) 	(1) 	1
Net income from unconsolidated investees 	27 	3
Income before income taxes 	488 	312
Income tax provision 	93 	79
Net income 	395 	233
Net loss attributable to noncontrolling interests 	— 	1
Net income attributable to Nasdaq 	$ 	395 $ 	234
Per share information:
Basic earnings per share 	$ 	0.69 $ 	0.41
Diluted earnings per share 	$ 	0.68 $ 	0.40
Cash dividends declared per common share 	$ 	0.24 $ 	0.22
See accompanying notes to condensed consolidated financial statements.
2

-- 7 of 155 --

Nasdaq, Inc.
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
(in millions)
Three Months Ended March 31,
2025 	2024
Net income 	$ 	395 $ 	233
Other comprehensive income (loss):
Foreign currency translation gains (losses) 	175 	(117)
Income tax benefit (expense) 	30 	(15)
Foreign currency translation, net 	205 	(132)
Employee benefit plan adjustment 	— 	19
Income tax expense 	— 	(5)
Employee benefit plan, net 	— 	14
Unrealized loss on derivatives instruments, net 	(2) 	(2)
Total other comprehensive income (loss), net of tax 	203 	(120)
Comprehensive income 	598 	113
Comprehensive loss attributable to noncontrolling interests 	— 	1
Comprehensive income attributable to Nasdaq 	$ 	598 $ 	114
____________
Primarily relates to the tax effect of unrealized gains and losses on our Euro Notes.
See accompanying notes to condensed consolidated financial statements.
(1)
(1)
3

-- 8 of 155 --

Nasdaq, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(unaudited)
(in millions)
Three Months Ended March 31,
2025 	2024
Shares 	$ 	Shares 	$
Common stock 	575 	6 	575 	6
Additional paid-in capital
Beginning balance 	5,530 	5,496
Share repurchase program 	(2) 	(115) 	— 	—
Share-based compensation 	2 	35 	1 	30
Ending balance 	5,450 	5,526
Common stock in treasury, at cost
Beginning balance 	(647) 	(587)
Other employee stock activity 	(1) 	(25) 	— 	(24)
Ending balance 	(672) 	(611)
Accumulated other comprehensive loss
Beginning balance 	(2,099) 	(1,924)
Other comprehensive income (loss) 	203 	(120)
Ending balance 	(1,896) 	(2,044)
Retained earnings
Beginning balance 	8,401 	7,825
Net income attributable to Nasdaq 	395 	234
Cash dividends declared and paid 	(138) 	(127)
Ending balance 	8,658 	7,932
Total Nasdaq stockholders’ equity 	11,546 	10,809
Noncontrolling interests
Beginning balance 	9 	11
Net activity related to noncontrolling interests 	— 	(1)
Ending balance 	9 	10
Total Equity 	574 $ 11,555 	576 $ 10,819
See accompanying notes to condensed consolidated financial statements.
4

-- 9 of 155 --

Nasdaq, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in millions)
Three Months Ended March 31,
2025 	2024
Cash flows from operating activities:
Net income 	$ 	395 $ 	233
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 	156 	155
Share-based compensation 	35 	30
Deferred income taxes 	6 	(2)
Net income from unconsolidated investees 	(27) 	(3)
Other reconciling items included in net income 	(11) 	27
Net change in operating assets and liabilities:
Receivables, net 	48 	(17)
Other assets 	66 	(5)
Accounts payable and accrued expenses 	(17) 	(73)
Section 31 fees payable to SEC 	(55) 	(14)
Accrued personnel costs 	(134) 	(110)
Deferred revenue 	257 	274
Other liabilities 	(56) 	35
Net cash provided by operating activities 	663 	530
Cash flows from investing activities:
Purchases of securities 	(105) 	(40)
Proceeds from sales and redemptions of securities 	105 	44
Purchases of property and equipment 	(49) 	(39)
Investments related to default funds and margin deposits, net 	(204) 	(184)
Other investing activities 	(5) 	(13)
Net cash used in investing activities 	(258) 	(232)
Cash flows from financing activities:
Repayments of commercial paper, net 	— 	(67)
Repayments of debt and credit commitment 	(257) 	(340)
Repurchases of common stock 	(115) 	—
Dividends paid 	(138) 	(127)
Payments related to employee shares withheld for taxes 	(25) 	(24)
Default funds and margin deposits 	(549) 	(1,317)
Other financing activities 	1 	—
Net cash used in financing activities 	(1,083) 	(1,875)
Effect of exchange rate changes on cash and cash equivalents and restricted cash and cash equivalents 	403 	(311)
Net decrease in cash and cash equivalents and restricted cash and cash equivalents 	(275) 	(1,888)
Cash and cash equivalents, restricted cash and cash equivalents at beginning of period 	5,006 	7,118
Cash and cash equivalents, restricted cash and cash equivalents at end of period 	$ 	4,731 $ 	5,230
Reconciliation of Cash, Cash Equivalents and Restricted Cash and Cash Equivalents
Cash and cash equivalents 	$ 	690 $ 	388
Restricted cash and cash equivalents 	18 	21
Restricted cash and cash equivalents (default funds and margin deposits) 	4,023 	4,821
Total 	$ 	4,731 $ 	5,230
Supplemental Disclosure Cash Flow Information
Interest paid 	$ 	125 $ 	145
Income taxes paid, net of refund 	$ 	45 $ 	23
__________________________
Includes purchases and proceeds from sales and redemptions related to the default funds and margin deposits of our clearing operations. For further information, see "Default
Fund Contributions and Margin Deposits," within Note 13, "Clearing Operations."
See accompanying notes to condensed consolidated financial statements.
(1)
(1)
5

-- 10 of 155 --

Nasdaq, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. ORGANIZATION AND NATURE OF OPERATIONS
Nasdaq is a global technology company serving corporate clients, investment
managers, banks, brokers, and exchange operators as they navigate and
interact with the global capital markets and the broader financial system. We
aspire to deliver world-leading platforms that improve the liquidity,
transparency, and integrity of the global economy. Our diverse offering of
data, analytics, software, exchange capabilities, and client-centric services
enables clients to optimize and execute their business vision with confidence.
Our organizational structure aligns our businesses with the foundational shifts
that are driving the evolution of the global financial system. We manage,
operate and provide our products and services in three business segments:
Capital Access Platforms, Financial Technology and Market Services.
Capital Access Platforms
Our Capital Access Platforms segment comprises Data & Listing Services,
Index and Workflow & Insights.
Our Data business distributes historical and real-time market data to sell-side
customers, the institutional investing community, retail online brokers,
proprietary trading firms and other venues, as well as various client portals
and data distributors. Our data products can enhance the transparency of
market activity within our exchanges and provide critical information to
professional and non-professional investors globally.
Our Listing Services business operates listing platforms in the U.S. and
Europe and provides multiple global capital raising solutions for public
companies. Our main listing markets are The Nasdaq Stock Market and the
Nasdaq Nordic and Nasdaq Baltic exchanges. Through Nasdaq First North,
our Nordic and Baltic operations also offer alternative marketplaces for
smaller companies and growth companies.
As of March 31, 2025, a total of 5,299 companies listed securities on our U.S.,
Nasdaq Nordic, Nasdaq Baltic and Nasdaq First North exchanges. As of
March 31, 2025, there were 4,139 total listings on The Nasdaq Stock Market,
including 833 ETPs. The combined market capitalization in the U.S. was
approximately $31.5 trillion. In Europe, the Nasdaq Nordic and Nasdaq Baltic
exchanges, together with Nasdaq First North, were home to 1,160 listed
companies with a combined market capitalization of approximately $2.0
trillion.
Our Index business develops and licenses Nasdaq-branded indices and
financial products. We also license cash-settled futures, options and options on
futures on our indices. As of March 31, 2025, 418 ETPs listed on 27
exchanges in over 20 countries tracked a Nasdaq index and accounted for
$622 billion in AUM.
Workflow & Insights includes our analytics and corporate solutions
businesses. Our analytics business provides hedge funds, asset managers,
investment consultants and institutional asset owners with information and
analytics to make data-driven investment decisions, deploy their resources
more productively, and provide liquidity solutions for private funds. Through
our eVestment and Solovis solutions, we provide a suite of cloud-based
solutions that help institutional investors and consultants conduct pre-
investment due diligence, and monitor their portfolios post-investment. The
eVestment platform also enables asset managers to efficiently distribute
information about their firms and funds to asset owners and consultants
worldwide.
The Nasdaq Fund Network and Nasdaq Data Link are additional platforms in
our suite of investment data analytics offerings and data management tools.
Our corporate solutions business serves both public and private companies and
organizations through our Investor Relations Intelligence, Sustainability
Solutions and Governance Solutions products. Our public company clients can
be companies listed on our exchanges or other U.S. and global exchanges. Our
private company clients include a diverse group of organizations ranging from
family-owned companies, government organizations, law firms, privately held
entities, and various non-profit organizations to hospitals and healthcare
systems. We help organizations enhance their ability to understand and expand
their global shareholder base, improve corporate governance, and navigate the
evolving sustainability landscape through our suite of advanced technology,
analytics, reporting and consulting services.
Financial Technology
Our Financial Technology segment comprises Financial Crime Management
Technology, Regulatory Technology and Capital Markets Technology
businesses.
Financial Crime Management Technology includes our Nasdaq Verafin
solution, a cloud-based platform, leveraging consortium data and AI, to help
over 2,600 financial institutions detect, investigate, and report money
laundering and financial fraud.
6

-- 11 of 155 --

Regulatory Technology comprises our AxiomSL and surveillance solutions.
AxiomSL is a global leader in risk data management and regulatory reporting
solutions for the financial industry, including banks, broker dealers and asset
managers. Its unique enterprise data management platform delivers data
lineage, risk aggregation, analytics, workflow automation, reconciliation,
validation and audit functionality, as well as disclosures. AxiomSL’s platform
supports compliance across a wide range of global and local regulations. Our
surveillance solutions are designed for banks, brokers and other market
participants to assist them in complying with market abuse and integrity rules
and regulations. In addition, we provide regulators and exchanges with a
platform for surveillance.
Capital Markets Technology includes market technology, trade management
services and Calypso solutions. Our market technology business is a leading
global technology solutions provider and partner to exchanges, clearing
organizations, central securities depositories, regulators, banks, brokers, buy-
side firms and corporate businesses. Our market technology solutions are
utilized by leading markets in North America, Europe and Asia as well as
emerging markets in the Middle East, Latin America, and Africa. Our trade
management services provide market participants with a wide variety of
alternatives for connecting to and accessing our markets for a fee. Our
marketplaces may be accessed via a number of different protocols used for
quoting, order entry, trade reporting and connectivity to various data feeds. We
also provide colocation services to market participants, whereby we offer
firms cabinet space and power to house their own equipment and servers
within our data centers. Additionally, we offer a number of wireless
connectivity offerings between select data centers using millimeter wave and
microwave technology. Calypso is a leading platform providing cross-asset,
front-to-back trading, treasury, risk and collateral management solutions. The
Calypso solution provides customers with a single platform designed from the
outset to enable consolidation, innovation and growth.
Market Services
Our Market Services segment includes revenues from equity derivatives
trading, cash equity trading, Nordic fixed income trading & clearing, Nordic
commodities and U.S. Tape plans data. We operate 19 exchanges across
several asset classes, including derivatives, commodities, cash equity, debt,
structured products and ETPs. In addition, in certain countries where we
operate exchanges, we also provide clearing, settlement and central depository
services. In January 2025, we entered into an agreement to transfer existing
open positions in our Nordic power derivatives trading and clearing business
to a European exchange. The completion of this transaction is subject to
customary regulatory approvals. Revenues from this business are reflected in
other revenues in the Condensed Consolidated Statements of Income for all
periods, and in our Corporate segment for our segment disclosures.
Our transaction-based platforms provide market participants with the ability to
access, process, display and integrate orders and quotes. The platforms allow
the routing and execution of buy and sell orders as well as the reporting of
transactions, providing fee-based revenues.
2. 	BASIS 	OF 	PRESENTATION 	AND 	PRINCIPLES 	OF
CONSOLIDATION
The condensed consolidated financial statements are prepared in accordance
with U.S. GAAP and include the accounts of Nasdaq, its wholly-owned
subsidiaries and other entities in which Nasdaq has a controlling financial
interest. When we do not have a controlling interest in an entity, but exercise
significant influence over the entity’s operating and financial policies, such
investment is accounted for under the equity method of accounting. We
recognize our share of earnings or losses of an equity method investee based
on our ownership percentage. See “Equity Method Investments,” of Note 5,
“Investments,” for further discussion of our equity method investments.
The accompanying condensed consolidated financial statements reflect all
adjustments which are, in the opinion of management, necessary for a fair
statement of the results. These adjustments are of a normal recurring nature.
All significant intercompany accounts and transactions have been eliminated
in consolidation.
As permitted under U.S. GAAP, certain footnotes or other financial
information can be condensed or omitted in the interim condensed
consolidated financial statements. The information included in this Quarterly
Report on Form 10-Q should be read in conjunction with the consolidated
financial statements and accompanying notes included in Nasdaq’s Form 10-
K. The year-end balance sheet data was derived from the audited financial
statements, but does not include all disclosures required by U.S. GAAP.
Certain percentages and per share amounts herein may not sum or recalculate
due to rounding.
Accounting Estimates
In preparing our condensed consolidated financial statements, we make
assumptions, judgments and estimates that can have a significant impact on
our revenues, operating income and net income, as well as on the value of
certain assets and liabilities in our Condensed Consolidated Balance Sheets.
At least quarterly, we evaluate our assumptions, judgments and estimates, and
make changes as deemed necessary.
Subsequent Events
We have evaluated subsequent events through the issuance date of this
Quarterly Report on Form 10-Q.
7

-- 12 of 155 --

3. REVENUE FROM CONTRACTS WITH CUSTOMERS
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by major
product and service and by segment for the three months ended March 31,
2025 and 2024:
Three Months Ended March 31,
2025 	2024
(in millions)
Capital Access Platforms:
Data & Listing Services 	$ 	192 $ 	186
Index 	193 	168
Workflow & Insights 	130 	125
Financial Technology:
Financial Crime Management Technology 	77 	64
Regulatory Technology 	101 	90
Capital Markets Technology 	254 	238
Market Services, net 	281 	237
Other revenues 	9 	9
Revenues less transaction-based
expenses 	$ 	1,237 $ 	1,117
Substantially all revenues from the Capital Access Platforms and Financial
Technology segments were recognized over time for the three months ended
March 31, 2025 and 2024. For the three months ended March 31, 2025 and
2024, approximately 95.0% and 97.3%, respectively, of Market Services
revenues were recognized at a point in time and 5.0% and 2.7%, respectively,
were recognized over time.
Contract Balances
Substantially all of our revenues are considered to be revenues from contracts
with customers. The related accounts receivable balances are recorded in the
Condensed Consolidated Balance Sheets as receivables, which are net of
allowance for doubtful accounts of $13 million as of March 31, 2025 and $10
million as of December 31, 2024. Changes to the allowance for doubtful
accounts during the three months ended March 31, 2025 were not material to
our condensed consolidated financial statements. We do not have obligations
for warranties, returns or refunds to customers.
Deferred revenue represents consideration received that is yet to be recognized
as revenue for unsatisfied performance obligations and is the only significant
contract asset or liability as of March 31, 2025. See Note 6, “Deferred
Revenue,” for our discussion on deferred revenue balances, activity, and
expected timing of recognition.
We do not provide disclosures about the transaction price allocated to
unsatisfied performance obligations if contract durations are less than one
year. For our initial listings, the transaction price allocated to remaining
performance obligations is included in deferred revenue, and therefore not
included below. For our Financial Crime Management Technology,
Regulatory Technology, Capital Markets Technology and Workflow &
Insights contracts, the portion of transaction price allocated to unsatisfied
performance obligations is presented in the table below. The timing in the
table below is based on our best estimates as, for certain contracts, the
recognition is primarily dependent upon the completion of customization and
any significant modifications made pursuant to existing contracts. To the
extent consideration has been received, unsatisfied performance obligations
would be included in the table below as well as deferred revenue.
The following table summarizes the amount of the transaction price allocated
to performance obligations that are unsatisfied, for contract durations greater
than one year, as of March 31, 2025:
Financial Crime
Management
Technology
Regulatory
Technology
Capital
Markets
Technology
Workflow &
Insights 	Total
(in millions)
Remainder of
2025 	$ 	228 $ 	261 $ 	278 $ 	139 $ 	906
2026 	262 	269 	289 	124 	944
2027 	174 	123 	220 	59 	576
2028 	74 	81 	153 	19 	327
2029 	19 	30 	85 	7 	141
2030+ 	5 	41 	172 	7 	225
Total 	$ 	762 $ 	805 $ 	1,197 $ 	355 $ 3,119
8

-- 13 of 155 --

4. GOODWILL AND ACQUIRED INTANGIBLE ASSETS
Goodwill
The following table presents the changes in goodwill by business segment
during the three months ended March 31, 2025:
(in millions)
Capital Access Platforms
Balance at December 31, 2024 	$ 	4,127
Foreign currency translation adjustments 	89
Balance at March 31, 2025 	$ 	4,216
Financial Technology
Balance at December 31, 2024 	$ 	7,925
Foreign currency translation adjustments 	16
Balance at March 31, 2025 	$ 	7,941
Market Services
Balance at December 31, 2024 	$ 	1,905
Foreign currency translation adjustments 	117
Balance at March 31, 2025 	$ 	2,022
Total
Balance at December 31, 2024 	$ 	13,957
Foreign currency translation adjustments 	222
Balance at March 31, 2025 	$ 	14,179
Goodwill represents the excess of purchase price over the value assigned to
the net assets, including identifiable intangible assets, of a business acquired.
Goodwill is allocated to our reporting units based on the assignment of the fair
values of each reporting unit of the acquired company. We test goodwill for
impairment at the reporting unit level annually, or in interim periods if certain
events occur indicating that the carrying amount may be impaired, such as
changes in the business climate, poor indicators of operating performance or
the sale or disposition of a significant portion of a reporting unit. There was no
impairment of goodwill for the three months ended March 31, 2025 and 2024;
however, events such as prolonged economic weakness or unexpected
significant declines in operating results of any of our reporting units or
businesses may result in goodwill impairment charges in the future.
Acquired Intangible Assets
The following table presents details of our total acquired intangible assets,
both finite- and indefinite-lived:
March 31, 2025 	December 31, 2024
Finite-Lived Intangible Assets 	(in millions)
Gross Amount:
Technology 	$ 	1,234 $ 	1,234
Customer relationships 	5,720 	5,720
Trade names and other 	417 	417
Foreign currency translation adjustment 	(202) 	(237)
Total gross amount 	$ 	7,169 $ 	7,134
Accumulated Amortization:
Technology 	$ 	(397) $ 	(348)
Customer relationships 	(1,232) 	(1,164)
Trade names and other 	(49) 	(43)
Foreign currency translation adjustment 	133 	153
Total accumulated amortization 	$ 	(1,545) $ 	(1,402)
Net Amount:
Technology 	$ 	837 $ 	886
Customer relationships 	4,488 	4,556
Trade names and other 	368 	374
Foreign currency translation adjustment 	(69) 	(84)
Total finite-lived intangible assets 	$ 	5,624 $ 	5,732
Indefinite-Lived Intangible Assets
Exchange and clearing registrations 	$ 	1,257 $ 	1,257
Trade names 	121 	121
Licenses 	52 	52
Foreign currency translation adjustment 	(224) 	(257)
Total indefinite-lived intangible assets $ 	1,206 $ 	1,173
Total intangible assets, net 	$ 	6,830 $ 	6,905
There was no impairment of intangible assets for the three months ended
March 31, 2025 and 2024.
The following table presents our amortization expense for acquired finite-
lived intangible assets:
Three Months Ended March 31,
2025 	2024
(in millions)
Amortization expense 	$ 	122 $ 	123
9

-- 14 of 155 --

The table below presents the estimated future amortization expense (excluding
the impact of foreign currency translation adjustments of $69 million as of
March 31, 2025) of acquired finite-lived intangible assets as of March 31,
2025:
(in millions)
Remainder of 2025 	$ 	370
2026 	497
2027 	494
2028 	460
2029 	433
2030+ 	3,439
Total 	$ 	5,693
5. INVESTMENTS
The following table presents the details of our investments:
March 31, 2025 	December 31, 2024
(in millions)
Financial investments 	$ 	201 $ 	184
Equity method investments 	444 	417
Equity securities 	123 	121
Financial Investments
Financial investments are comprised of trading securities, primarily highly
rated European government debt securities, of which $186 million as of March
31, 2025 and $171 million as of December 31, 2024 are assets primarily
utilized to meet regulatory capital requirements, mainly for our clearing
operations at Nasdaq Clearing.
Equity Method Investments
We record our estimated pro-rata share of earnings or losses each reporting
period and record any dividends as a reduction in the investment balance. As
of March 31, 2025 and 2024, our equity method investments primarily
included our 40.0% equity interest in OCC.
The carrying amounts of our equity method investments are included in other
non-current assets in the Condensed Consolidated Balance Sheets. No material
impairments were recorded for the three months ended March 31, 2025 and
2024.
Net income recognized from our equity interest in the earning of these equity
method investments was $27 million and $3 million for the three months
ended March 31, 2025 and 2024, respectively.
Equity Securities
The carrying amounts of our equity securities are included in other non-
current assets in the Condensed Consolidated Balance Sheets. We elected the
measurement alternative for substantially all of our equity securities as they do
not have a readily determinable fair value. No material adjustments were made
to the carrying value of our equity securities for the three months ended March
31, 2025 and 2024. As of March 31, 2025 and December 31, 2024, our equity
securities primarily represent various strategic minority investments made
through our corporate venture program.
6. DEFERRED REVENUE
Deferred revenue represents consideration received that is yet to be recognized
as revenue. The changes in our deferred revenue during the three months
ended March 31, 2025 are reflected in the following table:
Balance at
December 31, 2024 Additions Revenue Recognized
Foreign
Currency
Translation Balance at
March 31, 2025
(in millions)
Capital Access Platforms:
Initial Listings 	$ 	89 $ 	11 $ 	(11) $ 	2 $ 	91
Annual Listings 	2 	270 	(1) 	1 	272
Workflow &
Insights 	194 	99 	(80) 	— 	213
Financial Technology:
Financial Crime
Management
Technology 	148 	74 	(57) 	— 	165
Regulatory
Technology 	147 	28 	(53) 	1 	123
Capital Markets
Technology 	185 	42 	(68) 	3 	162
Other 	23 	13 	(6) 	2 	32
Total 	$ 	788 $ 	537 $ 	(276) $ 	9 $ 	1,058
In the above table:
• Additions reflect deferred revenue billed in the current period, net of
recognition.
• Revenue recognized includes revenue recognized during the current period
that was included in the beginning balance.
• Other primarily includes deferred revenue from our non-U.S. listing of
additional shares fees and our Index business. These fees are included in our
Capital Access Platforms segment.
10

-- 15 of 155 --

As of March 31, 2025, we estimate that our deferred revenue will be
recognized in the following years:
Fiscal year ended: 2025 	2026 	2027 	2028 	2029 	2030+ 	Total
(in millions)
Capital Access Platforms:
Initial Listings 	$ 	27 $ 	30 $ 	18 $ 	8 $ 	5 $ 	3 $ 	91
Annual Listings 	272 	— 	— 	— 	— 	— 	272
Workflow &
Insights 	197 	16 	— 	— 	— 	— 	213
Financial Technology:
Financial Crime
Management
Technology 	151 	12 	1 	1 	— 	— 	165
Regulatory
Technology 	117 	6 	— 	— 	— 	— 	123
Capital Markets
Technology 	150 	9 	2 	1 	— 	— 	162
Other 	20 	7 	4 	1 	— 	— 	32
Total 	$ 934 $ 	80 $ 	25 $ 	11 $ 	5 $ 	3 $ 1,058
In the above table, 2025 represents the remaining nine months of 2025.
Deferred revenue that will be recognized beyond March 31, 2026 is included
in other non-current liabilities in the Condensed Consolidated Balance Sheets.
The timing of recognition of deferred revenue related to certain contracts
represents our best estimates as the recognition is primarily dependent upon
the completion of customization and any significant modifications made
pursuant to existing contracts.
7. DEBT OBLIGATIONS
The following table presents the changes in the carrying amounts of our debt
obligations during the three months ended March 31, 2025:
December 31, 2024
Payments,
Foreign
Currency
Translation
and
Accretion 	March 31, 2025
Short-term debt: 	(in millions)
2025 Notes 	$ 	399 $ 	1 $ 	400
Total short-term debt 	$ 	399 $ 	1 $ 	400
Long-term debt - senior unsecured notes:
2026 Notes 	499 	— 	499
2028 Notes 	935 	(60) 	875
2029 Notes 	618 	28 	646
2030 Notes 	617 	28 	645
2031 Notes 	645 	1 	646
2032 Notes 	769 	35 	804
2033 Notes 	633 	28 	661
2034 Notes 	1,220 	(98) 	1,122
2040 Notes 	644 	1 	645
2050 Notes 	487 	— 	487
2052 Notes 	541 	(118) 	423
2053 Notes 	738 	— 	738
2063 Notes 	738 	— 	738
2022 Revolving Credit Facility 	(3) 	— 	(3)
Total long-term debt 	$ 	9,081 $ 	(155) $ 	8,926
Total debt obligations 	$ 	9,480 $ 	(154) $ 	9,326
Refer to “About this Form 10-Q” for further details about the aggregate
principal amounts issued, coupon rates and maturities of the senior unsecured
notes in the table above.
Senior Unsecured Notes
Our 2040 Notes were issued at par. All of our other outstanding senior
unsecured notes were issued at a discount. As a result of the discount, the
proceeds received from each issuance were less than the aggregate principal
amount. As of March 31, 2025, the amounts in the table above reflect the
aggregate principal amount, which is net of discount and debt issuance costs,
which are being accreted and amortized through interest expense over the life
of the applicable notes. The accretion of the discount and amortization of the
debt issuance costs was $3 million for the three months ended March 31,
2025. Our Euro Notes are adjusted for the impact of foreign currency
translation. Our senior unsecured notes are general unsecured obligations
which rank equally with all of our existing and future unsubordinated
obligations and are not guaranteed by any of our subsidiaries. The senior
unsecured notes were issued under indentures that, among other things, limit
our ability to consolidate, merge or sell all or substantially all of our assets,
create liens, and enter into sale and leaseback transactions. The senior
unsecured notes may be redeemed by Nasdaq at any time, subject to a make-
whole amount.
11

-- 16 of 155 --

In the first quarter of 2025, we repurchased an aggregate principal amount of
$279 million of our 2028, 2034 and 2052 Notes, for a net purchase price of
$257 million, excluding accrued interest. In the table above, the $279 million
of repurchased debt is partially offset by $3 million of accelerated accretion of
discount and debt issuance costs on the notes. As a result of the early
extinguishment of these notes, we recorded a pre-tax gain of $19 million in
general, administrative and other expense in the Condensed Consolidated
Statements of Income.
Upon a change of control triggering event (as defined in the various
supplemental indentures governing the applicable notes), the terms require us
to repurchase all or part of each holder’s notes for cash equal to 101% of the
aggregate principal amount purchased plus accrued and unpaid interest, if any.
The Euro Notes pay interest annually. All other notes pay interest semi-
annually. The U.S. dollar senior unsecured notes coupon rates may vary with
Nasdaq’s debt rating, to the extent Nasdaq is downgraded below investment
grade, up to an upward rate adjustment not to exceed 2%.
Net Investment Hedge
Our Euro Notes have been designated as a hedge of our net investment in
certain foreign subsidiaries to mitigate the foreign exchange risk associated
with certain investments in these subsidiaries. Accordingly, the
remeasurement of these notes is recorded in accumulated other comprehensive
loss in the Condensed Consolidated Balance Sheets. For the three months
ended March 31, 2025, the impact of translation increased the U.S. dollar
value of our Euro Notes by $119 million.
Credit Facilities
2022 Revolving Credit Facility
In December 2022, Nasdaq amended and restated its previously issued $1.25
billion five-year revolving credit facility, with a new maturity date of
December 16, 2027. Nasdaq intends to use funds available under the 2022
Revolving Credit Facility for general corporate purposes and to provide
liquidity support for the repayment of commercial paper issued through the
commercial paper program. Nasdaq is permitted to repay borrowings under
our 2022 Revolving Credit Facility at any time in whole or in part, without
penalty.
As of March 31, 2025, no amounts were outstanding on the 2022 Revolving
Credit Facility. The $(3) million balance represents unamortized debt issuance
costs which are being amortized through interest expense over the life of the
credit facility.
Borrowings under the revolving credit facility and swingline borrowings bear
interest on the principal amount outstanding at a variable interest rate based on
either the SOFR (or a successor rate to SOFR), the base rate (as defined in the
2022 Revolving Credit Facility agreement), or other applicable rate with
respect to non-dollar borrowings, plus an applicable margin that varies with
Nasdaq’s debt rating. We are charged commitment fees of 0.100% to 0.250%,
depending on our credit rating, whether or not amounts have been borrowed.
These commitment fees are included in interest expense and were not material
for the three months ended March 31, 2025 and 2024.
The 2022 Revolving Credit Facility contains financial and operating
covenants. Financial covenants include a maximum leverage ratio. Operating
covenants include, among other things, limitations on Nasdaq’s ability to incur
additional indebtedness, grant liens on assets, dispose of assets and make
certain restricted payments. The facility also contains customary affirmative
covenants, including access to financial statements, notice of defaults and
certain other material events, maintenance of properties and insurance, and
customary events of default, including cross-defaults to our material
indebtedness.
The 2022 Revolving Credit Facility includes an option for Nasdaq to increase
the available aggregate amount by up to $750 million, subject to the consent
of the lenders funding the increase and certain other conditions.
We maintain a U.S. dollar commercial paper program, which we may utilize at
various times to support liquidity needs. This program is supported by our
2022 Revolving Credit Facility.
Other Credit Facilities
Certain of our European subsidiaries have several other credit facilities, which
are available in multiple currencies, primarily to support our Nasdaq Clearing
operations in Europe, as well as to provide a cash pool credit line. These credit
facilities, in aggregate, totaled $191 million as of March 31, 2025 and $174
million as of December 31, 2024 in available liquidity, none of which was
utilized. Generally, these facilities each have a one-year term. The amounts
borrowed under these various credit facilities bear interest on the principal
amount outstanding at a variable interest rate based on a base rate (as defined
in the applicable credit agreement), plus an applicable margin. We are charged
commitment fees (as defined in the applicable credit agreement), whether or
not amounts have been borrowed. These commitment fees are included in
interest expense and were not material for the three months ended March 31,
2025 and 2024.
These facilities include customary affirmative and negative operating
covenants and events of default.
Debt Covenants
As of March 31, 2025, we were in compliance with the covenants of all of our
debt obligations.
12

-- 17 of 155 --

8. RETIREMENT PLANS
Defined Contribution Savings Plan
We sponsor a 401(k) plan, which is a voluntary defined contribution savings
plan, for U.S. employees. Employees are immediately eligible to make
contributions to the plan and are also eligible for an employer contribution
match at an amount equal to 100.0% of the first 6.0% of eligible employee
contributions. The following table presents the savings plan expense for the
three months ended March 31, 2025 and 2024, which is included in
compensation and benefits expense in the Condensed Consolidated Statements
of Income:
Three Months Ended March 31,
2025 	2024
(in millions)
Savings Plan expense 	$ 	5 $ 	5
Pension, SERP and Other Post-Retirement Benefit Plans
In June 2023, we terminated our U.S. pension plan and took steps to wind
down the plan and transfer the resulting liability to an insurance company. In
connection with the plan termination and partial settlement, a pre-tax charge
of $9 million was recorded to compensation and benefits expense in 2023.
This process was completed in 2024 and, as a result, we recorded a settlement
pre-tax loss of $23 million to compensation and benefits expense in the
Condensed Consolidated Statements of Income for the three months ended
March 31, 2024. We continue to maintain nonqualified SERPs for certain
senior executives and other post-retirement benefit plans for eligible
employees in the U.S. Most employees outside the U.S. are covered by local
retirement plans or by applicable social laws. Benefits under social laws are
generally expensed in the periods in which the costs are incurred.
The total expense for these plans is included in compensation and benefits
expense in the Condensed Consolidated Statements of Income:
Three Months Ended March 31,
2025 	2024
(in millions)
Retirement Plans expense 	$ 	7 $ 	31
Nonqualified Deferred Compensation Plan
We sponsor a nonqualified deferred compensation plan, the Nasdaq, Inc.
Deferred Compensation Plan. This plan provides certain eligible employees
with the opportunity to defer a portion of their annual salary and bonus up to
certain approval limits. All deferrals and associated earnings are our general
unsecured obligations and were immaterial for the three months ended March
31, 2025 and 2024.
9. SHARE-BASED COMPENSATION
We have a share-based compensation program for employees and non-
employee directors. Share-based awards granted under this program include
restricted stock (consisting of restricted stock units), PSUs and stock options.
For accounting purposes, we consider PSUs to be a form of restricted stock.
Generally, annual employee awards are granted on or about April 1 of each
year.
Summary of Share-Based Compensation Expense
The following table presents the total share-based compensation expense
resulting from equity awards and the 15.0% discount for the ESPP for the
three months ended March 31, 2025 and 2024, which is included in
compensation and benefits expense in the Condensed Consolidated Statements
of Income:
Three Months Ended March 31,
2025 	2024
(in millions)
Share-based compensation expense before
income taxes 	$ 	35 $ 	30
Common Shares Available Under Our Equity Plan
As of March 31, 2025, we had approximately 23.2 million shares of common
stock authorized for future issuance under our Equity Plan.
Restricted Stock
We grant restricted stock to most employees. The grant date fair value of
restricted stock units awarded are based on the closing stock price at the date
of grant less the present value of future cash dividends. Restricted stock unit
awards granted to employees below the manager level generally vest 33% on
the first anniversary of the grant date, 33% on the second anniversary of the
grant date, and the remainder on the third anniversary of the grant date.
Restricted stock unit awards granted to employees at or above the manager
level generally vest 33% on the second anniversary of the grant date, 33% on
the third anniversary of the grant date, and the remainder on the fourth
anniversary of the grant date.
The following table summarizes our restricted stock activity for the three
months ended March 31, 2025:
Restricted Stock
Number of Awards
Weighted-Average Grant
Date Fair Value
Unvested at December 31, 2024 	4,178,867 	56.30
Granted 	16,911 	76.03
Vested 	(135,330) 	54.10
Forfeited 	(38,218) 	56.49
Unvested at March 31, 2025 	4,022,230 $ 	56.46
As of March 31, 2025, $110 million of total unrecognized compensation cost
related to restricted stock is expected to be recognized over a weighted-
average period of 2.0 years.
st
13

-- 18 of 155 --

PSUs
We grant three-year PSUs to certain eligible employees. PSUs are based on
performance measures that impact the amount of shares that each PSU eligible
individual receives, subject to the satisfaction of applicable market
performance conditions, with a three-year cumulative performance period that
vest at the end of the performance period and which settle in shares of our
common stock. Compensation cost is recognized over the three-year
performance period, taking into account an estimated forfeiture rate,
regardless of whether the market condition is satisfied, provided that the
requisite service period has been completed. Performance will be determined
by comparing Nasdaq’s TSR to two peer groups, each weighted 50.0%. The
first peer group consists of exchange companies, and the second peer group
consists of all companies in the S&P 500. Beginning in 2024, we replaced the
exchange company peer group with the S&P 500 GICS 4020 Index, which is a
blend of exchanges, as well as data, financial technology and banking
companies to align more closely with Nasdaq’s business and competitors.
Nasdaq’s relative performance ranking against each of these groups will
determine the final number of shares delivered to each individual under the
program. The award issuance under this program will be between 0.0% and
200.0% of the number of PSUs granted and will be determined by Nasdaq’s
overall performance against both peer groups. However, if Nasdaq’s TSR is
negative for the three-year performance period, regardless of TSR ranking, the
award issuance will not exceed 100.0% of the number of PSUs granted. We
estimate the fair value of PSUs granted under the three-year PSU program
using the Monte Carlo simulation model, as these awards contain a market
condition.
In 2024, we also granted PSUs with a two-year performance period to certain
eligible executives at the senior vice president level and above. These PSUs
are based on performance measures relating to the implementation of certain
integration actions in connection with the Adenza acquisition. Achievement of
the targets impacts the amount of shares that each PSU eligible individual
receives. The PSUs have a two-year performance period and will vest one
year after the end of the performance period, and settle in shares of our
common stock. The award issuance under this program will be between 0.0%
and 200.0% of the number of PSUs granted.
Grants of PSUs that were issued in 2022 with a three-year performance period
exceeded the applicable performance metrics. As a result, an additional 32,802
units above the original aggregate target amount were granted in the first
quarter of 2025 and were fully vested upon issuance.
The following table summarizes our PSU activity for the three months ended
March 31, 2025:
PSUs
Three-Year Program
Number of Awards
Weighted-Average Grant
Date Fair Value
Unvested at December 31, 2024 	2,174,151 $ 	64.83
Granted 	48,670 	61.18
Vested 	(620,515) 	62.89
Forfeited 	(772) 	65.14
Unvested at March 31, 2025 	1,601,534 $ 	65.48
In the table above, the granted amount primarily includes additional awards
granted based on overachievement of performance metrics.
As of March 31, 2025, the total unrecognized compensation cost related to the
PSU program is $55 million and is expected to be recognized over a weighted-
average period of 1.3 years.
Stock Options
There were no stock option awards granted and no stock options exercised for
the three months ended March 31, 2025 and 2024.
A summary of our outstanding and exercisable stock options at March 31,
2025 is as follows:
Number of Stock
Options
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining
Contractual
Term (in
years)
Aggregate
Intrinsic
Value (in
millions)
Outstanding at March 31,
2025 	1,420,323 $ 	41.79 	3.9 $ 	48
Exercisable at March 31,
2025 	806,451 $ 	22.23 	1.8 $ 	43
As of March 31, 2025, the aggregate pre-tax intrinsic value of the outstanding
and exercisable stock options in the above table was $48 million and
represents the difference between our closing stock price on March 31, 2025
of $75.86 and the exercise price, times the number of shares that would have
been received by the option holder had the option holder exercised the stock
options on that date. This amount can change based on the fair market value of
our common stock. As of March 31, 2025 and 2024, 0.8 million outstanding
stock options were exercisable and the exercise price was $22.23.
ESPP
We have an ESPP under which approximately 10.7 million shares of our
common stock were available for future issuance as of March 31, 2025. Under
our ESPP, employees may purchase shares having a value not exceeding
10.0% of their annual compensation, subject to applicable annual Internal
Revenue Service limitations. We record compensation expense related to the
15.0% discount that is given to our employees.
14

-- 19 of 155 --

10. NASDAQ STOCKHOLDERS’ EQUITY
Common Stock
As of March 31, 2025, 900,000,000 shares of our common stock were
authorized, 598,118,694 shares were issued and 573,940,099 shares were
outstanding. As of December 31, 2024, 900,000,000 shares of our common
stock were authorized, 598,920,378 shares were issued and 575,062,217
shares were outstanding. The holders of common stock are entitled to one vote
per share, except that our certificate of incorporation limits the ability of any
shareholder to vote in excess of 5.0% of the then-outstanding shares of
Nasdaq common stock.
Common Stock in Treasury, at Cost
We account for the purchase of treasury stock under the cost method with the
shares of stock repurchased reflected as a reduction to Nasdaq stockholders’
equity and included in common stock in treasury, at cost in the Condensed
Consolidated Balance Sheets. Shares repurchased under our share repurchase
program are currently retired and canceled and are therefore not included in
the common stock in treasury balance. If treasury shares are reissued, they are
recorded at the average cost of the treasury shares acquired. We held
24,178,595 shares of common stock in treasury as of March 31, 2025 and
23,858,161 shares as of December 31, 2024, most of which are related to
shares of our common stock withheld for the settlement of employee tax
withholding obligations arising from the vesting of restricted stock and PSUs.
Share Repurchase Program
As of March 31, 2025, the remaining aggregate authorized amount under the
existing share repurchase program was $1.6 billion.
These repurchases may be made from time to time at prevailing market prices
in open market purchases, privately-negotiated transactions, block purchase
techniques, an accelerated share repurchase program or otherwise, as
determined by our management. The repurchases are primarily funded from
existing cash balances. The share repurchase program may be suspended,
modified or discontinued at any time, and has no defined expiration date.
The following is a summary of our share repurchase activity, reported based
on settlement date, for the three months ended March 31, 2025:
Three Months Ended March
31, 2025
Number of shares of common stock repurchased 	1,557,529
Average price paid per share 	$ 	73.57
Total purchase price (in millions) 	$ 	115
In the table above, the number of shares of common stock repurchased
excludes an aggregate of 320,434 shares withheld to satisfy tax obligations of
the grantee upon the vesting of restricted stock and PSUs, and these
repurchases are excluded from our repurchase program.
As discussed above in “Common Stock in Treasury, at Cost,” shares
repurchased under our share repurchase program are currently retired and
cancelled.
Preferred Stock
Our certificate of incorporation authorizes the issuance of 30,000,000 shares
of preferred stock, par value $0.01 per share, issuable from time to time in one
or more series. As of March 31, 2025 and December 31, 2024, no shares of
preferred stock were issued or outstanding.
Cash Dividends on Common Stock
During the first quarter of 2025, our board of directors declared and paid the
following cash dividends:
Declaration Date
Dividend Per
Common
Share 	Record Date
Total Amount
Paid 	Payment Date
(in millions)
January 28, 2025 	$ 	0.24 March 14,
2025 	$ 	138 March 28,
2025
$ 	138
The total amount paid of $138 million was recorded in retained earnings in the
Condensed Consolidated Balance Sheets at March 31, 2025.
In April 2025, the board of directors approved a regular quarterly cash
dividend of $0.27 per share on our outstanding common stock, which reflects
an increase of 13% from our most recent quarterly cash dividend of $0.24 per
share. The dividend is payable on June 27, 2025 to shareholders of record at
the close of business on June 13, 2025. The estimated aggregate payment of
this dividend is $155 million. Future declarations of quarterly dividends and
the establishment of future record and payment dates are subject to approval
by the board of directors.
The board of directors maintains a dividend policy with the intention to
provide shareholders with regular and increasing dividends as earnings and
cash flows increase.
15

-- 20 of 155 --

11. EARNINGS PER SHARE
The following table sets forth the computation of basic and diluted earnings
per share:
Three Months Ended March 31,
2025 	2024
Numerator: 	(in millions, except share and per share amounts)
Net income attributable to common
shareholders 	$ 	395 $ 	234
Denominator:
Weighted-average common shares
outstanding for basic earnings per share 	575,045,177 	575,451,665
Weighted-average effect of dilutive securities:
Weighted-average effect of dilutive
securities - Employee equity awards 	4,937,681 	3,479,425
Weighted-average common shares
outstanding for diluted earnings per share 	579,982,858 	578,931,090
Basic and diluted earnings per share:
Basic earnings per share 	$ 	0.69 $ 	0.41
Diluted earnings per share 	$ 	0.68 $ 	0.40
In the table above, employee equity awards from our PSU program, which are
considered contingently issuable, are included in the computation of dilutive
earnings per share on a weighted average basis when management determines
that the applicable performance criteria would have been met if the
performance period ended as of the date of the relevant computation.
Securities that were not included in the computation of diluted earnings per
share because their effect was antidilutive were immaterial for the three
months ended March 31, 2025 and 2024.
12. FAIR VALUE OF FINANCIAL INSTRUMENTS
The following tables present our financial assets and financial liabilities that
were measured at fair value on a recurring basis as of March 31, 2025 and
December 31, 2024.
March 31, 2025
Total 	Level 1 	Level 2 	Level 3
(in millions)
European government
debt securities $ 	195 $ 	195 $ 	— $ 	—
Time deposits 	6 	— 	6 	—
Total assets at fair value $ 	201 $ 	195 $ 	6 $ 	—
December 31, 2024
Total 	Level 1 	Level 2 	Level 3
(in millions)
European government
debt securities $ 	166 $ 	166 $ 	— $ 	—
Swedish mortgage
bonds 13 	— 	13 	—
Time deposits 	5 	— 	5 	—
Total assets at fair value $ 	184 $ 	166 $ 	18 $ 	—
Financial Instruments Not Measured at Fair Value on a Recurring Basis
Some of our financial instruments are not measured at fair value on a
recurring basis but are recorded at amounts that approximate fair value due to
their liquid or short-term nature. Such financial assets and financial liabilities
include: cash and cash equivalents, restricted cash and cash equivalents,
receivables, net, certain other current assets, accounts payable and accrued
expenses, Section 31 fees payable to SEC, accrued personnel costs,
commercial paper and certain other current liabilities.
We have certain investments, primarily our investment in OCC, which are
accounted for under the equity method of accounting. We have elected the
measurement alternative for the majority of our equity securities, which
primarily represent various strategic investments made through our corporate
venture program. See “Equity Method Investments,” and “Equity Securities,”
of Note 5, “Investments,” for further discussion.
We also consider our debt obligations to be financial instruments. As of March
31, 2025, the majority of our debt obligations were fixed-rate obligations. We
are exposed to changes in interest rates as a result of borrowings under our
2022 Revolving Credit Facility, as the interest rates on this facility have a
variable rate depending on the maturity of the borrowing and the implied
underlying reference rate. We are also exposed to changes in interest rates on
amounts outstanding from the sale of commercial paper under our commercial
paper program. The fair value of our remaining debt obligations utilizing
discounted cash flow analyses for our floating rate debt, and prevailing market
rates for our
16

-- 21 of 155 --

fixed rate debt was $8.7 billion as of March 31, 2025 and $8.8 billion as of
December 31, 2024. The discounted cash flow analyses are based on
borrowing rates currently available to us for debt with similar terms and
maturities. Our commercial paper and our fixed rate and floating rate debt are
categorized as Level 2 in the fair value hierarchy.
For further discussion of our debt obligations, see Note 7, “Debt Obligations.”
Non-Financial Assets Measured at Fair Value on a Non-Recurring Basis
Our non-financial assets, which include goodwill, intangible assets, and other
long-lived assets, are not required to be carried at fair value on a recurring
basis. Fair value measures of non-financial assets are primarily used in the
impairment analysis of these assets. Any resulting asset impairment would
require that the non-financial asset be recorded at its fair value. Nasdaq uses
Level 3 inputs to measure the fair value of the above assets on a non-recurring
basis. As of March 31, 2025 and December 31, 2024, there were no non-
financial assets measured at fair value on a non-recurring basis.
13. CLEARING OPERATIONS
Nasdaq Clearing
Nasdaq Clearing is authorized and supervised under EMIR as a multi-asset
clearinghouse by the SFSA. Such authorization is effective for all member
states of the European Union and certain other non-member states that are part
of the European Economic Area, including Norway. The clearinghouse acts as
the CCP for exchange and OTC trades in equity derivatives, fixed income
derivatives, resale and repurchase contracts, power derivatives, emission
allowance derivatives, and seafood derivatives. In January 2025, we entered
into an agreement to transfer existing open positions in our Nordic power
derivatives trading and clearing business to a European exchange. The
completion of this transaction is subject to customary regulatory approvals.
See “Market Services” of Note 1, “Organization and Nature of Operations,”
for further discussion. Additionally, beginning in January 2025, Nasdaq no
longer offered seafood derivatives clearing and has settled all open positions
as of March 31, 2025.
Through our clearing operations in the financial markets, which include the
resale and repurchase market and the commodities markets, Nasdaq Clearing
is the legal counterparty for, and guarantees the fulfillment of, each contract
cleared. These contracts are not used by Nasdaq Clearing for the purpose of
trading on its own behalf. As the legal counterparty of each transaction,
Nasdaq Clearing bears the counterparty risk between the purchaser and seller
in the contract. In its guarantor role, Nasdaq Clearing has precisely equal and
offsetting claims to and from clearing members on opposite sides of each
contract, standing as the CCP on every contract cleared. In accordance with
the rules and regulations of Nasdaq Clearing, default fund and margin
collateral requirements are calculated for each clearing member’s positions in
accounts with the CCP. See “Default Fund Contributions and Margin
Deposits” below for further discussion of Nasdaq Clearing’s default fund and
margin requirements.
Nasdaq Clearing maintains two member sponsored default funds: one related
to financial markets and one related to commodities markets. Under this
structure, Nasdaq Clearing and its clearing members must contribute to the
total regulatory capital related to the clearing operations of Nasdaq Clearing.
This structure applies an initial separation of default fund contributions for the
financial and commodities markets in order to create a buffer for each
market’s counterparty risks. See “Default Fund Contributions” below for
further discussion of Nasdaq Clearing’s default fund. A power of assessment
and a liability waterfall have also been implemented to further align risk
between Nasdaq Clearing and its clearing members. See “Power of
Assessment” and “Liability Waterfall” below for further discussion.
Default Fund Contributions and Margin Deposits
As of March 31, 2025, clearing member default fund contributions and margin
deposits were as follows:
March 31, 2025
Cash Contributions
Non-Cash
Contributions 	Total Contributions
(in millions)
Default fund
contributions 	$ 	1,142 $ 	148 $ 	1,290
Margin deposits 	4,544 	5,912 	10,456
Total 	$ 	5,686 $ 	6,060 $ 	11,746
Of the total default fund contributions of $1,290 million, Nasdaq Clearing can
utilize $1,266 million as capital resources in the event of a counterparty
default. The remaining balance of $24 million pertains to member posted
surplus balances.
Our clearinghouse holds material amounts of clearing member cash deposits
which are held or invested primarily to provide security of capital while
minimizing credit, market and liquidity risks. While we seek to achieve a
reasonable rate of return, we are primarily concerned with preservation of
capital and managing the risks associated with these deposits.
17

-- 22 of 155 --

Clearing member cash contributions are maintained in demand deposits held
at central banks and large, highly rated financial institutions or secured
through direct investments, primarily central bank certificates and highly rated
European government debt securities with original maturities primarily one
year or less, reverse repurchase agreements and multilateral development bank
debt securities. Investments in reverse repurchase agreements range in
maturity from 1 to 8 days and are secured with highly rated government
securities and multilateral development banks. The carrying value of these
securities approximates their fair value due to the short-term nature of the
instruments and reverse repurchase agreements.
Nasdaq Clearing has invested the total cash contributions of $5,686 million as
of March 31, 2025 and $5,664 million as of December 31, 2024, in
accordance with its investment policy as follows:
March 31, 2025 	December 31, 2024
(in millions)
Demand deposits 	$ 	2,489 $ 	3,616
Central bank certificates 	1,534 	767
Restricted cash and cash equivalents $ 	4,023 $ 	4,383
European government debt securities 	245 	465
Reverse repurchase agreements 	1,085 	610
Multilateral development bank debt
securities 	333 	206
Investments 	$ 	1,663 $ 	1,281
Total 	$ 	5,686 $ 	5,664
In the table above, the change from December 31, 2024 to March 31, 2025
includes currency translation adjustments of $393 million for restricted cash
and cash equivalents and $178 million for investments.
For the three months ended March 31, 2025 and 2024, investments related to
default funds and margin deposits, net includes purchases of investment
securities of $24,021 million and $16,745 million, respectively, and proceeds
from sales and redemptions of investment securities of $23,817 million and
$16,561 million, respectively.
In the investment activity related to default fund and margin contributions, we
are exposed to counterparty risk related to reverse repurchase agreement
transactions, which reflect the risk that the counterparty might become
insolvent and, thus, fail to meet its obligations to Nasdaq Clearing. We
mitigate this risk by only engaging in transactions with high credit quality
reverse repurchase agreement counterparties and by limiting the acceptable
collateral under the reverse repurchase agreement to high quality issuers,
primarily government securities and other securities explicitly guaranteed by a
government. The value of the underlying security is monitored during the
lifetime of the contract, and in the event the market value of the underlying
security falls below the reverse repurchase amount, our clearinghouse may
require additional collateral or a reset of the contract.
Default Fund Contributions
Required contributions to the default funds are proportional to the exposures
of each clearing member. When a clearing member is active in more than one
market, contributions must be made to all markets’ default funds in which the
member is active. Clearing members’ eligible contributions may include cash
and non-cash contributions. Cash contributions received are maintained in
demand deposits held at central banks and large, highly rated financial
institutions or invested by Nasdaq Clearing, in accordance with its investment
policy, either in central bank certificates, highly rated government debt
securities, reverse repurchase agreements with highly rated government debt
securities as collateral, or multilateral development bank debt securities.
Nasdaq Clearing maintains and manages all cash deposits related to margin
collateral. All risks and rewards of collateral ownership, including interest,
belong to Nasdaq Clearing. Clearing members’ cash contributions are
included in default funds and margin deposits in the Condensed Consolidated
Balance Sheets as both a current asset and a current liability. Non-cash
contributions include highly rated government debt securities that must meet
specific criteria approved by Nasdaq Clearing. Non-cash contributions are
pledged assets that are not recorded in the Condensed Consolidated Balance
Sheets as Nasdaq Clearing does not take legal ownership of these assets and
the risks and rewards remain with the clearing members. These balances may
fluctuate over time due to changes in the amount of deposits required and
whether members choose to provide cash or non-cash contributions.
In addition to clearing members’ required contributions to the liability
waterfall, Nasdaq Clearing is also required to contribute capital to the liability
waterfall and overall regulatory capital as specified under its clearinghouse
rules. As of March 31, 2025, Nasdaq Clearing committed capital totaling $140
million to the liability waterfall and overall regulatory capital, in the form of
government debt securities, which are recorded as financial investments in the
Condensed Consolidated Balance Sheets. The combined regulatory capital of
the clearing members and Nasdaq Clearing is intended to secure the
obligations of a clearing member exceeding such member’s own margin and
default fund deposits and may be used to cover losses sustained by a clearing
member in the event of a default.
Margin Deposits
Nasdaq Clearing requires all clearing members to provide collateral, which
may consist of cash and non-cash contributions, to guarantee performance on
the clearing members’ open positions, or initial margin. In addition, clearing
members must also provide collateral to cover the daily margin call if needed.
See “Default Fund Contributions” above for further discussion of cash and
non-cash contributions.
18

-- 23 of 155 --

Similar to default fund contributions, Nasdaq Clearing maintains and manages
all cash deposits related to margin collateral. All risks and rewards of
collateral ownership, including interest, belong to Nasdaq Clearing and are
recorded in revenues. These cash deposits are recorded in default funds and
margin deposits in the Condensed Consolidated Balance Sheets as both a
current asset and a current liability. Pledged margin collateral is not recorded
in the Condensed Consolidated Balance Sheets as all risks and rewards of
collateral ownership, including interest, belong to the counterparty.
Nasdaq Clearing marks to market all outstanding contracts and requires
payment from clearing members whose positions have lost value. The mark-
to-market process helps identify any clearing members that may not be able to
satisfy their financial obligations in a timely manner allowing Nasdaq
Clearing the ability to mitigate the risk of a clearing member defaulting due to
exceptionally large losses. In the event of a default, Nasdaq Clearing can
access the defaulting member’s margin and default fund deposits to cover the
defaulting member’s losses.
Regulatory Capital and Risk Management Calculations
Nasdaq Clearing manages risk through a comprehensive counterparty risk
management framework, which comprises policies, procedures, standards and
financial resources. The level of regulatory capital is determined in
accordance with Nasdaq Clearing’s regulatory capital and default fund policy,
as approved by the SFSA. Regulatory capital calculations are continuously
updated through a proprietary capital-at-risk calculation model that establishes
the appropriate level of capital.
As mentioned above, Nasdaq Clearing is the legal counterparty for each
contract cleared and thereby guarantees the fulfillment of each contract.
Nasdaq Clearing accounts for this guarantee as a performance guarantee. We
determine the fair value of the performance guarantee by considering daily
settlement of contracts and other margining and default fund requirements, the
risk management program, historical evidence of default payments, and the
estimated probability of potential default payouts. The calculation is
determined using proprietary risk management software that simulates gains
and losses based on historical market prices, extreme but plausible market
scenarios, volatility and other factors present at that point in time for those
particular unsettled contracts. Based on this analysis the estimated liability
was nominal and no liability was recorded as of March 31, 2025.
Power of Assessment
To further strengthen the contingent financial resources of the clearinghouse,
Nasdaq Clearing has power of assessment that provides the ability to collect
additional funds from its clearing members to cover a defaulting member’s
remaining obligations up to the limits established under the terms of the
clearinghouse rules. The power of assessment corresponds to 230% of the
clearing member’s aggregate contribution to the financial and commodities
markets’ default funds.
Liability Waterfall
The liability waterfall is the priority order in which the capital resources
would be utilized in the event of a default where the defaulting clearing
member’s collateral and default fund contribution would not be sufficient to
cover the cost to settle its portfolio. If a default occurs and the defaulting
clearing member’s collateral, including cash deposits and pledged assets, is
depleted, then capital is utilized in the following amount and order:
• junior capital contributed by Nasdaq Clearing, which totaled $42 million as
of March 31, 2025;
• a loss-sharing pool related only to the financial market that is contributed to
by clearing members and only applies if the defaulting member’s portfolio
includes interest rate swap products;
• specific market default fund where the loss occurred (i.e., the financial or
commodities market), which includes capital contributions of the clearing
members on a pro-rata basis; and
• fully segregated senior capital for each specific market contributed by
Nasdaq Clearing, calculated in accordance with clearinghouse rules, which
totaled $20 million as of March 31, 2025.
If additional funds are needed after utilization of the liability waterfall, or if
part of the waterfall has been utilized and needs to be replenished, then
Nasdaq Clearing will utilize its power of assessment and additional capital
contributions will be required by non-defaulting members up to the limits
established under the terms of the clearinghouse rules.
In addition to the capital held to withstand counterparty defaults described
above, Nasdaq Clearing also has committed capital of $78 million to ensure
that it can handle an orderly wind-down of its operation, and that it is
adequately protected against investment, operational, legal, and business risks.
19

-- 24 of 155 --

Market Value of Derivative Contracts Outstanding
The following table presents the market value of derivative contracts
outstanding prior to netting:
March 31, 2025
(in millions)
Commodity options, futures and forwards 	$ 	31
Fixed-income options and futures 	653
Stock options and futures 	359
Index options and futures 	71
Total 	$ 	1,114
In the table above:
• We determined the fair value of our option contracts using standard
valuation models that were based on market-based observable inputs
including implied volatility, interest rates and the spot price of the
underlying instrument.
• We determined the fair value of our futures contracts based upon quoted
market prices and average quoted market yields.
• We determined the fair value of our forward contracts using standard
valuation models that were based on market-based observable inputs
including benchmark rates and the spot price of the underlying instrument.
Derivative Contracts Cleared
The following table presents the total number of derivative contracts cleared
through Nasdaq Clearing for the three months ended March 31, 2025 and
2024:
Three Months Ended March 31,
2025 	2024
Commodity and seafood options, futures
and forwards 	71,140 	56,497
Fixed-income options and futures 	4,373,731 	4,914,000
Stock options and futures 	6,765,209 	5,909,474
Index options and futures 	9,107,386 	9,311,902
Total 	20,317,466 	20,191,873
In the table above, the total volume in cleared power related to commodity
contracts was 138 Terawatt hours (TWh) and 135 TWh for the three months
ended March 31, 2025 and 2024, respectively. As noted above, beginning in
January 2025, Nasdaq no longer offered seafood derivatives clearing.
Resale and Repurchase Agreements Contracts Outstanding and Cleared
The outstanding contract value of resale and repurchase agreements was $0.9
billion and $5.0 billion as of March 31, 2025 and 2024, respectively. The total
number of resale and repurchase agreements contracts cleared was 860,271
and 1,264,000 for the three months ended March 31, 2025 and 2024,
respectively.
14. LEASES
We have operating leases, which are primarily real estate leases,
predominantly for our U.S. and European headquarters, data centers and for
general office space. The following table provides supplemental balance sheet
information related to Nasdaq’s operating leases:
Balance Sheet
Classification 	March 31, 2025 	December 31, 2024
Assets: 	(in millions)
Operating lease
assets Operating lease
assets 	$ 	381 $ 	375
Liabilities:
Current lease
liabilities Other current
liabilities 	$ 	55 $ 	55
Non-current
lease liabilities Operating lease
liabilities 	393 	388
Total lease
liabilities 	$ 	448 $ 	443
The following table summarizes Nasdaq’s lease cost:
Three Months Ended March 31,
2025 	2024
(in millions)
Operating lease cost 	$ 	19 $ 	21
Variable lease cost 	10 	8
Sublease income 	(1) 	(1)
Total lease cost 	$ 	28 $ 	28
In the table above, operating lease costs include short-term lease costs, which
were immaterial.
The following table reconciles the undiscounted cash flows for the following
years and total of the remaining years to the operating lease liabilities recorded
in the Condensed Consolidated Balance Sheets.
March 31, 2025
(in millions)
Remainder of 2025 	$ 	57
2026 	66
2027 	61
2028 	58
2029 	56
2030+ 	237
Total lease payments 	$ 	535
Less: interest 	(87)
Present value of lease liabilities 	$ 	448
In the table above, interest is calculated using the interest rate for each lease.
Present value of lease liabilities includes the current portion of $55 million.
20

-- 25 of 155 --

Total lease payments in the table above excludes $65 million of legally
binding minimum lease payments for leases signed but not yet commenced.
This primarily relates to a new lease signed in the first quarter of 2024 for our
European headquarters. This lease commenced in April 2025 with a lease term
of 10 years. These payments also include a data center lease for which we
have not yet obtained full control of the leased premises.
The following table provides information related to Nasdaq’s lease term and
discount rate:
March 31, 2025
Weighted-average remaining lease term (in years) 	8.8
Weighted-average discount rate 	4.0 %
The following table provides supplemental cash flow information related to
Nasdaq’s operating leases:
Three Months Ended March 31,
2025 	2024
(in millions)
Cash paid for amounts included in the
measurement of operating lease liabilities $ 	20 $ 	21
Lease assets obtained in exchange for
operating lease liabilities 	$ 	20 $ 	12
15. INCOME TAXES
Income Tax Provision
The following table presents our income tax provision and effective tax rate:
Three Months Ended March 31,
2025 	2024
(in millions)
Income tax provision 	$ 	93 	$ 	79
Effective tax rate 	19.1 % 	25.3 %
The lower effective tax rate for the three months ended March 31, 2025 was
primarily due to a tax benefit related to a favorable audit settlement.
The effective tax rate may vary from period to period depending on, among
other factors, the geographic and business mix of earnings and losses. These
and other factors, including history of pre-tax earnings and losses, are taken
into account in assessing the ability to realize deferred tax assets.
Tax Audits
Nasdaq and its eligible subsidiaries file a consolidated U.S. federal income tax
return, applicable state and local income tax returns and non-U.S. income tax
returns. We are subject to examination by federal, state and local, and foreign
tax authorities. Our federal income tax return is subject to examination by the
Internal Revenue Service for the years 2021 through 2023. Several state tax
returns are currently under examination by the respective tax authorities for
the years 2014 through 2023. Non-U.S. tax returns are subject to examination
by the respective tax authorities for the years 2019 through 2024.
We regularly assess the likelihood of additional assessments by each
jurisdiction and have established tax reserves that we believe are adequate in
relation to the potential for additional assessments. Examination outcomes and
the timing of examination settlements are subject to uncertainty. Although the
results of such examinations may have an impact on our unrecognized tax
benefits, we do not anticipate that such impact will be material to our
condensed consolidated financial position or results of operations, but may be
material to our operating results for a particular period and the effective tax
rate for that period. We do not expect the settlement of any tax audits to be
material in the next twelve months.
16. COMMITMENTS, CONTINGENCIES AND GUARANTEES
Guarantees Issued and Credit Facilities Available
In addition to the default fund contributions and margin collateral pledged by
clearing members discussed in Note 13, “Clearing Operations,” we have
obtained financial guarantees and credit facilities, which are guaranteed by us
through counter indemnities, to provide further liquidity related to our clearing
businesses. Financial guarantees issued to us totaled $4 million as of March
31, 2025 and December 31, 2024. As discussed in “Other Credit Facilities,” of
Note 7, “Debt Obligations,” we also have credit facilities primarily related to
our Nasdaq Clearing operations, which are available in multiple currencies,
and totaled $191 million as of March 31, 2025 and $174 million as of
December 31, 2024 in available liquidity, none of which was utilized.
Other Guarantees
Through our clearing operations in the financial markets, Nasdaq Clearing is
the legal counterparty for, and guarantees the performance of, its clearing
members. See Note 13, “Clearing Operations,” for further discussion of
Nasdaq Clearing performance guarantees.
We have provided a guarantee related to lease obligations for The Nasdaq
Entrepreneurial Center, Inc., which is a not-for-profit organization designed to
convene, connect and engage aspiring and current entrepreneurs. This entity is
not included in the condensed consolidated financial statements of Nasdaq.
21

-- 26 of 155 --

We believe that the potential for us to be required to make payments under
these arrangements is unlikely. Accordingly, no contingent liability is recorded
in the Condensed Consolidated Balance Sheets for the above guarantees.
Routing Brokerage Activities
One of our broker-dealer subsidiaries, Nasdaq Execution Services, provides a
guarantee to securities clearinghouses and exchanges under its standard
membership agreements, which require members to guarantee the
performance of other members. If a member becomes unable to satisfy its
obligations to a clearinghouse or exchange, other members would be required
to meet its shortfalls. To mitigate these performance risks, the exchanges and
clearinghouses often require members to post collateral, as well as meet
certain minimum financial standards. Nasdaq Execution Services’ maximum
potential liability under these arrangements cannot be quantified. However, we
believe that the potential for Nasdaq Execution Services to be required to
make payments under these arrangements is unlikely. Accordingly, no
contingent liability is recorded in the Condensed Consolidated Balance Sheets
for these arrangements.
Legal and Regulatory Matters
European Commission Matter
In September 2024, the European Commission conducted an inspection at the
Nasdaq Stockholm offices. The inspection related to a potential competition
law concern regarding the trading of Nordics financial derivatives. We have
been cooperating with the European Commission, but are uncertain about the
duration or ultimate outcome of the European Commission’s review, or to the
extent there is any finding against us, the nature of any remedies or the
amount of any fines.
Other Matters
Except as disclosed above and in our prior reports filed under the Exchange
Act, we are not currently a party to any litigation or proceeding that we
believe could have a material adverse effect on our business, consolidated
financial condition, or operating results. However, from time to time, we have
been threatened with, or named as a defendant in, lawsuits or involved in
regulatory proceedings.
In the normal course of business, Nasdaq discusses matters with its regulators
raised during regulatory examinations or otherwise subject to their inquiries.
Management believes that censures, fines, penalties or other sanctions that
could result from any ongoing examinations or inquiries will not have a
material impact on our consolidated financial position or results of operations.
However, we are unable to predict the outcome or the timing of the ultimate
resolution of these matters, or the potential fines, penalties or injunctive or
other equitable relief, if any, that may result from these matters.
Tax Audits
We are engaged in ongoing discussions and audits with taxing authorities on
various tax matters, the resolutions of which are uncertain. Currently, there are
matters that may lead to assessments, some of which may not be resolved for
several years. Based on currently available information, we believe we have
adequately provided for any assessments that could result from those
proceedings where it is more likely than not that we will be assessed. We
review our positions on these matters as they progress. See “Tax Audits,” of
Note 15, “Income Taxes,” for further discussion.
17. BUSINESS SEGMENTS
We manage, operate and provide our products and services in three business
segments: Capital Access Platforms, Financial Technology and Market
Services. See Note 1, “Organization and Nature of Operations,” for further
discussion of our reportable segments.
Our management allocates resources, assesses performance and manages these
businesses as three separate segments. We evaluate the performance of our
segments based on several factors, of which the primary financial measure is
operating income. Our CODM, who is our Chair and Chief Executive Officer,
does not review total assets or statements of income below operating income
by segments as key performance metrics; therefore, such information is not
presented below.
22

-- 27 of 155 --

The following table presents certain information regarding our business
segments for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
2025 	2024
(in millions)
Capital Access Platforms:
Total revenues 	$ 	515 $ 	479
Direct and directly consumed expenses 	168 	157
Other expenses 	41 	43
Operating income 	306 	279
Depreciation and amortization 	11 	10
Purchase of property and equipment 	13 	8
Financial Technology:
Total revenues 	432 	392
Direct and directly consumed expenses 	205 	193
Other expenses 	29 	23
Operating income 	198 	176
Depreciation and amortization 	12 	12
Purchase of property and equipment 	22 	21
Market Services:
Total revenues 	1,134 	794
Transaction-based expenses 	(853) 	(557)
Revenues less transaction-based expenses 	281 	237
Direct and directly consumed expenses 	88 	82
Other expenses 	20 	22
Operating income 	173 	133
Depreciation and amortization 	11 	10
Purchase of property and equipment 	14 	10
Corporate Items:
Total revenues 	9 	9
Other expenses 	139 	187
Operating loss 	(130) 	(178)
Depreciation and amortization 	122 	123
Consolidated:
Total revenues 	$ 	2,090 $ 	1,674
Transaction-based expenses 	(853) 	(557)
Revenues less transaction-based expenses 	$ 	1,237 $ 	1,117
Direct and directly consumed expenses 	461 	432
Other expenses 	229 	275
Operating income 	$ 	547 $ 	410
Depreciation and amortization 	156 	155
Purchase of property and equipment 	49 	39
Direct and directly consumed expenses in the preceding table represent costs
for resources directly used by the segment for revenue generating activities.
Other expenses include indirect overhead costs allocated to our segments.
During the first year of integration of certain significant acquisitions such as
Adenza or Verafin, the allocation of these indirect overhead costs to the
Financial Technology segment were phased in and therefore these allocations
may change in the future. Other expenses also includes expenses allocated to
our Corporate segment. The following table summarizes revenues and
expenses allocated to our Corporate segment:
Three Months Ended March 31,
2025 	2024
(in millions)
Revenues:
Divested business 	$ 	9 $ 	9
Expenses:
Amortization expense of acquired
intangible assets 	122 	123
Merger and strategic initiatives expense 	24 	9
Restructuring charges 	5 	26
Legal and regulatory matters 	2 	2
Gain on extinguishment of debt 	(19) 	—
Pension settlement charge 	— 	23
Expenses - divested business 	4 	4
Other 	1 	—
Total expenses 	$ 	139 $ 	187
Operating loss 	$ 	(130) $ 	(178)
For further discussion of our segments’ results, see “Segment Operating
Results,” of “Part I, Item 2. Management’s Discussion and Analysis of
Financial Condition and Results of Operations.”
The items in the preceding table are not included in the measurement of
segment profitability reviewed by our CODM, as we believe they do not
contribute to a meaningful evaluation of a particular segment’s ongoing
operating performance. Management does not consider these items for the
purpose of evaluating the performance of our segments or their managers or
when making decisions to allocate resources. Therefore, we believe
performance measures excluding the below items provide management with a
useful representation of our segments’ ongoing activity in each period. These
items, which are presented in the tables above, include the following:
• Revenues and expenses - divested business: In January 2025, we entered
into an agreement to transfer existing open positions in our Nordic power
derivatives trading and clearing business to a European exchange. The
completion of this transaction is subject to customary regulatory approvals.
Revenues and expenses related to this transaction are included as revenues
and expenses - divested businesses.
23

-- 28 of 155 --

• Amortization expense of acquired intangible assets: We amortize intangible
assets acquired in connection with various acquisitions. Intangible asset
amortization expense can vary from period to period due to episodic
acquisitions completed, rather than from our ongoing business operations.
As such, if intangible asset amortization is included in performance
measures, it is more difficult to assess the day-to-day operating performance
of the segments, and the relative operating performance of the segments
between periods.
• Merger and strategic initiatives expense: We have pursued various strategic
initiatives and completed acquisitions and divestitures in recent years that
have resulted in expenses which would not have otherwise been incurred.
These expenses generally include integration costs, as well as legal, due
diligence and other third-party transaction costs. The frequency and the
amount of such expenses vary significantly based on the size, timing and
complexity of the transaction. For the three months ended March 31, 2025,
these amounts are primarily driven by the timing of recognition associated
with the transfer of open positions in our Nordic power derivatives trading
and clearing business, Adenza integration costs and other strategic initiative
costs. For the three months ended March 31, 2024, these costs were
primarily related to the integration of Adenza.
• Restructuring charges: See Note 18, “Restructuring Charges,” for further
discussion of these plans.
• Other items: We have included certain other charges or gains in corporate
items, to the extent we believe they should be excluded when evaluating the
ongoing operating performance of each individual segment. Other items
primarily include:
◦ Gain on extinguishment of debt: For the three months ended March 31,
2025, this includes a gain on extinguishment of debt, which is recorded in
general, administrative and other expense in the Condensed Consolidated
Statements of Income.
◦ Legal and regulatory matters: For the three months ended March 31,
2025, this includes accruals relating to certain legal matters, which are
recorded in professional and contract services in the Condensed
Consolidated Statements of Income.
◦ Pension settlement charge: For the three months ended March 31, 2024,
we recorded a pre-tax loss as a result of settling our U.S. pension plan.
The plan was terminated and partially settled in 2023, with final
settlement occurring during the first quarter of 2024. The pre-tax charge is
recorded in compensation and benefits in the Condensed Consolidated
Statements of Income. See Note 8, “Retirement Plans,” for further
discussion.
Geographic Data
The following table presents total revenues by geographic area for the three
months ended March 31, 2025 and 2024. Revenues are classified based upon
the 	location 	of 	the 	customer.
Three Months Ended March 31,
2025 	2024
(in millions)
United States 	$ 	1,700 $ 	1,304
All other countries 	390 	370
Total 	$ 	2,090 $ 	1,674
No single customer accounted for 10.0% or more of our revenues in 2025 and
2024.
The following table presents property and equipment, net by geographic area
as of March 31, 2025 and December 31, 2024. Property and equipment
information is based on the physical location of the assets.
(in millions) 	March 31, 2025 	December 31, 2024
United States 	$ 	431 $ 	425
All other countries 	190 	168
Total 	$ 	621 $ 	593
Property and equipment, net for all other countries primarily includes assets
held in Sweden.
18. RESTRUCTURING CHARGES
In the fourth quarter of 2023, following the closing of the Adenza acquisition,
our management approved, committed to and initiated a restructuring
program, “Adenza Restructuring” to optimize our efficiencies as a combined
organization. We further expanded this program in the fourth quarter of 2024
to accelerate our momentum. In connection with this program, we expect to
incur approximately $140 million in pre-tax charges. We have incurred costs
principally related to employee-related costs, contract terminations, asset
impairments and other related costs and expect to incur additional costs in
these areas in an effort to accelerate efficiencies through location strategy and
enhanced AI capabilities. Actions taken as part of this program are expected to
be completed by the end of 2025, while certain costs may be recognized in the
first half of 2026. We expect to achieve benefits primarily in the form of
expense synergies with over $100 million net expense synergies actioned
through March 31, 2025.
In October 2022, following our September 2022 announcement to realign our
segments and leadership, we initiated a divisional realignment program with a
focus on realizing the full potential of this structure. As of September 30,
2024, we completed our divisional realignment program and recognized total
pre-tax charges of $139 million over a two-year period, within the anticipated
range of $115 million to $145 million.
24

-- 29 of 155 --

Costs related to these programs are recorded as restructuring charges in the
Condensed Consolidated Statements of Income.
The following table presents a summary of the Adenza restructuring program
and our divisional realignment program charges for the three months ended
March 31, 2025 and 2024 as well as total program costs incurred since the
inception date of each program.
Three Months Ended March 31,
2025 	2024
(in millions)
Consulting services
Adenza restructuring 	$ 	1 $ 	—
Divisional realignment 	— 	10
Employee-related costs
Adenza restructuring 	4 	4
Divisional realignment 	— 	3
Other
Adenza restructuring 	— 	3
Divisional realignment 	— 	6
Total restructuring charges 	$ 	5 $ 	26
Total Program Costs Incurred
Adenza restructuring 	$ 	77
Divisional realignment 	$ 	139
25

-- 30 of 155 --

Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
The following discussion and analysis of the financial condition and results of
operations of Nasdaq should be read in conjunction with our condensed
consolidated financial statements and related notes included in this Form 10-
Q.
Certain percentages and per share amounts herein may not sum or recalculate
due to rounding.
EXECUTIVE OVERVIEW
Nasdaq is a global technology company serving corporate clients, investment
managers, banks, brokers, and exchange operators as they navigate and
interact with the global capital markets and the broader financial system. We
aspire to deliver world-leading platforms that improve the liquidity,
transparency, and integrity of the global economy. Our diverse offering of
data, analytics, software, exchange capabilities, and client-centric services
enables clients to optimize and execute their business vision with confidence.
We manage, operate and provide our products and services in three business
segments: Capital Access Platforms, Financial Technology and Market
Services.
First Quarter 2025 Highlights
• In the first quarter of 2025, Nasdaq achieved an 82.0% win rate among
Nasdaq-eligible operating company IPOs in the U.S., representing 45
offerings and $5 billion in total proceeds raised.
• Market Services delivered record revenues for the segment and record
volumes across cash equities, equity options and index options volumes.
• Our Financial Technology segment delivered 11% ARR growth, reflecting
an increase in new clients, cross-sells and upsells.
• Index achieved a sixth consecutive record quarter, reaching an average ETP
AUM of $662 billion and $27 billion of net inflows in the first quarter.
Macroeconomic environment
Our business performance can be positively or negatively impacted by a
number of factors, including general economic conditions, the geopolitical
environment, current or expected inflation, interest rate fluctuations, the threat
or imposition of broad-based tariffs, market volatility, changes in investment
patterns and priorities, regulatory changes, pandemics and other factors that
are generally beyond our control. For example, higher overall U.S. trading
volumes in the first quarter of 2025, as compared to the same period in 2024,
has led to an increase in our U.S. Equity Derivative Trading and U.S. Cash
Equity Trading revenues. Market factors also contributed to higher valuations
in Nasdaq Indices and higher overall volumes in Index derivatives. To the
extent that global or national economic conditions weaken and result in slower
growth or recessions, our business may be negatively impacted.
Nasdaq’s Operating Results
The following table summarizes our financial performance for the three
months ended March 31, 2025 compared to the same period in 2024. For a
detailed discussion of our results of operations, see “Segment Operating
Results” below.
Three Months Ended March 31,
Percentage Change	2025 	2024
(in millions, except per share amounts)
Revenues less transaction-
based expenses 	$ 	1,237 $ 	1,117 	10.7 %
Operating expenses 	690 	707 	(2.5)%
Operating income 	$ 	547 $ 	410 	33.5 %
Net income attributable to
Nasdaq 	$ 	395 $ 	234 	68.9 %
Diluted earnings per share $ 	0.68 $ 	0.40 	68.6 %
Cash dividends declared per
common share 	$ 	0.24 $ 	0.22 	9.1 %
In countries with currencies other than the U.S. dollar, revenues and expenses
are translated using monthly average exchange rates. Impacts on our revenues
less transaction-based expenses and operating income associated with
fluctuations in foreign currency are discussed in more detail under “Item 3.
Quantitative and Qualitative Disclosures About Market Risk.”
The following chart summarizes our ARR (in millions):
26

-- 31 of 155 --

ARR for a given period is the current annualized value derived from
subscription contracts with a defined contract value. This excludes contracts
that are not recurring, are one-time in nature, or where the contract value
fluctuates based on defined metrics. ARR is currently one of our key
performance metrics to assess the health and trajectory of our recurring
business. ARR does not have any standardized definition and is therefore
unlikely to be comparable to similarly titled measures presented by other
companies. ARR should be viewed independently of revenue and deferred
revenue and is not intended to be combined with or to replace either of those
items. For AxiomSL and Calypso recurring revenue contracts, the amount
included in ARR is consistent with the amount that we invoice the customer
during the current period. Additionally, for AxiomSL and Calypso recurring
revenue contracts that include annual values that increase over time, we
include in ARR only the annualized value of components of the contract that
are considered active as of the date of the ARR calculation. We do not include
the future committed increases in the contract value as of the date of the ARR
calculation. ARR is not a forecast and the active contracts at the end of a
reporting period used in calculating ARR may or may not be extended or
renewed by our customers.
The ARR chart includes:
▪ 	Capital Access Platforms
◦ Proprietary market data subscriptions and annual listing
fees within our Data & Listing Services business
◦ Index data subscriptions and guaranteed minimum on
futures contracts within our Index business
◦ Subscription contracts under our Workflow & Insights
business
▪ 	Financial Technology
◦ Financial Crime Management Technology SaaS
subscription contracts excluding one-time service
requests
◦ Regulatory Technology SaaS and subscription and
support contracts excluding one-time service requests
◦ Capital Markets Technology SaaS and subscription and
support contracts excluding one-time service requests
The following chart summarizes our quarterly annualized SaaS revenues for
Solutions, which comprises our Capital Access Platforms and Financial
Technology segments, for March 31, 2025 and 2024 (in millions):
SEGMENT OPERATING RESULTS
The following table presents our revenues by segment:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Capital Access Platforms 	$ 	515 $ 	479 	7.4 %
Financial Technology 	432 	392 	10.3 %
Market Services 	1,134 	794 	42.8 %
Other revenues 	9 	9 	(5.8)%
Total revenues 	$ 	2,090 $ 	1,674 	24.8 %
Transaction rebates 	(579) 	(481) 	20.3 %
Brokerage, clearance and
exchange fees 	(274) 	(76) 	260.0 %
Total revenues less
transaction-based expenses $ 	1,237 $ 	1,117 	10.7 %
27

-- 32 of 155 --

The following chart presents our Capital Access Platforms, Financial
Technology and Market Services segments as a percentage of our total
revenues, less transaction-based expenses.
Capital Access Platforms
The following tables present revenues and ARR from our Capital Access
Platforms segment:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Data & Listing Services 	$ 	192 $ 	186 	3.5 %
Index 	193 	168 	14.3 %
Workflow & Insights 	130 	125 	3.8 %
Total Capital Access
Platforms 	$ 	515 $ 	479 	7.4 %
As of March 31,
2025 	2024
ARR (in millions) 	$ 	1,281 $ 	1,220
Data & Listing Services Revenues
The following tables present key drivers from our Data & Listing Services
business:
Three Months Ended March 31,
2025 	2024
IPOs
The Nasdaq Stock Market 	63 	27
Exchanges that comprise Nasdaq Nordic
and Nasdaq Baltic 	4 	1
Total new listings
The Nasdaq Stock Market 	170 	79
Exchanges that comprise Nasdaq Nordic
and Nasdaq Baltic 	9 	2
As of March 31,
2025 	2024
Number of listed companies
The Nasdaq Stock Market 	4,139 	4,020
Exchanges that comprise Nasdaq Nordic
and Nasdaq Baltic 	1,160 	1,203
ARR (in millions) 	701 	665
In the table above:
• For the three months ended March 31, 2025 and 2024, IPOs included 18 and
5 SPACs, respectively. The number of total listed companies on The Nasdaq
Stock Market for the three months ended March 31, 2025 and 2024 included
833 and 619 ETPs, respectively.
• IPOs, new listings (which includes IPOs) and total listed companies for
exchanges that comprise Nasdaq Nordic and Nasdaq Baltic represent
companies listed on the Nasdaq Nordic and Nasdaq Baltic exchanges and
companies listed on the alternative markets of Nasdaq First North.
Data & Listing Services revenues increased in the first quarter of 2025
compared with the same period in 2024 due to higher sales, increased usage
and pricing in our data business.
28

-- 33 of 155 --

Index Revenues
The following table presents key drivers from our Index business:
As of or
Three Months Ended March 31,
2025 	2024
Number of licensed ETPs 	418 	362
TTM change in period end ETP AUM tracking Nasdaq indices (in
billions)
Beginning balance 	$ 	519 $ 	366
Net appreciation (depreciation) 	17 	124
Net impact of ETP sponsor switches 	— 	(17)
Net inflows 	86 	46
Ending balance 	$ 	622 $ 	519
Quarterly average ETP AUM tracking
Nasdaq indices (in billions) 	$ 	662 $ 	492
ARR (in millions) 	$ 	79 $ 	74
In the table above, TTM represents trailing twelve months.
Index revenues increased in the first quarter of 2025 compared with the same
period in 2024 primarily due to higher average AUM in exchange traded
products linked to Nasdaq indices and growth in trading volume on futures
contracts linked to the Nasdaq-100 Index, partially offset by a $16 million
one-time item recognized in the first quarter of 2024 related to a legal
settlement to recoup revenue.
Workflow & Insights Revenues
The following table presents key drivers from our Workflow & Insights
business:
As of or
Three Months Ended March 31,
2025 	2024
(in millions)
ARR 	$ 	501 $ 	481
Quarterly annualized SaaS revenues 	430 	411
Workflow & Insights revenues increased in the first quarter of 2025 compared
with the same period in 2024 reflecting an increase in analytics revenues,
largely driven by eVestment.
Financial Technology
The following table presents revenues from our Financial Technology
segment:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Financial Crime Management
Technology 	$ 	77 $ 	64 	20.5 %
Regulatory Technology 	101 	90 	11.9 %
Capital Markets Technology 	254 	238 	7.0 %
Total Financial Technology 	$ 	432 $ 	392 	10.3 %
Financial Crime Management Technology Revenues
The following table presents key drivers for our Financial Crime Management
Technology business:
As of or
Three Months Ended March 31,
2025 	2024
(in millions)
ARR and Quarterly annualized SaaS
revenues 	$ 	295 $ 	243
Financial Crime Management Technology revenues increased in the first
quarter of 2025 compared with the same period in 2024 primarily due to
higher subscription revenues from new sales and price increases to existing
clients, and revenue from new clients.
Regulatory Technology Revenues
The following table presents key drivers for our Regulatory Technology
business:
As of or
Three Months Ended March 31,
2025 	2024
(in millions)
ARR 	$ 	362 $ 	328
Quarterly annualized SaaS revenues 	197 	168
Regulatory Technology revenues increased in the first quarter of 2025
compared with the same period in 2024 primarily due to increased
subscriptions from our AxiomSL and Surveillance product offerings.
Capital Markets Technology Revenues
The following table presents key drivers for our Capital Markets Technology
business:
As of or
Three Months Ended March 31,
2025 	2024
(in millions)
ARR 	$ 	893 $ 	821
Quarterly annualized SaaS revenues 	139 	110
29

-- 34 of 155 --

Capital Markets Technology revenues increased in the first quarter of 2025
compared with the same period in 2024. The increase was primarily due to
higher subscription revenues in our trade management services and market
technology businesses as well as higher market technology and Calypso
professional services revenues.
Market Services
The following table presents revenues from our Market Services segment:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Market Services 	$ 	1,134 $ 	794 	42.8 %
Transaction-based expenses:
Transaction rebates 	(579) 	(481) 	20.3 %
Brokerage, clearance and
exchange fees 	(274) 	(76) 	260.0 %
Total Market Services, net 	$ 	281 $ 	237 	18.7 %
The following table presents net revenues by product from our Market
Services segment:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
U.S. Equity Derivative Trading $ 	108 $ 	91 	18.2 %
Cash Equity Trading 	121 	100 	21.0 %
U.S. Tape plans 	33 	28 	17.8 %
Other 	19 	18 	14.6 %
Total Market Services, net 	$ 	281 $ 	237 	18.7 %
In the preceding table, Other includes Nordic fixed income trading & clearing,
Nordic derivatives and Canadian cash equities trading.
U.S. Equity Derivative Trading
The following tables present total revenues, transaction-based expenses, and
total revenues less transaction-based expenses as well as key drivers from our
U.S. Equity Derivative Trading business:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
U.S. Equity Derivative Trading
Revenues 	$ 	403 $ 	323 	24.4 %
Section 31 fees 	32 	11 	190.6 %
Transaction-based expenses:
Transaction rebates 	(293) 	(231) 	26.7 %
Section 31 fees 	(32) 	(11) 	190.6 %
Brokerage and clearance fees 	(2) 	(1) 	81.7 %
U.S. Equity Derivative Trading
Revenues, net 	$ 	108 $ 	91 	18.2 %
Section 31 fees are recorded as U.S. equity derivative and U.S. cash equity
trading revenues with a corresponding
amount recorded in transaction-based expenses. We are assessed these fees
from the SEC and pass them through to our customers in the form of
incremental fees. Pass-through fees can increase or decrease due to rate
changes by the SEC, our percentage of the overall industry volumes processed
on our systems, and differences in actual dollar value traded. Section 31 fees
increased in the first quarter of 2025 compared with the same period in 2024
primarily due to higher average SEC fee rates. Since the amount recorded in
revenues is equal to the amount recorded as Section 31 fees, there is no impact
on our net revenues.
Three Months Ended March 31,
2025 	2024
Total industry average daily volume (in
millions) 	53.6 	43.3
Nasdaq PHLX matched market share 	9.1 % 	10.3 %
The Nasdaq Options Market matched market
share 	5.1 % 	5.4 %
Nasdaq BX Options matched market share 	1.7 % 	2.2 %
Nasdaq ISE Options matched market share 	6.8 % 	6.3 %
Nasdaq GEMX Options matched market share 	3.6 % 	2.5 %
Nasdaq MRX Options matched market share 	2.8 % 	2.5 %
Total matched market share executed on
Nasdaq’s exchanges 	29.1 % 	29.2 %
U.S. equity derivative trading revenues and U.S. equity derivative trading
revenues, net increased in the first quarter of 2025 compared with the same
period in 2024 primarily due to higher industry trading volumes, partially
offset by lower overall matched market share executed on Nasdaq’s
exchanges. The increase in U.S. equity derivative trading revenues in the first
quarter of 2025 also reflects a higher gross capture rate. The increase in U.S.
equity derivative trading revenues, net was partially offset by a lower capture
rate driven by higher rebate capture rate.
Transaction rebates, in which we credit a portion of the execution charge to
the market participant, increased in the first quarter of 2025 compared with the
same period in 2024 primarily due to higher industry trading volumes and
higher rebate capture rate, partially offset by lower overall U.S. matched
market share executed on Nasdaq’s exchanges.
30

-- 35 of 155 --

Cash Equity Trading Revenues
The following tables present total revenues, transaction-based expenses, and
total revenues less transaction-based expenses as well as key drivers and other
metrics from our Cash Equity Trading business:
Three Months Ended March 31,
Percentage Change	2025 	2024
(in millions)
Cash Equity Trading
Revenues 	$ 	407 $ 	350 	16.2 %
Section 31 fees 	234 	59 	294.4 %
Transaction-based expenses:
Transaction rebates 	(280) 	(245) 	14.2 %
Section 31 fees 	(234) 	(59) 	294.4 %
Brokerage and clearance
fees 	(6) 	(5) 	37.2 %
Cash equity trading revenues,
net 	$ 	121 $ 	100 	21.0 %
See the discussion above for an explanation of Section 31 fees for the first
quarter of 2025 as compared with the same period in 2024.
Three Months Ended March 31,
2025 	2024
Total U.S.-listed securities
Total industry average daily share volume (in
billions) 	15.7 	11.8
Matched share volume (in billions) 	137.6 	116.7
The Nasdaq Stock Market matched market
share 	14.2 % 	15.7 %
Nasdaq BX matched market share 	0.3 % 	0.4 %
Nasdaq PSX matched market share 	0.1 % 	0.2 %
Total matched market share executed on
Nasdaq’s exchanges 	14.6 % 	16.3 %
Market share reported to the FINRA/Nasdaq
Trade Reporting Facility 	48.1 % 	41.4 %
Total market share 	62.7 % 	57.7 %
Nasdaq Nordic and Nasdaq Baltic securities
Average daily number of equity trades
executed on Nasdaq’s exchanges 	789,103 	666,408
Total average daily value of shares traded (in
billions) 	$ 	5.4 	$ 	4.7
Total market share executed on Nasdaq’s
exchanges 	69.9 % 	71.7 %
Cash equity trading revenues and cash equity trading revenues, net increased
in the first quarter of 2025 compared with the same period in 2024 primarily
due to higher U.S. industry trading volumes, partially offset by lower overall
U.S. matched market share executed on Nasdaq's exchanges.
Transaction rebates increased in the first quarter of 2025 compared with the
same period in 2024 primarily due to higher U.S. industry volumes, partially
offset by lower overall U.S. matched market share executed on Nasdaq’s
exchanges and lower rebate capture rates. For The Nasdaq Stock Market and
Nasdaq PSX, we credit a portion of the per share execution charge to the
market participant that provides the liquidity, and for Nasdaq BX, we credit a
portion of the per share execution charge to the market participant that takes
the liquidity.
U.S. Tape Plans
The following table presents revenues from our U.S. Tape plans business:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
U.S. Tape plans 	$ 	33 $ 	28 	17.8 %
U.S. Tape plans revenues increased in the first quarter of 2025 compared with
the same period in 2024 primarily due to higher one-time industry-wide
adjustments and usage volume.
Other
Other includes Nordic fixed income trading and clearing, Nordic derivatives
and Canadian cash equities trading. The following table presents revenues
from our Other business:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Other 	$ 	19 $ 	18 	14.6 %
In the preceding table, Other is presented net of Canadian cash equity
transaction rebates of $6 million and $5 million for the three months ended
March 31, 2025 and 2024, respectively.
Other revenues increased slightly in the first quarter of 2025 as compared with
the same period in 2024 due to an increase in Nordic fixed income trading and
clearing and Nordic derivatives revenues.
Other Revenues
For the three months ended March 31, 2025 and 2024, Other revenues include
revenues related to our Nordic power trading and clearing business. In January
2025, we entered into an agreement to transfer existing open positions in our
Nordic power derivatives trading and clearing business to a European
exchange. The completion of this transaction is subject to customary
regulatory approvals.
31

-- 36 of 155 --

EXPENSES
Operating Expenses
The following table presents our operating expenses:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Compensation and benefits $ 	329 $ 	340 	(3.5)%
Professional and contract
services 	36 	34 	8.3 %
Technology and
communication
infrastructure 	77 	67 	15.9 %
Occupancy 	28 	28 	(0.1)%
General, administrative and
other 	6 	28 	(81.3)%
Marketing and advertising 	14 	11 	25.8 %
Depreciation and
amortization 	156 	155 	0.7 %
Regulatory 	15 	9 	55.1 %
Merger and strategic
initiatives 	24 	9 	160.1 %
Restructuring charges 	5 	26 	(79.6)%
Total operating expenses $ 	690 $ 	707 	(2.5)%
The decrease in compensation and benefits expense in the first quarter of 2025
compared with the same period in 2024 was primarily driven by a pre-tax
charge of $23 million in the first quarter of 2024 resulting from the
finalization of the termination of our pension plan, partially offset by higher
incentive compensation.
Headcount, including employees of non-wholly owned consolidated
subsidiaries, increased to 9,377 employees as of March 31, 2025 from 8,568
employees as of March 31, 2024, primarily due to an increase in our Financial
Technology segment as we support revenue growth and innovation.
Professional and contract services expense increased in the first quarter of
2025 compared with the same period in 2024 primarily due to certain legal fee
accruals.
Technology and communication infrastructure expense increased in the first
quarter of 2025 compared with the same period in 2024 primarily due to
increased investment in technology, particularly our cloud initiatives and
software licensing.
Occupancy expense remained flat in the first quarter of 2025 compared with
the same period in 2024.
General, administrative and other expense decreased in the first quarter of
2025 compared with the same period in 2024 primarily due to a gain on
extinguishment of debt. See Note 7, “Debt Obligations,” to the condensed
consolidated financial statements for further discussion.
Marketing and advertising expense increased in the first quarter of 2025
compared with the same period in 2024 primarily due to higher client
incentive spending resulting from increased IPO activity.
Depreciation and amortization expense remained relatively flat in the first
quarter of 2025 compared with the same period in 2024.
Regulatory expense increased in the first quarter of 2025 compared with the
same period in 2024 primarily due to a change in classification of costs related
to the CAT from general, administrative and other expense to regulatory
expense, beginning in the fourth quarter of 2024, as well as a slight increase in
the CAT operating fees.
We have pursued various strategic initiatives and completed acquisitions and
divestitures in recent years, which have resulted in expenses which would not
have otherwise been incurred. These expenses generally include integration
costs, as well as legal, due diligence and other third-party transaction costs and
vary based on the size and frequency of the activities described above. For the
first quarter of 2025, these amounts are primarily driven by the timing of
recognition associated with the transfer of open positions in our Nordic power
derivatives trading and clearing business, Adenza integration costs and other
strategic initiative costs. For the first quarter of 2024, these costs were
primarily related to the integration of Adenza.
Restructuring charges decreased in the first quarter of 2025 compared with the
same period in 2024 primarily due to the completion of our divisional
realignment program in September 2024.
We further expanded our Adenza restructuring program in the fourth quarter
of 2024 to accelerate our momentum. In connection with this program, we
expect to incur approximately $140 million in pre-tax charges. Actions taken
as part of this program are expected to be completed by the end of 2025, while
certain costs may be recognized in the first half of 2026. We expect to achieve
benefits primarily in the form of expense synergies with annual cost savings of
$140 million by the end of 2025, inclusive of the $80 million of net expense
synergies related to the AxiomSL and Calypso acquisition. We have actioned
over $100 million net expense synergies through March 31, 2025.
For further discussion related to both programs described above, see Note 18,
“Restructuring Charges,” to the condensed consolidated financial statements.
32

-- 37 of 155 --

Non-Operating Income and Expenses
The following table presents our non-operating income and expenses:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Interest income 	$ 	11 $ 	6 	85.1%
Interest expense 	(96) 	(108) 	(10.8)%
Net interest expense 	(85) 	(102) 	(16.5)%
Other income (loss) 	(1) 	1 	(172.2)%
Net income from
unconsolidated investees 	27 	3 	618.1 %
Total non-operating expense $ 	(59) $ 	(98) 	(39.7)%
The following table presents our interest expense:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
(in millions)
Interest expense on debt 	$ 	92 $ 	103 	(10.3)%
Accretion of debt issuance
costs and debt discount 	3 	4 	(29.0)%
Other fees 	1 	1 	7.4 %
Interest expense 	$ 	96 $ 	108 	(10.8)%
Interest income increased in the first quarter of 2025 compared with the same
period in 2024 primarily due to a higher average cash balance.
Interest expense decreased in the first quarter of 2025 compared with the same
period in 2024 primarily due to lower outstanding debt following our partial
repurchases of several series of outstanding senior unsecured notes. See Note
7, “Debt Obligations,” to the condensed consolidated financial statements for
further discussion.
Net income from unconsolidated investees increased in the first quarter of
2025 compared with the same period in 2024 due to higher income recognized
from our equity method investment in OCC driven by higher industry
volumes. See “Equity Method Investments,” of Note 5, “Investments,” to the
condensed consolidated financial statements for further discussion.
Tax Matters
The following table presents our income tax provision and effective tax rate:
Three Months Ended March 31, 	Percentage
Change	2025 	2024
($ in millions)
Income tax provision 	$ 	93 	$ 	79 	18.7 %
Effective tax rate 	19.1 % 	25.3 %
For further discussion of our tax matters, see Note 15, “Income Taxes,” to the
condensed consolidated financial statements.
NON-GAAP FINANCIAL MEASURES
In addition to disclosing results determined in accordance with U.S. GAAP,
we also provide non-GAAP net income attributable to Nasdaq and non-GAAP
diluted earnings per share in this Quarterly Report on Form 10-Q.
Management uses this non-GAAP information internally, along with U.S.
GAAP information, in evaluating our performance and in making financial
and operational decisions. We believe our presentation of these measures
provides investors with greater transparency and supplemental data relating to
our financial condition and results of operations. In addition, we believe the
presentation of these measures is useful to investors for period-to-period
comparisons of our ongoing operating performance.
These measures are not in accordance with, or an alternative to, U.S. GAAP,
and may be different from non-GAAP measures used by other companies. In
addition, other companies, including companies in our industry, may calculate
such measures differently, which reduces their usefulness as comparative
measures. Investors should not rely on any single financial measure when
evaluating our business. This non-GAAP information should be considered as
supplemental in nature and is not meant as a substitute for our operating
results in accordance with U.S. GAAP. We recommend investors review the
U.S. GAAP financial measures included in this Quarterly Report on Form 10-
Q, including our condensed consolidated financial statements and the notes
thereto. When viewed in conjunction with our U.S. GAAP results and the
accompanying reconciliation, we believe these non-GAAP measures provide
greater transparency and a more complete understanding of factors affecting
our business than U.S. GAAP measures alone.
We understand that analysts and investors regularly rely on non-GAAP
financial measures, such as non-GAAP net income attributable to Nasdaq and
non-GAAP diluted earnings per share, to assess operating performance. We
use non-GAAP net income attributable to Nasdaq and non-GAAP diluted
earnings per share because they highlight trends more clearly in our business
that may not otherwise be apparent when relying solely on U.S. GAAP
financial measures, since these measures eliminate from our results specific
financial items that have less bearing on our ongoing operating performance.
33

-- 38 of 155 --

The following table presents reconciliations between U.S. GAAP net income
attributable to Nasdaq and diluted earnings per share and non-GAAP net
income attributable to Nasdaq and diluted earnings per share:
Three Months Ended March 31,
2025 	2024
(in millions, except per share amounts)
U.S. GAAP net income attributable to
Nasdaq 	$ 	395 	$ 	234
Non-GAAP adjustments:
Amortization expense of acquired intangible
assets 	122 	123
Merger and strategic initiatives expense 	24 	9
Restructuring charges 	5 	26
Gain on extinguishment of debt 	(19) 	—
Net income from unconsolidated investees 	(27) 	(3)
Legal and regulatory matters 	2 	2
Pension settlement charge 	— 	23
Other 	1 	—
Total non-GAAP adjustments 	$ 	108 	$ 	180
Total non-GAAP tax adjustments 	(47) 	(47)
Total non-GAAP adjustments, net of tax $ 	61 	$ 	133
Non-GAAP net income attributable to
Nasdaq 	$ 	456 	$ 	367
U.S. GAAP effective tax rate 	19.1 % 	25.3 %
Total adjustments from non-GAAP tax rate 	4.4 % 	0.3 %
Non-GAAP effective tax rate 	23.5 % 	25.6 %
Weighted-average common shares
outstanding for diluted earnings per share 	580.0 	578.9
U.S. GAAP diluted earnings per share 	$ 	0.68 	$ 	0.40
Total adjustments from non-GAAP net
income 	0.11 	0.23
Non-GAAP diluted earnings per share 	$ 	0.79 	$ 	0.63
We believe that excluding the following items from the non-GAAP net income
attributable to Nasdaq provides a more meaningful analysis of Nasdaq’s
ongoing operating performance and comparisons in Nasdaq’s performance
between periods:
• Amortization expense of acquired intangible assets: We amortize intangible
assets acquired in connection with various acquisitions. Intangible asset
amortization expense can vary from period to period due to episodic
acquisitions completed, rather than from our ongoing business operations.
As such, if intangible asset amortization is included in performance
measures, it is more difficult to assess the day-to-day operating performance
of the businesses and the relative operating performance of the businesses
between periods.
• Merger and strategic initiatives expense: We have pursued various strategic
initiatives and completed acquisitions and divestitures in recent years that
have resulted in expenses which would not have otherwise been incurred.
The frequency and the amount of such expenses vary significantly based on
the size, timing and complexity of the transaction. These expenses primarily
include integration costs, as well as legal, due diligence and other third-
party transaction costs. For the three months ended March 31, 2025, these
amounts are primarily driven by the timing of recognition associated with
the transfer of open positions in our Nordic power derivatives trading and
clearing business, Adenza integration costs and other strategic initiative
costs. For the three months ended March 31, 2024, these costs were
primarily related to the integration of Adenza.
• Restructuring charges: In the fourth quarter of 2023, following the closing
of the Adenza acquisition, our management approved, committed to and
initiated a restructuring program, to optimize our efficiencies as a combined
organization. We further expanded this restructuring program in the fourth
quarter of 2024 to accelerate our momentum. In addition, we completed
divisional realignment program in September 2024. See Note 18,
“Restructuring Charges,” to the condensed consolidated financial statements
for further discussion of these programs.
• Net income from unconsolidated investees: We exclude our share of the
earnings and losses of our equity method investments. This provides a more
meaningful analysis of Nasdaq’s ongoing operating performance or
comparisons in Nasdaq’s performance between periods. See “Equity
Method Investments,” of Note 5, “Investments,” to the condensed
consolidated financial statements for further discussion.
• Other items: We have excluded certain other charges or gains, including
certain tax items, that are the result of other non-comparable events to
measure operating performance. We believe the exclusion of such amounts
allows management and investors to better understand the ongoing financial
results of Nasdaq. Other significant items include:
◦ Gain on extinguishment of debt: For the three months ended March 31,
2025, this includes a gain on extinguishment of debt, which is recorded
under general, administrative and other expense in the Condensed
34

-- 39 of 155 --

Consolidated Statements of Income. See Note 7, “Debt Obligations,” to
the condensed consolidated financial statements for further discussion.
◦ Legal and regulatory matters: For the three months ended March 31,
2025 and 2024, this includes accruals relating to certain legal matters,
which are recorded in professional and contract services in the Condensed
Consolidated Statements of Income.
◦ Pension settlement charge: For the three months ended March 31, 2024,
we recorded a pre-tax charge as a result of settling our U.S. pension plan.
The plan was terminated and partially settled in 2023, with final
settlement occurring during the first quarter of 2024. The pre-tax charge is
recorded in compensation and benefits expense in the Condensed
Consolidated Statements of Income.
• Significant tax items: The non-GAAP adjustment to the income tax
provision for all periods primarily includes the tax impact of each non-
GAAP adjustment. For the three months ended March 31, 2025, this also
includes the release of the prior year's reserves following a favorable audit
settlement.
LIQUIDITY AND CAPITAL RESOURCES
Historically, we have funded our operating activities and met our
commitments through cash generated by operations, augmented by the
periodic issuance of debt. Currently, our cost and availability of funding
remain healthy. We continue to prudently assess our capital deployment
strategy through balancing internal investments, debt repayments, and
shareholder return activity, including dividends and share repurchases, and
potential acquisitions.
We expect that our current cash and cash equivalents combined with cash
flows provided by operating activities, supplemented with our borrowing
capacity and access to additional financing, including our revolving credit
facility and our commercial paper program, provides us additional flexibility
to meet our ongoing obligations and the capital deployment strategic actions
described above, while allowing us to invest in activities and product
development that support the long-term growth of our operations.
Principal factors that could affect the availability of our internally-generated
funds include:
• deterioration of our revenues in any of our business segments;
• changes in regulatory and working capital requirements; and
• an increase in our expenses.
Principal factors that could affect our ability to obtain cash from external
sources include:
• operating covenants contained in our credit facilities that limit our total
borrowing capacity;
• credit rating downgrades, which could limit our access to additional debt;
• a significant decrease in the market price of our common stock; and
• volatility or disruption in the public debt and equity markets.
The following table summarizes selected measures of our liquidity and capital
resources:
March 31, 2025 	December 31, 2024
(in millions)
Working capital 	$ 	(153) $ 	(116)
Cash and cash equivalents 	690 	592
Financial investments 	201 	184
Working Capital
The decrease in working capital is due to current liabilities increasing more
than current assets between December 31, 2024, and March 31, 2025. Higher
deferred revenue from billing annual listing revenue in the first quarter of
2025 and higher accrued tax liability, due to the timing of payments,
contributed to the increase in current liabilities, partially offset by a decrease
in accrued personnel costs after payment of annual incentive compensation in
the first quarter of 2025, and lower Section 31 fees payable to the SEC.
Current assets increased mainly due to higher cash and cash equivalents.
Cash and Cash Equivalents
Cash and cash equivalents includes all non-restricted cash in banks and highly
liquid investments with original maturities of 90 days or less at the time of
purchase. The balance retained in cash and cash equivalents is a function of
anticipated or possible short-term cash needs, prevailing interest rates, our
investment policy, and alternative investment choices. As of March 31, 2025,
our cash and cash equivalents of $690 million were primarily invested in
money market funds, bank deposits, commercial paper, repurchase agreements
and bank deposits.
Repatriation of Cash
Our cash and cash equivalents held outside of the U.S. in various foreign
subsidiaries totaled $297 million as of March 31, 2025 and $181 million as of
December 31, 2024. The remaining balance held in the U.S. totaled $393
million as of March 31, 2025 and $411 million as of December 31, 2024.
Cash Flow Analysis
The following table summarizes the changes in cash flows:
Three Months Ended March 31,
2025 	2024
Net cash provided by (used in): 	(in millions)
Operating activities 	$ 	663 $ 	530
Investing activities 	(258) 	(232)
Financing activities 	(1,083) 	(1,875)
35

-- 40 of 155 --

Net Cash Provided by Operating Activities
Net cash provided by operating activities primarily consists of net income
adjusted for certain non-cash items, including, but not limited to, depreciation
and amortization expense, expense associated with share-based compensation,
deferred income taxes and the effects of changes in working capital. Changes
in working capital include changes in accounts receivable and deferred
revenue which are impacted by the timing of customer billings and related
collections from our customers; accounts payable and accrued expenses due to
timing of payments; accrued personnel costs, which are impacted by employee
performance targets and the timing of payments related to employee bonus
incentives; and Section 31 fees payable to the SEC, which is impacted by the
changes in SEC fee rates and the timing of collections from customers and
payments to the SEC.
Net cash provided by operating activities increased $133 million for the three
months ended March 31, 2025 compared with the same period in 2024. The
increase was primarily driven by an increase in net income, partially offset by
a decrease in working capital.
Net Cash Used in Investing Activities
Net cash used in investing activities for the three months ended March 31,
2025 primarily relates to net purchases of investments related to default funds
and margin deposits of $204 million and purchases of property and equipment
of $49 million.
Net cash used in investing activities for the three months ended March 31,
2024 primarily related to net purchases of investments related to default funds
and margin deposits of $184 million, purchases of property and equipment of
$39 million and other investing activities of $13 million, partially offset by
proceeds from the sale and redemption of trading securities, net of $4 million.
Net Cash Used in Financing Activities
Net cash used in financing activities for the three months ended March 31,
2025 primarily relates to a decrease in default funds and margin deposits of
$549 million, partial repayment of our 2028, 2034 and 2052 Notes for $257
million, dividend payments to our shareholders of $138 million, repurchases
of common stock of $115 million and payments related to employee shares
withheld for taxes $25 million.
Net cash used in financing activities for the three months ended March 31,
2024 related to a decrease in default funds and margin deposits of $1,317
million, repayment of the 2023 Term Loan of $340 million, dividend
payments to our shareholders of $127 million, repayments of our commercial
paper, net of $67 million and payments related to employee shares withheld
for taxes $24 million.
See Note 7, “Debt Obligations,” to the condensed consolidated financial
statements for further discussion of our debt obligations.
See “Share Repurchase Program,” and “Cash Dividends on Common Stock,”
of Note 10, “Nasdaq Stockholders’ Equity,” to the condensed consolidated
financial statements for further discussion of our share repurchase program
and cash dividends declared and paid on our common stock.
Financial Investments
Our financial investments totaled $201 million as of March 31, 2025 and $184
million as of December 31, 2024. Of these securities, $186 million as of
March 31, 2025 and $171 million as of December 31, 2024 are assets
primarily utilized to meet regulatory capital requirements, mainly for our
clearing operations at Nasdaq Clearing. See Note 5, “Investments,” to the
condensed consolidated financial statements for further discussion.
Regulatory Capital Requirements
Clearing Operations Regulatory Capital Requirements
We are required to maintain minimum levels of regulatory capital for the
clearing operations of Nasdaq Clearing. The level of regulatory capital
required to be maintained is dependent upon many factors, including market
conditions and creditworthiness of the counterparty. As of March 31, 2025,
our required regulatory capital of $140 million was primarily comprised of
highly rated European government debt securities that are included in
financial investments in the Condensed Consolidated Balance Sheets.
Broker-Dealer Net Capital Requirements
Our broker-dealer subsidiaries, Nasdaq Execution Services, NFSTX, LLC,
and Nasdaq Capital Markets Advisory, are subject to regulatory requirements
intended to ensure their general financial soundness and liquidity. These
requirements obligate these subsidiaries to comply with minimum net capital
requirements. As of March 31, 2025, the combined required minimum net
capital totaled $1 million and the combined excess capital totaled $23 million,
substantially all of which is held in cash and cash equivalents in the
Condensed Consolidated Balance Sheets. The required minimum net capital is
included in restricted cash and cash equivalents in the Condensed
Consolidated Balance Sheets.
36

-- 41 of 155 --

Nordic and Baltic Exchange Regulatory Capital Requirements
The entities that operate trading venues in the Nordic and Baltic countries are
each subject to local regulations and are required to maintain regulatory
capital intended to ensure their general financial soundness and liquidity. As
of March 31, 2025, our required regulatory capital of $37 million was
primarily invested in European government bills that are included in financial
investments in the Condensed Consolidated Balance Sheets and cash, which is
included in restricted cash and cash equivalents in the Condensed
Consolidated Balance Sheets.
Other Capital Requirements
We operate several other businesses which are subject to local regulation and
are required to maintain certain levels of regulatory capital. As of March 31,
2025, other required regulatory capital of $12 million, primarily related to
Nasdaq Central Securities Depository, was primarily invested in European
government debt securities that are included in financial investments in the
Condensed Consolidated Balance Sheets.
Equity and dividends
Share Repurchase Program
See “Share Repurchase Program,” of Note 10, “Nasdaq Stockholders’ Equity,”
to the condensed consolidated financial statements for further discussion of
our share repurchase program.
Cash Dividends on Common Stock
The following table presents our quarterly cash dividends paid per common
share on our outstanding common stock:
2025 	2024
First quarter 	$ 	0.24 $ 	0.22
See “Cash Dividends on Common Stock,” of Note 10, “Nasdaq Stockholders’
Equity,” to the condensed consolidated financial statements for further
discussion of the dividends.
Debt Obligations
Our debt obligations, by contractual maturity, at March 31, 2025 are as follows (in U.S. Dollar millions):
 Euro Notes  U.S. Notes
37

-- 42 of 155 --

In the first quarter of 2025, we repurchased an aggregate principal amount of
$279 million of our 2028, 2034 and 2052 Notes, for a net purchase price of
$257 million, excluding accrued interest.
For the three months ended March 31, 2025, the weighted average interest rate
on our debt obligations was approximately 3.90%. This rate can fluctuate
based on changes in interest rates for our variable rate debts, changes in
foreign currency exchange rates and changes in the amount and duration of
outstanding debt. In addition to the 2022 Revolving Credit Facility, we also
have other credit facilities primarily to support our Nasdaq Clearing
operations in Europe, as well as to provide a cash pool credit line. These
European credit facilities, which are available in multiple currencies, totaled
$191 million as of March 31, 2025 and $174 million as of December 31, 2024
in available liquidity, none of which was utilized.
As of March 31, 2025, we were in compliance with the covenants of all of our
debt obligations.
See Note 7, “Debt Obligations,” to the condensed consolidated financial
statements for further discussion of our debt obligations.
CONTRACTUAL OBLIGATIONS AND CONTINGENT
COMMITMENTS
Nasdaq has contractual obligations to make future payments under debt
obligations by contract maturity, operating lease payments, and other
obligations. The following table summarizes material cash requirements for
known contractual and other obligations as of March 31, 2025, and the
estimated timing thereof.
Payments Due by Period
(in millions) 	Total 	<1 year 	1-3 years 	3-5 years 	5+ years
Debt obligation by
contractual maturity 	$ 14,797 $ 	750 $ 1,149 $ 2,736 $ 10,162
Operating lease obligations 	601 	73 	140 	127 	261
Purchase obligations 	1,494 	133 	205 	238 	918
Total 	$ 16,892 $ 	956 $ 1,494 $ 3,101 $ 11,341
In the table above:
• Debt obligations by contractual maturity include both principal and interest
obligations. For our Euro Notes, interest is calculated on an actual basis
while all other debt obligations were primarily calculated on a 365-day basis
at the contractual fixed rate multiplied by the aggregate principal amount as
of March 31, 2025. See Note 7, “Debt Obligations,” to the condensed
consolidated financial statements for further discussion.
• Operating lease obligations represent our undiscounted operating lease
liabilities as of March 31, 2025, as well as legally binding minimum lease
payments for leases signed but not yet commenced. See Note 14, “Leases,”
to the condensed consolidated financial statements for further discussion of
our leases.
• Purchase obligations primarily represent minimum outstanding obligations
due under software license agreements. The balance as of March 31, 2025 is
primarily comprised of our multi-year Amazon Web Services partnership
contract, which we expanded and extended in the first quarter of 2025. This
contract will benefit both our Financial Technology and Market Services
segments, including their modernization. The expansion of this contract is
not expected to increase our cloud expense compared to our expectation
over the short term or the life of the contract, and preserves flexibility
beyond our forecast.
OFF-BALANCE SHEET ARRANGEMENTS
For discussion of off-balance sheet arrangements see:
• Note 13, “Clearing Operations,” to the condensed consolidated financial
statements for further discussion of our non-cash default fund contributions
and margin deposits received for clearing operations; and
• Note 16, “Commitments, Contingencies and Guarantees,” to the condensed
consolidated financial statements for further discussion of:
◦ Guarantees issued and credit facilities available;
◦ Other guarantees; and
◦ Routing brokerage activities.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a result of our operating, investing and financing activities, we are exposed
to market risks such as interest rate risk and foreign currency exchange rate
risk. We are also exposed to credit risk as a result of our normal business
activities.
We have implemented policies and procedures to measure, manage, monitor
and report risk exposures, which are reviewed regularly by management and
the board of directors. We identify risk exposures and monitor and manage
such risks on a daily basis.
We perform sensitivity analyses to determine the effects of market risk
exposures. We may use derivative instruments solely to hedge financial risks
related to our financial positions or risks that are incurred during the normal
course of business. We do not use derivative instruments for speculative
purposes.
Interest Rate Risk
We are subject to the risk of fluctuating interest rates in the normal course of
business. Our exposure to market risk for changes in interest rates relates
primarily to our financial investments and debt obligations, which are
discussed below. Substantially all of our debt obligations are fixed-rate
obligations. We may enter into transactions that expose us to interest rate risk,
for which we may utilize interest rate derivatives agreements to manage that
risk.
38

-- 43 of 155 --

Financial Investments
As of March 31, 2025, our investment portfolio was primarily comprised of
highly rated European government debt securities, which pay a fixed rate of
interest. These securities are subject to interest rate risk and the fair value of
these securities will decrease if market interest rates increase. The impact of
an immediate increase to market interest rates, uniformly, by a hypothetical
100 basis points from levels as of March 31, 2025, would not have a material
impact on our financial statements.
Debt Obligations
As of March 31, 2025, substantially all of our debt obligations are fixed-rate
obligations. Interest rates on certain tranches of notes are subject to adjustment
to the extent our debt rating is downgraded below investment grade, as further
discussed in Note 7, “Debt Obligations,” to the condensed consolidated
financial statements. While changes in interest rates will have no impact on
the interest we pay on fixed-rate obligations, we are exposed to changes in
interest rates as a result of the borrowings under our 2022 Revolving Credit
Facility, as this facility has a variable interest rate. We are also exposed to
changes in interest rates as a result of the amounts outstanding from the sale of
commercial paper under our commercial paper program, which have variable
interest rates. As of March 31, 2025, there were no outstanding borrowings
under our 2022 Revolving Credit Facility or commercial paper program.
Foreign Currency Exchange Rate Risk
We are subject to foreign currency exchange rate risk. Our primary
transactional exposure to foreign currency denominated revenues less
transaction-based expenses and operating income for the three months ended
March 31, 2025 is presented in the following table:
Euro
Swedish
Krona Canadian
Dollar Other Foreign
Currencies 	U.S. Dollar
(in millions, except currency rate)
Three Months Ended March 31, 2025
Average foreign
currency rate to the
U.S. dollar 	1.099 	0.096 	0.733 	# 	N/A
Percentage of
revenues less
transaction-based
expenses 	7.2% 	3.4% 	0.6% 	3.5% 	85.3%
Percentage of
operating income 	10.9% 	(1.6)% 	(6.3)% 	(8.3)% 	105.3%
Impact of a 10%
adverse currency
fluctuation on
revenues less
transaction-based
expenses 	$(9) 	$(4) 	$(1) 	$(4) 	$—
Impact of a 10%
adverse currency
fluctuation on
operating income 	$(6) 	$(1) 	$(3) 	$(5) 	$—
__________
# Represents multiple foreign currency rates.
N/A Not applicable.
The adverse impacts shown in the preceding table should be viewed
individually by currency and not in aggregate, due to the correlation between
changes in exchange rates for certain currencies. Additionally, the table does
not include the offsetting impact of our hedging programs.
39

-- 44 of 155 --

We may use foreign exchange contracts to hedge a portion of our forecasted
foreign currency denominated revenues and expenses in the normal course of
business. We do not use these contracts for speculative trading purposes. We
hedge these cash flow exposures to reduce the risk that our earnings and cash
flows will be adversely affected by changes in exchange rates. These foreign
exchange contracts are carried at fair value, with maturities that can range up
to 24 months. We record changes in fair value of these cash flow hedges of
foreign currency denominated revenue and expenses in accumulated other
comprehensive loss in the Condensed Consolidated Balance Sheets, until the
forecasted transaction occurs. When the forecasted transaction affects
earnings, we reclassify the related gain or loss on the cash flow hedge to
revenue or operating expenses, as applicable. In the event the underlying
forecasted transaction does not occur, or it becomes probable that it will not
occur, we reclassify the gain or loss on the related cash flow hedge from
accumulated other comprehensive loss to revenue or operating expenses, as
applicable. As of March 31, 2025, the fair value of our derivatives designated
as cash flow hedging instruments are not material.
Our investments in foreign subsidiaries are exposed to volatility in currency
exchange rates through translation of the foreign subsidiaries’ net assets or
equity to U.S. dollars. Substantially all of our foreign subsidiaries operate in
functional currencies other than the U.S. dollar. The financial statements of
these subsidiaries are translated into U.S. dollars for consolidated reporting
using a current rate of exchange, with net gains or losses recorded in
accumulated other comprehensive loss in the Condensed Consolidated
Balance Sheets.
Our primary exposure to net assets in foreign currencies as of March 31, 2025
is presented in the following table:
Net Assets
Impact of a 10% Adverse
Currency Fluctuation
(in millions)
Swedish Krona 	$ 	3,073 $ 	307
British Pound 	147 	15
Norwegian Krone 	137 	14
Canadian Dollar 	130 	13
Australian Dollar 	96 	10
In the table above, Swedish Krona includes goodwill of $2,236 million and
intangible assets, net of $480 million.
Credit Risk
Credit risk is the potential loss due to the default or deterioration in credit
quality of customers or counterparties. We are exposed to credit risk from
third parties, including customers, counterparties and clearing agents. These
parties may default on their obligations to us due to bankruptcy, lack of
liquidity, operational failure or other reasons. We limit our exposure to credit
risk by evaluating the counterparties with which we make investments and
execute agreements. For our investment portfolio, our objective is to invest in
securities to preserve principal while maximizing yields, without significantly
increasing risk. Credit risk associated with
investments is minimized substantially by ensuring that these financial assets
are placed with governments which have investment grade ratings, well-
capitalized financial institutions and other creditworthy counterparties.
Our subsidiary, Nasdaq Execution Services, may be exposed to credit risk due
to the default of trading counterparties in connection with the routing services
it provides for our trading customers. System trades in cash equities routed to
other market centers for members of our cash equity exchanges are routed by
Nasdaq Execution Services for clearing to the NSCC. In this function, Nasdaq
Execution Services is to be neutral by the end of the trading day, but may be
exposed to intraday risk if a trade extends beyond the trading day and into the
next day, thereby leaving Nasdaq Execution Services susceptible to
counterparty risk in the period between accepting the trade and routing it to
the clearinghouse. In this interim period, Nasdaq Execution Services is not
novating like a clearing broker but instead is subject to the short-term risk of
counterparty failure before the clearinghouse enters the transaction. Once the
clearinghouse officially accepts the trade for novation, Nasdaq Execution
Services is legally removed from trade execution risk. However, Nasdaq has
membership obligations to NSCC independent of Nasdaq Execution Services’
arrangements.
Pursuant to the rules of the NSCC and Nasdaq Execution Services’ clearing
agreement, Nasdaq Execution Services is liable for any losses incurred due to
a counterparty or a clearing agent’s failure to satisfy its contractual
obligations, either by making payment or delivering securities. Adverse
movements in the prices of securities that are subject to these transactions can
increase our credit risk. However, we believe that the risk of material loss is
limited, as Nasdaq Execution Services’ customers are not permitted to trade
on margin and NSCC rules limit counterparty risk on self-cleared transactions
by establishing credit limits and capital deposit requirements for all brokers
that clear with NSCC. Historically, Nasdaq Execution Services has never
incurred a liability due to a customer’s failure to satisfy its contractual
obligations as counterparty to a system trade. Credit difficulties or insolvency,
or the perceived possibility of credit difficulties or insolvency, of one or more
larger or visible market participants could also result in market-wide credit
difficulties or other market disruptions.
We have credit risk related to transaction and subscription-based revenues that
are billed to customers on a monthly or quarterly basis, in arrears. Our
potential exposure to credit losses on these transactions is represented by the
receivable balances in the Condensed Consolidated Balance Sheets. We
review and evaluate changes in the status of our counterparties’
creditworthiness. Credit losses such as those described above could adversely
affect our consolidated financial position and results of operations.
40

-- 45 of 155 --

We also are exposed to credit risk through our clearing operations with
Nasdaq Clearing. See Note 13, “Clearing Operations,” to the condensed
consolidated financial statements for further discussion. Our clearinghouse
holds material amounts of clearing member cash deposits, which are held or
invested primarily to provide security of capital while minimizing credit,
market and liquidity risks. While we seek to achieve a reasonable rate of
return, we are primarily concerned with preservation of capital and managing
the risks associated with these deposits. As the clearinghouse may remit to the
members interest earned at prevailing market rates, less a spread, this could
include negative or reduced yield due to market conditions. The following is a
summary of the risks associated with these deposits and how these risks are
mitigated.
• Credit Risk: When the clearinghouse has the ability to hold cash collateral at
a central bank, the clearinghouse utilizes its access to the central bank
system to minimize credit risk exposures. When funds are not held at a
central bank, we seek to substantially mitigate credit risk by ensuring that
investments are primarily placed in large, highly rated financial institutions,
highly rated government debt instruments and other creditworthy
counterparties.
• Liquidity Risk: Liquidity risk is the risk a clearinghouse may not be able to
meet its payment obligations in the right currency, in the right place and the
right time. To mitigate this risk, the clearinghouse monitors liquidity
requirements closely and maintains funds and assets in a manner which
minimizes the risk of loss or delay in the access by the clearinghouse to
such funds and assets. For example, holding funds with a central bank
where possible or investing in highly liquid government debt instruments
serves to reduce liquidity risks.
• Interest Rate Risk: Interest rate risk is the risk that interest rates rise causing
the value of purchased securities to decline. If we were required to sell
securities prior to maturity, and interest rates had risen, the sale of the
securities might be made at a loss relative to the latest market price. Our
clearinghouse seeks to manage this risk by making short term investments
of members’ cash deposits. In addition, the clearinghouse investment
guidelines allow for direct purchases or repurchase agreements with short
dated maturities of high quality sovereign debt (for example, European
government and U.S. Treasury securities), central bank certificates and
multilateral development bank debt instruments.
• Security Issuer Risk: Security issuer risk is the risk that an issuer of a
security defaults on its payment when the security matures. This risk is
mitigated by limiting allowable investments and collateral under reverse
repurchase agreements to high quality sovereign, government agency or
multilateral development bank debt instruments.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Nasdaq’s management, with the participation of Nasdaq’s Chief Executive
Officer, and Executive Vice President and Chief Financial Officer, has
evaluated the effectiveness of Nasdaq’s disclosure controls and procedures (as
defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) as of
the end of the period covered by this report. Based upon that evaluation,
Nasdaq’s Chief Executive Officer and Executive Vice President and Chief
Financial Officer, have concluded that, as of the end of such period, Nasdaq’s
disclosure controls and procedures are effective.
Changes in Internal Control Over Financial Reporting
There have been no changes in Nasdaq’s internal control over financial
reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the
Exchange Act) that occurred during the quarter ended March 31, 2025 that
have materially affected, or are reasonably likely to materially affect, Nasdaq’s
internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
See “Legal and Regulatory Matters” of Note 16, “Commitments,
Contingencies and Guarantees,” to the condensed consolidated financial
statements for a description of our legal proceedings, if any.
Item 1A. Risk Factors
In addition to the other information set forth in this Quarterly Report on Form
10-Q, you should carefully consider the factors discussed under “Risk
Factors” in our most recent Form 10-K. These risks could materially and
adversely affect our business, financial condition and results of operations.
These risks and uncertainties are not the only ones facing us. Additional risks
and uncertainties not presently known to us or that we currently believe to be
immaterial may also adversely affect our business.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
Share Repurchase Program
See “Share Repurchase Program,” of Note 10, “Nasdaq Stockholders’ Equity,”
to the condensed consolidated financial statements for further discussion of
our share repurchase program.
41

-- 46 of 155 --

Purchases of Equity Securities by the Issuer and Affiliated Purchasers
The table below represents repurchases made by or on behalf of us or any
“affiliated purchaser” of our common stock during the fiscal quarter ended
March 31, 2025:
Period
Total Number of
Shares Purchased Average Price
Paid Per Share
Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans
or Programs
Maximum
Dollar Value of
Shares that
May Yet Be
Purchased
Under the Plans
or Programs (in
millions)
January 2025
Share repurchase
program 	— $ 	— 	— $ 	1,745
Employee
transactions 	52,106 $ 	77.41 	N/A 	N/A
February 2025
Share repurchase
program 	— $ 	— 	— $ 	1,745
Employee
transactions 	183,317 $ 	81.23 	N/A 	N/A
March 2025
Share repurchase
program 	1,557,529 $ 	73.57 	1,557,529 $ 	1,630
Employee
transactions 	85,011 $ 	72.29 	N/A 	N/A
Total Quarter Ended March 31, 2025
Share repurchase
program 	1,557,529 $ 	73.57 	1,557,529 $ 	1,630
Employee
transactions 	320,434 $ 	78.24 	N/A 	N/A
In the preceding table:
• N/A - Not applicable.
• See “Share Repurchase Program,” of Note 10, “Nasdaq Stockholders’
Equity,” to the condensed consolidated financial statements for further
discussion of our share repurchase program.
• Employee transactions represents shares surrendered to us to satisfy tax
withholding obligations arising from the vesting of restricted stock and
PSUs previously issued to employees.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the three months ended March 31, 2025, none of the Company’s
directors or officers adopted, terminated or modified a “Rule 10b5-1 trading
arrangement” or “non-Rule 10b5-1 trading arrangement” (as such terms are
defined in Item 408 of Regulation S-K) except as follows and which is
intended to satisfy the affirmative defense of Rule 10b5-1(c): on February 10,
2025, Jeremy Skule, Chief Strategy Officer and Executive Chair, Financial
Crime Management Technology, adopted a Rule 10b5-1 trading plan for the
sale of 16,840 shares of our common stock subject to certain conditions and
which plan expires on December 31, 2025.
Item 6. Exhibits
Exhibit Number
10.1 	Employment Agreement between Nasdaq, Inc. and Adena
T. Friedman, dated as of March 11, 2025.*
10.2 	Employment Agreement between Nasdaq, Inc. and Tal
Cohen, dated as of March 10, 2025.*
10.3 	Employment Agreement between Nasdaq, Inc. and
Bradley J. Peterson, dated as of March 10, 2025.*
31.1 Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
(“Sarbanes-Oxley”).
31.2 Certification of Executive Vice President and Chief
Financial Officer pursuant to Section 302 of Sarbanes-
Oxley.
32.1 	Certifications Pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of Sarbanes-Oxley.
101
The following materials from the Nasdaq, Inc. Quarterly
Report on Form 10-Q for the quarter ended March 31,
2025, formatted in iXBRL (Inline eXtensible Business
Reporting Language): (i) Condensed Consolidated
Balance Sheets as of March 31, 2025 and December 31,
2024; (ii) Condensed Consolidated Statements of Income
for the three months ended March 31, 2025 and 2024; (iii)
Condensed Consolidated Statements of Comprehensive
Income for the three months ended March 31, 2025 and
2024; (iv) Condensed Consolidated Statements of
Changes in Stockholders’ Equity for the three months
ended March 31, 2025 and 2024; (v) Condensed
Consolidated Statements of Cash Flows for the three
months ended March 31, 2025 and 2024; and (vi) notes to
condensed consolidated financial statements.
104 	Cover Page Interactive Data File, formatted in iXBRL and
contained in Exhibit 101.
____________
* Management contract or compensatory plan or arrangement.
42

-- 47 of 155 --

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized, on April 28, 2025.
Nasdaq, Inc.
(Registrant)
By: 	/s/ Adena T. Friedman
Name: 	Adena T. Friedman
Title: 	Chief Executive Officer
Date: 	April 28, 2025
By: 	/s/ Sarah Youngwood
Name: 	Sarah Youngwood
Title: 	Executive Vice President and
Chief Financial Officer
Date: 	April 28, 2025
43

-- 48 of 155 --

Exhibit 10.1
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into on March 11, 2025 (the “Effective Date”), by and
between Nasdaq, Inc. (the “Company”) and Adena Friedman (the “Executive”), hereby superseding the terms of Executive’s prior
employment agreement effective January 1, 2022.
In consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties hereby
agree as follows:
1. 	Term of Agreement. Subject to Section 8 below, the term of this Agreement shall commence on the Effective Date and end on
January 1, 2030 (the “Term”). The Term may be extended by mutual agreement of the parties. In the event of a Change in
Control (as defined in Section 8(g)), the Term shall automatically be extended until the end of the CIC Protection Period (as
defined in Section 8(g)) below if the Term would otherwise expire during such period absent the extension.
2. 	Position.
(a) 	Duties. The Executive shall serve as the Company’s Chair and Chief Executive Officer and shall have such other duties
as agreed to by the Executive and the Board of Directors of the Company (the “Board”). In such position, the Executive
shall have such duties and authority as shall be determined from time to time by the Board and as shall be consistent
with the bylaws of the Company as in effect from time to time; provided, however, that, at all times, the Executive’s
duties and responsibilities hereunder shall be commensurate in all material respects with her status as the senior-most
officer of the Company. During the Term, the Executive shall devote her full time and best efforts to her duties
hereunder. The Executive shall report directly to the Board (or any Committee of the Board designated for this purpose).
In addition, the Executive agrees to serve during the Term as a member of the Board to the extent she is periodically
elected or appointed to such position in accordance with the bylaws of the Company and applicable law.
(b) 	Company Code of Ethics. The Executive shall comply in all respects with the Company’s Code of Ethics and all
applicable corporate policies referenced in the Code of Ethics, as may be amended from time to time (the “Code of
Ethics”). The Executive may, in accordance with the Code of Ethics, (i) engage in personal activities involving
charitable, community, educational, religious or similar organizations and (ii) manage her personal investments;
provided, however, that, in each case, such activities are in all respects consistent with applicable law, the Nasdaq
Continuing Obligations Agreement attached as Exhibit A (“Continuing Obligations Agreement”), and Section 9 below.
3. 	Base Salary. During the Term, the Company shall pay the Executive a base salary (the “Base Salary”) at an annual rate of not
less than $1,400,000. The Base Salary shall be payable in regular payroll installments in accordance with the Company’s payroll
practices as in effect from time to time (but no less frequently than monthly). The Management Compensation Committee of the
Board (the “Compensation Committee”) shall review the Base Salary at least annually and may (but shall be under no obligation
to) increase (but not decrease) the Base Salary on the basis of such review.

-- 49 of 155 --

4. 	Annual Bonus.
(a) 	Annual Bonus. For each calendar year during the Term, the Executive shall be eligible to participate in the Executive
Corporate Incentive Plan of the Company (the “Bonus Program”) in accordance with the terms and provisions of such
Bonus Program as established from time to time by the Compensation Committee and pursuant to which the Executive
will be eligible to earn an annual cash bonus (the “Annual Bonus”). Pursuant to the terms of the Bonus Program, the
Executive shall be eligible to earn, for each full calendar year during the Term, a target Annual Bonus of not less than
300% of Base Salary (the “Target Bonus”) based upon the achievement of one or more performance goals established for
such year by the Compensation Committee. The Executive shall have the opportunity to make suggestions to the
Compensation Committee prior to the determination of the performance goals for the Bonus Program for each
performance period, but the Compensation Committee will have final power and authority concerning the establishment
of such goals. The Compensation Committee shall review the Target Bonus at least annually and may (but shall be under
no obligation to) increase (but shall not decrease) the Target Bonus on the basis of such review. The Target Bonus for
each year during the Term shall never be less than the Target Bonus for the immediately preceding year.
(b) 	Timing of Annual Bonus. The Annual Bonus for each year shall be paid to the Executive as soon as reasonably
practicable following the end of such year, but in no event later than March 15 following the end of the calendar year to
which such Annual Bonus relates.
5. 	Equity Compensation. Based on the Compensation Committee’s evaluation of the performance of the Company and Executive,
peer group market data, internal equity and consistent with past practices with respect to the combined aggregate value of the
grants of options, restricted share units and performance share units, the Executive shall be eligible to receive an annual equity
compensation award (an “Annual Equity Award”), in accordance with the terms and provisions of the Company’s Equity
Incentive Plan (the “Stock Plan”), which has been adopted by the Board and may from time to time be amended. The applicable
provisions of the Company’s Stock Plan and each equity award agreement to be executed by the Executive and the Company (to
the extent not inconsistent with this Agreement) shall govern the treatment of the equity awards. The Executive shall receive an
Annual Equity Award for 2025 with a target value at the time of grant of not less than $15,000,000.
6. 	Employee Benefits. During the Term, and except as otherwise noted herein, the Company shall provide the Executive with
benefits on the same basis as benefits are generally made available to other senior executives of the Company, including,
without limitation, medical, dental, vision, disability and life insurance, financial and tax planning services and retirement
benefits. The Executive shall be allocated five weeks of paid vacation. However, due to the Company’s unlimited time off
policy, in the event the Executive’s employment ends for any reason, the Executive shall not be paid for unused vacation.
7. 	Business and Other Expenses.
(a) 	Business Expenses. During the Term, the Company shall reimburse the Executive for reasonable business expenses
incurred by her in the performance of her duties hereunder in accordance with the policy established by the
Compensation Committee.
th
2

-- 50 of 155 --

(b) 	Transportation and Security. During the Term, in accordance with the directives of the Compensation Committee, the
Company shall provide the Executive with an automobile, driver, and security officer for business and limited,
reasonable personal use. The driver and security officer shall have security training as necessary and advisable for the
personal safety of the Executive or her family.
8. 	Termination. Notwithstanding any other provision of this Agreement, subject to the further provisions of this Section 8, the
Company may terminate the Executive’s employment or the Executive may resign such employment for any reason or no stated
reason at any time, subject to the notice and other provisions set forth below:
(a) 	Generally. In the event of the termination of the Executive’s employment for any reason, the Executive shall receive
payment of (i) any unpaid Base Salary through the Date of Termination (as defined below), to be paid in accordance with
Section 3 above and (ii) any earned but unpaid Annual Bonus with respect to the calendar year ended prior to the Date of
Termination, payable in accordance with Section 4(b) (the “Base Obligations”). In addition, in the event of the
Executive’s termination of employment, the applicable provisions of the Company’s Stock Plan or each equity award
agreement executed by the Executive and the Company shall govern the treatment of the equity awards.
For purposes of this Agreement, “Date of Termination” means (i) in the event of a termination of the Executive’s employment by the
Company for Cause or by the Executive for Good Reason, the date specified in a written notice of termination (or, if not specified
therein, the date of delivery of such notice), but in no event earlier than the expiration of the cure periods set forth in Section 8(b)(ii) or
8(b)(iii) below, respectively; (ii) in the event of a termination of the Executive’s employment by the Company without Cause, the date
specified in a written notice of termination (or if not specified therein, the date of delivery of such notice); (iii) in the event of a
termination of the Executive’s employment by the Executive without Good Reason, the date specified in a written notice of termination,
but in no event less than sixty (60) days following the date of delivery of such notice; (iv) in the event of a termination of the
Executive’s employment due to Permanent Disability (as defined below), the date the Company terminates the Executive’s employment
following the certification of the Executive’s Permanent Disability; (v) in the event of a termination of employment due to the
Executive’s death, the date of the Executive’s death; or (vi) in the event of a termination of Executive’s employment due to Retirement
(as defined below), the earlier to occur of (1) the last day of the Retirement Notice Period (as defined below) or (2) the date specified in
a written notice of termination by the Company, in each case pursuant to Section 8(c).
(b) 	Termination by the Company Without Cause or by the Executive for Good Reason Other Than in Connection with
Change in Control.
(i) 	The Executive’s employment hereunder may be terminated by the Company without Cause or by the Executive
for Good Reason, on or before the last day of the Term. Upon the termination of the Executive’s employment by
the Company without Cause or by the Executive for Good Reason pursuant to this Section 8(b), which occurs
more than six months prior to Change in Control or at least two years after a Change in Control, the Executive
shall, subject to Section 8(i) below, be entitled to receive, in
3

-- 51 of 155 --

addition to the Base Obligations, the following payments and benefits (the “Severance Benefits”):
(A) 	Severance Payment. The Company shall pay the Executive an amount (the “Severance Payment”)
equal to the sum of (I) two times the Base Salary paid to the Executive with respect to the
calendar year immediately preceding the Executive’s Date of Termination, (II) two times the
Target Bonus and (III) a pro rata Target Bonus with respect to the calendar year in which the Date
of Termination occurs, determined in accordance with the Pro-Rata Target Bonus Calculation (the
“Pro-Rata Target Bonus”).
“Pro-Rata Target Bonus Calculation” is determined by multiplying the Executive’s Target Bonus
under Section 4(a) for the fiscal year in which the Date of Termination occurs by a fraction, the
numerator of which is the number of days in the fiscal year in which the Date of Termination
occurs through the Date of Termination and the denominator of which is the total number of days
in the calendar year.
The Severance Payment (other than the Pro-Rata Target Bonus) is payable, subject to Section 12(h), in substantially equal monthly
installments for the twelve (12)-month period following the Executive’s Date of Termination, with the first installment to be paid in the
month following the month in which the Release Effective Date occurs; provided, however (consistent with the requirements of
Section 409A), that if the sixty (60)-day period described in Section 8(i) below begins in one calendar year and ends in another, the first
installment of the Severance Payment shall be paid not earlier than January 1 of the calendar year following the Date of Termination
(the period during which the Severance Benefits are paid being the “Severance Period”). The Pro-Rata Target Bonus shall be paid,
subject to Section 12(h), in a lump sum within sixty (30) days following the Release Effective Date (provided that if the 60-day period
described in Section 8(i) below begins in one calendar year and ends in another, the Pro-Rata Target Bonus shall be paid not earlier than
January 1 of the calendar year following the Date of Termination); and
(B) 	Equity Vesting. The Executive shall, subject to Section 8(i), be entitled to receive twenty-four (24)
months of continued vesting of outstanding Performance Share Units (“PSUs”), stock options, and
restricted stock units (“RSUs”). Any performance-based vesting will be based on actual
performance goals during the respective performance periods. Any stock options will remain
exercisable for twenty-four (24) months after the Date of Termination (but no later than its
original scheduled expiration date).
(C) 	Health Care Coverage Payments. Provided that the Executive timely elects to continue coverage
under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), the Company agrees to
continue to pay the
4

-- 52 of 155 --

employer’s share of the medical, dental and vision premiums for the Executive and her eligible
dependents from the expiration date of the Executive’s coverage under the Company plan (which
is at the end of month in which the Executive’s Date of Termination occurs), for eighteen (18)
months (“COBRA Continuation Period”). The Executive will still be responsible for paying the
employee share of the premium as specified by the plan administrator. If, during the COBRA
Continuation Period, the Executive begins work with an employer who provides health insurance
benefits for which the Executive is eligible, the Company’s obligation under this section shall
forever cease upon the expiration of the waiting period (if any) for entitlement to insurance
coverage through the Executive’s new employer. The Executive agrees to promptly notify the
Company in writing within seven (7) days of the Executive’s commencement of full-time
employment during the COBRA Continuation Period. In any event, and notwithstanding any
provision to the contrary in this section, the Company shall have no obligation to make any
payments for COBRA premiums paid for health insurance coverage beyond the expiration of the
COBRA Continuation Period.
(D) 	Other Benefits. The Company will make a one-time cash payment to the Executive in the amount
of $45,000 to subsidize the cost of continuation of financial and tax services (currently provided
by Ayco) for a period of twenty-four (24) months following the Date of Termination. Additionally,
upon the Executive’s request, at any time within eighteen (18) months following the Date of
Termination, the Company will provide third-party concierge advisory services at the Company’s
expense, to assist the Executive with the procurement of private health care coverage.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(b) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The Severance Benefits are payments and benefits to which the Executive is not otherwise entitled,
are given in consideration for the Release (as described in Section 8(i) below) and are in lieu of any severance plan, policy or program
of the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant to this
Section 8(b)(i) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all obligations of
the Company to the Executive under this Agreement. The Executive acknowledges and agrees that such amounts are fair and
reasonable, and are her sole and exclusive remedy, in lieu of all other remedies at law or in equity, with respect to the termination of her
employment hereunder. If, during the Severance Period, the Executive breaches in any material respect any of her obligations under
Section 9, or the Continuing Obligations Agreement, the Company may, upon written notice to the Executive (x) terminate the
Severance Period and cease to make any further payments of the Severance
5

-- 53 of 155 --

Payment and (y) cease any health care coverage payments, except in each case as required by applicable law.
(ii) 	For purposes of this Agreement, “Cause” shall mean (A) the Executive’s conviction of, or pleading nolo
contendere to, any crime, whether a felony or misdemeanor, involving the purchase or sale of any security, mail
or wire fraud, theft, embezzlement, moral turpitude, or Company property (with the exception of minor traffic
violations or similar misdemeanors); (B) the Executive’s repeated neglect of her duties to the Company; or
(C) the Executive’s willful misconduct in connection with the performance of her duties or other material breach
by the Executive of this Agreement provided that the Company may not terminate the Executive’s employment
for Cause unless (x) the Company first gives the Executive written notice of its intention to terminate and of the
grounds for such termination within ninety (90) days following the date the Board is informed of such grounds at
a meeting of the Board and (y) the Executive has not, within thirty (30) days following receipt of such notice,
cured such Cause (if capable of cure) in a manner that is reasonably satisfactory to the Board.
(iii) 	For purposes of this Agreement, “Good Reason” shall mean the Company (A) reducing the Executive’s position,
duties, or authority, other than during the Retirement Notice Period; (B) failing to secure the agreement of any
successor entity to the Company that the Executive shall continue in her position without reduction in position,
duties or authority; (C) relocating the Executive’s principal work location beyond a fifty (50)-mile radius of her
work location as of the Effective Date (provided that this Clause (C) shall apply only to a relocation that occurs
during the two-year period beginning upon a Change of Control, as defined below, and ending two years
thereafter); or (D) committing any other material breach of this Agreement; provided, however, that the
occurrence of a Change in Control, following which the Company continues to have its common stock publicly
traded and the Executive is offered continued employment as Chief Executive Officer, with substantially the
same duties and authority as she has hereunder of such publicly traded entity, shall not be deemed to give rise to
an event or condition constituting Good Reason; and provided, further, that no event or condition shall constitute
Good Reason unless (x) the Executive gives the Company a Notice of Termination specifying her objection to
such event or condition within 90 days following the occurrence of such event or condition, (y) such event or
condition is not corrected, in all material respects, by the Company in a manner that is reasonably satisfactory to
the Executive within 30 days following the Company’s receipt of such notice and (z) the Executive resigns from
her employment with the Company not more than thirty (30) days following the expiration of the thirty (30)-day
period described in the foregoing clause (y).
(c) 	Retirement.
(i) 	The Executive may terminate her employment without Good Reason and such termination of employment shall
be deemed a termination due to retirement (“Retirement”) by providing the Company with twelve (12) months’
written notice (or such shorter period as may be approved by the
6

-- 54 of 155 --

Board) (the “Retirement Notice Period”) of such termination pursuant to Section 12(f) of this Agreement;
provided that the Executive may not provide notice of Retirement any earlier than December 31, 2027 (or such
earlier date as may be approved by the Board). The Term shall automatically be extended until the end of the
Retirement Notice Period, if notice is given less than one year prior to the end of the Term. In the event of a
termination due to Retirement, the Company may, it its sole and absolute discretion, by written notice pursuant to
Section 12(f) of this Agreement, accelerate the Date of Termination without changing the characterization of
such termination as a Retirement; and more specifically, such written notice and acceleration shall not constitute
a termination without Cause by the Company nor provide a basis for a claim of Good Reason. Upon the
termination of the Executive’s employment pursuant to this Section 8(c), the Executive shall, subject to
Section 8(i) below, be entitled to receive, in addition to the Base Obligations, the following payments and
benefits:
(A) 	Payments. The Executive shall be entitled to receive continued Base Salary through the end of the
Retirement Notice Period and a pro-rata Target Bonus determined in accordance with the Pro-Rata
Retirement Target Bonus Calculation and payable, subject to Section 12(h), in a lump sum within
thirty (30) days following the Release Effective Date (provided that if the sixty (60)-day period
described in Section 8(i) below begins in one calendar year and ends in another, the pro rata
Target Bonus shall be paid not earlier than January 1 of the calendar year following the Date of
Termination). For the avoidance of doubt, the Executive shall also remain entitled to any Annual
Bonus for a year that ends during the Retirement Notice Period, the amount of which to be
calculated in accordance with the Bonus Program for such year and without any adjustment as a
result of the Executive’s decision to elect Retirement.
“Pro-Rata Retirement Target Bonus Calculation” is determined by multiplying the Executive’s
Target Bonus under Section 4(a) by a fraction, the numerator of which is the number of days in the
fiscal year in which the last day of the Retirement Notice Period occurs through the last day of the
Retirement Notice Period and the denominator of which is the total number of days in the calendar
year.
(B) 	Equity Vesting. The Executive shall continue to be eligible to receive an Annual Equity Award, in
accordance with Section 5 of this Agreement, and shall be entitled to continued vesting of all
outstanding forms of equity compensation issued prior to the Date of Termination as though the
Executive were employed through the applicable vesting dates (“Continued Vesting Period for
Retirement”), with performance share units vesting based on actual performance during the
respective performance periods. Any vested stock options shall remain exercisable until the
expiration date specified in the applicable award agreement.
7

-- 55 of 155 --

(C) 	Health Care Coverage Payments. Provided that the Executive timely elects to continue COBRA
coverage, the Company agrees to continue to pay the employer’s share of the medical, dental and
vision premiums for the Executive and her eligible dependents for the COBRA Continuation
Period. The Executive will still be responsible for paying the employee share of the premium as
specified by the plan administrator. If, during the COBRA Continuation Period, the Executive
begins work with an employer who provides health insurance benefits for which the Executive is
eligible, the Company’s obligation under this section shall forever cease upon the expiration of the
waiting period (if any) for entitlement to insurance coverage through the Executive’s new
employer. The Executive agrees to promptly notify the Company in writing within seven (7) days
of the Executive’s commencement of full-time employment during the COBRA Continuation
Period. In any event, and notwithstanding any provision to the contrary in this section, the
Company shall have no obligation to make any payments for COBRA premiums paid for health
insurance coverage beyond the expiration of the COBRA Continuation Period.
(D) 	Other Benefits. The Company will make a one-time cash payment to the Executive in the amount
of $45,000 to subsidize the cost of continuation of financial and tax services (currently provided
by Ayco) for a period of twenty-four (24) months following the Date of Termination. Additionally,
upon the Executive’s request, at any time within eighteen (18) months following the Date of
Termination, the Company will provide third-party concierge advisory services at the Company’s
expense, to assist the Executive with the procurement of private health care coverage.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(c) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The payments and benefits in this Section 8(c) to which the Executive is not otherwise entitled are
given in consideration for the Release (as described in Section 8(i) below) and are in lieu of any severance plan, policy or program of
the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant to this
Section 8(c) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all obligations of
the Company to the Executive under this Agreement.
The Executive acknowledges and agrees that such amounts are fair and reasonable, and are her sole and exclusive remedy, in lieu of all
other remedies at law or in equity, with respect to the termination of her employment hereunder. If, during the Continued Vesting Period
for Retirement, the Executive breaches in any material respect any of her obligations under Section 9, the Continuing Obligations
Agreement, or commences employment in an operating
8

-- 56 of 155 --

chief executive officer role at a for-profit operating company, either publicly listed or privately owned (a “Disqualifying Operational
Role”), the Company may, upon written notice to the Executive terminate the Continued Vesting Period for Retirement and cease any
benefits continuation coverage or payments, except in each case as required by applicable law. For the avoidance of doubt, the
following will not constitute a Disqualifying Operational Role: (i) an operating executive role in a non-profit organization or in a
government agency or other government position, (ii) a role as an investment management professional, (iii) a role as an Operating
Executive, Executive Chair or other advisor to, in each case, a private equity firm or venture capital firm (provided that such role is not
an operating role within a portfolio company or at the General Partner itself), or (iv) a role as a Non-Executive Chair or on the board of
directors of any organization, including a for-profit operating company or a private equity or venture capital firm.
If, during the twelve (12) month period following the Date of Termination due to Retirement, the Executive commences employment in
a Disqualifying Operational Role, then the Executive shall promptly repay to the Company all payments and benefits received pursuant
to this Section 8(c). Further, if during the period between twelve (12) and thirty-six (36) months following the Date of Termination due
to Retirement, the Executive commences employment in a Disqualifying Operational Role, then all continued vesting of equity awards
pursuant to Section 8(c)(i)(B) shall immediately cease. If the Executive seeks to obtain a Disqualifying Operational Role during such
three-year period, the Executive may seek a waiver of this provision upon written request to the Board of Directors and the Board shall
reasonably consider such request in good faith. Any such waiver, if granted, must be in writing.
(d) 	Permanent Disability.
(i) 	The Executive’s employment hereunder shall terminate upon her Permanent Disability. Upon termination of the
Executive’s employment due to Permanent Disability, the Executive shall, subject to Section 8(i) below, be
entitled to receive, in addition to the Base Obligations, (A) the Pro-Rata Target Bonus paid, subject to
Section 12(h), in a lump sum within 30 days following the Release Effective Date (provided that if the 60-day
period described in Section 8(i) below begins in one calendar year and ends in another, the Pro-Rata Target
Bonus shall be paid not earlier than January 1 of the calendar year following the Date of Termination) and
(B) accelerated vesting of all unvested equity compensation awarded to the Executive by the Company, effective
as of December 31 of the year of termination and, in accordance with Section 5, each equity award agreement
executed by the Executive and the Company shall describe the treatment of the equity awards under this
Section 8(d). Any performance-based vesting will be based on actual performance goals during any complete
performance period; vesting will be at target performance for grants vesting prior to the completion of a
performance cycle. All other benefits, if any, due the Executive following termination pursuant to this
Section 8(d) shall be determined in accordance with the plans, policies and practices of the Company; provided,
however, that the Executive shall not participate in any other severance plan, policy or program of the Company.
st
9

-- 57 of 155 --

(ii) 	For purposes of this Agreement, “Permanent Disability” means either (A) the inability of the Executive to
engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment
that can be expected to result in death or can be expected to last for a continuous period of not less than twelve
(12) months or (B) the Executive is, by reason of any medically determinable physical or mental impairment that
can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12)
months, receiving income replacement benefits for a period of not less than three months under an accident and
health plan covering employees of the Company. The Executive shall be deemed Permanently Disabled if she is
determined to be (A) totally disabled by the Social Security Administration or (B) disabled in accordance with a
disability insurance program, provided such definition of disabled under the program complies with the
definition of Permanent Disability hereunder. Otherwise, such Permanent Disability shall be certified by a
physician chosen by the Company and reasonably acceptable to the Executive (unless she is then legally
incapacitated, in which case such physician shall be reasonably acceptable to the Executive’s authorized legal
representative).
(e) 	Death. The Executive’s employment hereunder shall terminate due to her death. Upon termination of the Executive’s
employment hereunder due to death, the Executive’s estate shall, subject to Section 8(i) below, be entitled to receive, in
addition to the Base Obligations,(A) the Pro-Rata Target Bonus paid, subject to Section 12(h), in a lump sum within 30
days following the Release Effective Date (provided that if the sixty (60)-day period described in Section 8(i) below
begins in one calendar year and ends in another, the Pro-Rata Target Bonus shall be paid not earlier than January 1 of the
calendar year following the Date of Termination) and (B) accelerated vesting of all unvested equity compensation
awarded to the Executive by the Company, effective as of December 31 of the year of termination and, in accordance
with Section 5, each equity award agreement executed by the Executive and the Company shall describe the treatment of
the equity awards under this Section 8(e). Any performance-based vesting will be based on actual performance goals
during any complete performance period; vesting will be at target performance for grants vesting prior to the completion
of a performance cycle. All other benefits, if any, due the Executive’s estate following termination pursuant to this
Section 8(e) shall be determined in accordance with the plans, policies and practices of the Company.
(f) 	For Cause by the Company or Without Good Reason by the Executive. The Executive’s employment hereunder may be
terminated by the Company for Cause or by the Executive without Good Reason (other than Retirement). Upon
termination of the Executive’s employment for Cause or without Good Reason (other than Retirement) pursuant to this
Section 8(f), the Executive shall have no further rights to any compensation (including any Annual Bonus) or any other
benefits under this Agreement other than the Base Obligations. All other benefits, if any, due the Executive following the
Executive’s termination of employment pursuant to this Section 8(f) shall be determined in accordance with the plans,
policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy, or program of the Company.
(g) 	Termination in Connection with Change in Control by the Company Without Cause or by the Executive for Good
Reason.
st
10

-- 58 of 155 --

(i) 	If the Executive’s employment is terminated by the Company without Cause or by the Executive for Good
Reason during the CIC Protection Period (as defined herein below), the Executive shall, subject to Section 8(i)
below, be entitled to receive, in addition to the Base Obligations, the following payments and benefits (the “CIC
Severance Benefits”):
(A) 	CIC Severance Payment. The Company shall pay the Executive a lump sum cash payment equal
to (I) the sum of (x) two times the Base Salary paid to the Executive with respect to the calendar
year immediately preceding the Executive’s Date of Termination and (y) two times the Target
Bonus and (II) the Pro-Rata Target Bonus, which shall be paid, subject to Section 12(h), within
thirty (30) days following the Release Effective Date (provided that if the sixty (60)-day period
described in Section 8(i) below begins in one calendar year and ends in another, the cash payment
shall be paid not earlier than January 1 of the calendar year following the Date of Termination).
If (i) any amounts payable to the Executive under this Agreement or otherwise are characterized as excess parachute payments pursuant
to Section 4999 of the Internal Revenue Code of 1986, as amended (the “Section 4999”), and (ii) the Executive thereby would be
subject to any United States federal excise tax due to that characterization, the Executive’s termination benefits hereunder will be
reduced to an amount so that none of the amounts payable constitute excess parachute amounts payments if this would result, after
taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, in Executive’s
receipt on an after-tax basis of the greatest amount of termination and other benefits. The determination of any reduction required
pursuant to this section (including the determination as to which specific payments shall be reduced) shall be made by a neutral party
designated by the Company and such determination shall be conclusive and binding upon the Company or any related corporation for
all purposes.
(B) 	Equity Vesting. The Executive shall, subject to Section 8(i), be entitled to receive accelerated
vesting of all outstanding, unvested equity awards. The schedule for acceleration of the various
equity awards will be governed by Section 12 (Change in Control) of the Stock Plan.
(C) 	Health and Welfare Benefits. The Company shall pay to Executive on a monthly basis during the
CIC Coverage Period a taxable monthly cash payment equal to the COBRA premium for the
highest level of coverage available under the Company’s group health plans, but reduced by the
monthly amount that Executive would pay for such coverage if the Executive was an active
employee. “CIC Coverage Period” shall mean the period (I) commencing on the first day of the
month following the Release Effective Date (provided that if the sixty (60)-day period described
in Section 8(i) below begins in one calendar year and ends in another, the CIC Coverage Period
11

-- 59 of 155 --

shall commence not earlier than January 1 of the calendar year following the Date of Termination)
and (II) ending on the earlier of (x) the expiration of eighteen (18) months from the first day of the
CIC Coverage Period, and (y) the date that the Executive is eligible for coverage under the health
care plans of a subsequent employer. The payments provided by this Section shall be conditioned
upon the Executive being covered by the Company’s health care plans immediately prior to the
Date of Termination. The foregoing payments are not intended to limit or otherwise reduce any
entitlements that Executive may have under COBRA. In addition, the Company shall continue to
provide the Executive with the same level of accident (AD&D) and life insurance benefits upon
substantially the same terms and conditions (including contributions required by the Executive for
such benefits) as existed immediately prior to the Executive’s Date of Termination (or, if more
favorable to the Executive, as such benefits and terms and conditions existed immediately prior to
the Change in Control) for the same period for which the Company shall provide the Executive
with continued health care coverage payments.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(g) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The payments and other benefits provided for in this Section 8(g) are payments and benefits to
which the Executive is not otherwise entitled, are given in consideration for the Release and are in lieu of any severance plan, policy or
program of the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant
to this Section 8(g)(i) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all
obligations of the Company to the Executive under this Agreement. The Executive acknowledges and agrees that such amounts are fair
and reasonable, and are her sole and exclusive remedy, in lieu of all other remedies at law or in equity, with respect to the termination of
her employment hereunder. If, during the CIC Coverage Period, the Executive breaches in any material respect any of her obligations
under Section 9 or the Continuing Obligations Agreement, the Company may, upon written notice to the Executive, (x) terminate the
CIC Coverage Period and cease to make any further payments of the CIC Severance Payment and (y) cease any health and welfare
benefits and payments, except in each case as required by applicable law.
(ii) 	For purposes of this Agreement “Change in Control” means the first to occur of any one of the following events:
(A) 	any “Person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of
1934 (the “Exchange Act”) (other than (1) the Company, (2) any Person who becomes the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act) of more than 50% of the
Company’s then outstanding securities eligible to vote
12

-- 60 of 155 --

in the election of the Board (“Voting Securities”) as a result of a reduction in the number of Voting
Securities outstanding due to the repurchase of Voting Securities by the Company unless and until
such Person, after becoming aware that such Person has become the beneficial owner of more than
50% of the then outstanding Voting Securities, acquires beneficial ownership of additional Voting
Securities representing 1% or more of the Voting Securities then outstanding, (3) any trustee or
other fiduciary holding securities under an employee benefit plan of the Company, and (4) any
entity owned, directly or indirectly, by the stockholders of the Company in substantially the same
proportions as their ownership of Voting Securities), is or becomes the beneficial owner, directly
or indirectly, of more than 50% of the Voting Securities (not including any securities acquired
directly (or through an underwriter) from the Company or the Companies);
(B) 	the date on which, within any twelve (12) month period (beginning on or after the Effective Date),
a majority of the directors then serving on the Board are replaced by directors not endorsed by at
least two-thirds (2/3) of the members of the Board before the date of appointment or election;
(C) 	there is consummated a merger or consolidation of the Company with any other corporation or
entity or the Company issues Voting Securities in connection with a merger or consolidation of
any direct or indirect subsidiary of the Company with any other corporation, other than (1) a
merger or consolidation that would result in the Voting Securities outstanding immediately prior
thereto continuing to represent (either by remaining outstanding or by being converted into Voting
Securities of the surviving or parent entity) more than 50% of the Company’s then outstanding
Voting Securities or more than 50% of the combined voting power of such surviving or parent
entity outstanding immediately after such merger or consolidation or (2) a merger or consolidation
effected to implement a recapitalization of the Company (or similar transaction) in which no
Person, directly or indirectly, acquired more than 50% of the Company’s then outstanding Voting
Securities (not including any securities acquired directly (or through an underwriter) from the
Company or the Companies); or
(D) 	the consummation of an agreement for the sale or disposition by the Company of all or
substantially all of the Company’s assets (or any transaction having a similar effect), provided that
such agreement or transaction of similar effect shall in all events require the disposition, within
any twelve (12) month period, of at least 40% of the gross fair market value of all of the
Company’s then assets; other than a sale or disposition by the Company of all or substantially all
of the Company’s assets to an entity, at
13

-- 61 of 155 --

least 50% of the combined voting power of the voting securities of which are owned directly or
indirectly by stockholders of the Company in substantially the same proportions as their
ownership of the Company immediately prior to such sale.
Notwithstanding the foregoing, in no event shall a Change in Control be deemed to occur hereunder unless such event constitutes a
change in ownership of the Company, a change in effective control of the Company or a change in ownership of a substantial portion of
the Company’s assets within the meaning of Section 409A.
(iii) 	For purposes of this Agreement “CIC Protection Period” means the two (2) years following the occurrence of a
Change in Control, provided that, if the Executive’s employment is terminated by the Company without Cause or
by the Executive for Good Reason within six (6) months prior to a Change in Control, then the termination will
be treated for all purposes of this Agreement as having occurred immediately following the Change in Control
and during the CIC Protection Period (provided such protection will end if such agreement is terminated or the
transaction is abandoned).
(h) 	Mitigation; Offset. Following the termination of her employment under any of the above clauses of this Section 8, the
Executive shall have no obligation or duty to seek subsequent employment or engagement as an employee (including
self-employment) or as a consultant or otherwise mitigate the Company’s obligations hereunder; nor shall the payments
provided by this Section 8 be reduced by the compensation earned by the Executive as an employee or consultant from
such subsequent employment or consultancy.
(i) 	Release. Notwithstanding anything to the contrary in this Agreement, receipt of the Severance Benefits and the CIC
Severance Benefits or other compensation or benefits under this Section 8 (other than the Base Obligations), if any, by
the Executive is subject to the Executive executing and delivering to the Company a general release of claims following
the Date of Termination, in substantially the form attached as Exhibit B (the “Release”), that, within sixty (60) days
following the Executive’s Date of Termination, has become irrevocable by the Executive (such date the Release becomes
irrevocable being the “Release Effective Date”). If the Executive dies or becomes legally incapacitated prior to the
Release Effective Date, then the Release requirements described in the preceding sentence shall apply with respect to the
Executive’s estate and the Release shall be modified as reasonably necessary to allow for execution and delivery by the
personal representative of the Executive’s estate or the Executive’s authorized legal representative, as applicable.
9. 	Non-Competition. The Executive acknowledges and recognizes the highly competitive nature of the businesses of the Company
and accordingly agrees as follows:
(a) 	Non-Competition. For a period of two (2) years following the Date of Termination (the “Restricted Period”), regardless
of the circumstances surrounding such termination of employment, the Executive will not, directly or indirectly without
prior “Written Permission” (as defined below), (i) engage in any “Competitive Business” (as defined below) for the
Executive’s own account while she is in self-employment or acting as a sole proprietor, (ii) enter the employ of, or
render any services to, any person engaged in a Competitive
14

-- 62 of 155 --

Business, (iii) acquire a financial interest in, or otherwise become actively involved with, any person engaged in a
Competitive Business, directly or indirectly, as an individual, partner, shareholder, officer, director, principal, agent,
trustee or consultant, or (iv) interfere with business relationships (whether formed before or after the Effective Date)
between the Company and customers or suppliers of the Company. For the avoidance of doubt, the Restricted Period
shall apply only if the Date of Termination occurs on or before the last day of the Term, but if the Date of Termination
occurs on or before the last day of the Term, the full Restricted Period shall apply regardless of the time remaining in the
Term on the Date of Termination. The Executive may seek a waiver of all or part of his Restricted Period upon written
request to the Board, who shall reasonably consider such request in good faith. Any such waiver, if granted, must be in
writing, in advance of the Executive accepting any offers of engagement from the applicable entity.
For purposes of this Agreement, “Competitive Business” shall mean (x) any national securities exchange registered with the Securities
and Exchange Commission, (y) any electronic communications network or (z) any other entity that engages in substantially the same
business as the Company, but only to the extent that (i) the Company’s most recent annual revenue for that similar business unit equals
or exceeds 5% of the Company’s revenues (less transaction-based contra-revenues (i.e., rebates)), as reported in the Company’s most
recent Form 10-K, or (ii) the entity’s most recent annual revenue for that similar business unit equals or exceeds 5% of the entity’s
revenues (less transaction-based contra-revenues (i.e., rebates)) as reported in the entity’s most recent Form 10-K (if applicable) or
other financial statements (if such entity does not file a Form 10-K). For purposes of this Agreement, “person” shall mean an
individual, corporation, partnership, limited partnership, limited liability company, syndicate, person (including, without limitation, a
“person” as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended), trust, or association. “Written
Permission” shall mean any permission granted by the Company’s Board of Directors in writing, which shall apply a reasonable, good
faith consideration of the request based on factors including, without limitation, the role the Executive will occupy, the Company’s
strategic plans, any potential competitive threats posed, and the size of revenue associated with any competing products and services
offered by the Competitive Business.
(b) 	Securities Ownership. Notwithstanding anything to the contrary in this Agreement, the Executive may, directly or
indirectly, own, solely as an investment, securities of any person engaged in the business of the Company which are
publicly traded on a national or regional stock exchange or on the over-the-counter market if the Executive (i) is not a
controlling person of, or a member of a group which controls, such person and (ii) does not, directly or indirectly, own
five percent or more of any class of securities of such person.
(c) 	Severability. It is expressly understood and agreed that, although the Executive and the Company consider the
restrictions contained in this Section 9 to be reasonable, if a final judicial determination is made by a court of competent
jurisdiction that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction
against the Executive, the provisions of this Agreement shall not be rendered void, but shall be deemed amended to
apply as to such maximum time and territory and to such maximum extent as such court may judicially determine or
indicate to be enforceable. Alternatively, in the event
15

-- 63 of 155 --

that any one or more of the provisions of this Agreement shall be or become invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected
thereby.
10. 	Specific Performance. The Executive acknowledges and agrees that the Company’s remedies at law for a breach or threatened
breach of Section 9 above would be inadequate and, in recognition of this fact, the Executive agrees that, in the event of such a
breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or
any other equitable remedy which may then be available.
11. 	Disputes. Except as provided in Section 10 above, any dispute arising between the parties under this Agreement, under any
statute, regulation, or ordinance, under any other agreement between the parties, and/or in way relating to the Executive’s
employment, shall be submitted to binding arbitration before the American Arbitration Association (“AAA”) for resolution. Such
arbitration shall be conducted in New York, New York, and the arbitrator will apply New York law, including federal law as
applied in New York courts. The arbitration shall be conducted in accordance with the AAA’s Employment Arbitration Rules as
modified herein. The arbitration shall be conducted by a panel of three arbitrators that is mutually agreeable to both the
Executive and the Company, all in accordance with AAA’s Employment Arbitration Rules then in effect. If the Executive and
the Company cannot agree upon the panel of arbitrators, the arbitration shall be settled before a panel of three arbitrators, one to
be selected by the Company, one by the Executive, and the third to be selected by the two persons so selected, all in accordance
with AAA’s Employment Arbitration Rules. Each party shall pay their own costs and expenses, including without limitation,
attorney’s fees and costs, except that the Company shall pay the cost of the arbitrators and the filing fees charged to Executive
by the AAA, provided that she has not brought a frivolous claim (as determined by the arbitrator). The award of the arbitrators
shall be final and binding on the parties, and judgment on the award may be confirmed and entered in any state or federal court
in the State and City of New York. The arbitration shall be conducted on a strictly confidential basis, and Executive shall not
disclose the existence of a claim, the nature of a claim, any documents, exhibits, or information exchanged or presented in
connection with such a claim, or the result of any action (collectively, “Arbitration Materials”), to any third party, with the sole
exception of the Executive’s legal counsel, who also shall be bound by confidentiality obligations no less protective than the
provisions set forth in the Continuing Obligations Agreement. In the event of any court proceeding to challenge or enforce an
arbitrators’ award, the parties hereby consent to the exclusive jurisdiction of the state and federal courts in New York, New York
and agree to venue in that jurisdiction. The parties agree to take all steps necessary to protect the confidentiality of the
Arbitration Materials in connection with any such proceeding, agree to file all Confidential Information, as defined in the
Continuing Obligations Agreement (and documents containing Confidential Information) under seal, subject to court order and
agree to the entry of an appropriate protective order encompassing the confidentiality terms of this Agreement. Nothing
contained in this Section 11 shall be construed to preclude the Company from exercising its rights under Section 10 above.
12. 	Miscellaneous.
(a) 	Acceptance. The Executive hereby represents and warrants, as a material inducement to the Company’s agreement to
enter into this Agreement, that there are no legal, contractual or other impediments precluding the Executive from
16

-- 64 of 155 --

entering into this Agreement or from performing the services with the Company contemplated hereby. Any violation of
this representation and warranty by the Executive shall render all of the obligations of the Company under this
Agreement void ab initio and of no force and effect.
(b) 	Entire Agreement; Amendments. This Agreement, together with the equity award agreements between the Executive and
the Company contain the entire understanding of the parties with respect to the employment of the Executive by the
Company, and shall supersede any and all previous contracts, arrangements or understandings between the Company and
the Executive with respect to the subject matter set forth herein. There are no restrictions, agreements, promises,
warranties, or covenants by and between the Company and the Executive and undertakings between the parties with
respect to the subject matter herein other than those expressly set forth herein. This Agreement may not be altered,
modified or amended except by written instrument signed by the parties hereto.
(c) 	No Waiver. The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not
be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence
to that term or any other term of this Agreement.
(d) 	Successor; Assignment. This Agreement is confidential and personal and neither of the parties hereto shall, without the
consent of the other, assign or transfer this Agreement or any rights or obligations hereunder. Without limiting the
foregoing, the Executive’s right to receive payments hereunder shall not be assignable or transferable whether by pledge,
creation of a security interest or otherwise, other than a transfer by the Executive’s will or by the laws of descent and
distribution. In the event of any attempted assignment or transfer contrary to this Section 12(d), the Company shall have
no liability to pay the assignee or transferee any amount so attempted to be assigned or transferred. The Company shall
cause this Agreement to be assumed by any entity that succeeds to all or substantially all of the Company’s business or
assets and this Agreement shall be binding upon any successor to all or substantially all of the Company’s business or
assets; provided, however, that no such assumption shall release the Company of its obligations hereunder, to the extent
not satisfied by such successor, without the Executive’s prior written consent.
(e) 	Confidentiality of Tax Treatment and Structure. Notwithstanding anything herein to the contrary, each party and its
representatives may consult any tax advisor regarding the tax treatment and tax structure of this Agreement and may
disclose to any person, without limitation of any kind, the tax treatment and tax structure of this Agreement and all
materials (including opinions or other tax analyses) that are provided relating to such treatment or structure.
(f) 	Notice. For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be
in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail,
return receipt requested, postage prepaid, addressed to the respective addresses set forth on the execution page of this
Agreement, provided that all notices to the Company shall be directed to the attention of the General Counsel or to such
other address as either party may have furnished to the other in writing in accordance herewith, except that notice of
change of address shall be effective only upon receipt:
17

-- 65 of 155 --

if to the Company:
The Office of the General Counsel
Nasdaq, Inc.
151 W. 42 Street
New York, NY 10036
if to the Executive:
her address as shown in the records of the Company
(g) 	Withholding Taxes. The Company may withhold from any amounts payable under this Agreement such federal, state and
local taxes as may be required to be withheld pursuant to any applicable law or regulation.
(h) 	Section 409A. Notwithstanding any other provision of this Agreement, any payment, settlement or benefit triggered by
termination of the Executive’s employment with the Company shall not be made until six months and one day following
Date of Termination if such delay is necessary to avoid the imposition of any tax, penalty or interest under Section 409A
of the Internal Revenue Code of 1986, as amended (“Section 409A”). Any installment payments that are delayed
pursuant to this Section 12(h) shall be accumulated and paid in a lump sum on the day that is six months and one day
following the Date of Termination (or, if earlier, upon the Executive’s death) and the remaining installment payments
shall begin on such date in accordance with the schedule provided in this Agreement. For purposes of this Agreement,
termination or severance of employment will be read to mean a “separation from service” within the meaning of
Section 409A where it is reasonably anticipated that no further services would be performed after that date or that the
level of services the Executive would perform after that date (whether as an employee or independent contractor) would
permanently decrease to no more than 20% of the average level of bona fide services performed over the immediately
preceding thirty-six (36) month period. Additionally, the amount of expenses eligible for reimbursement or in-kind
benefits to be provided during one calendar year may not affect the expenses eligible for reimbursement or any in-kind
benefits to be provided in any other calendar year and the right to reimbursement or in-kind benefits is not subject to
liquidation or exchange for another benefit. All reimbursements shall be made no later than the last day of the calendar
year following the calendar year in which the Executive incurs the reimbursable expense. This Agreement is intended to
comply with the requirements of Section 409A (including the exceptions thereto), to the extent applicable, and the
Agreement shall be administered and interpreted in accordance with such intent. If any provision contained in the
Agreement conflicts with the requirements of Section 409A (or the exemptions intended to apply under the Agreement),
the Agreement shall be deemed to be reformed to comply with the requirements of Section 409A (or the applicable
exemptions thereto). The Company, after consulting with the Executive, may amend this Agreement or the terms of any
award provided for herein in any manner that the Company considers necessary or advisable to ensure that cash
compensation, equity awards or other benefits provided for herein are not subject to United States federal income tax,
state or local income tax or any equivalent taxes in territories outside the United States prior to payment, exercise,
vesting or settlement, as applicable, or any tax, interest or penalties pursuant to
nd
18

-- 66 of 155 --

Section 409A. Any such amendments shall be made in a manner that preserves to the maximum extent possible the
intended benefits to the Executive. This Section 12(h) does not create an obligation on the part of the Company to
modify this Agreement and does not guarantee that the amounts or benefits owed under the Agreement will not be
subject to interest and penalties under Section 409A. For purposes of this Agreement, all rights to payments and benefits
hereunder shall be treated as rights to receive a series of separate payments and benefits to the fullest extent allowed by
Section 409A.
(i) 	Clawback. The Executive agrees that compensation and benefits provided by the Company under this Agreement or
otherwise will be subject to recoupment or clawback by the Company under any applicable clawback or recoupment
policy of the Company that is generally applicable to the Company’s executives, as may be in effect from time-to-time,
or as required by applicable law.
(j) 	Audit Rights. Any and all equity compensation of any kind due hereunder to Executive after the Date of Termination
shall be accompanied by a detailed statement from the Company showing the calculation for such compensation for the
period being measured. Within thirty (30) days after the delivery of such statement, the Executive may notify the
Company of any objections or changes thereto, specifying in reasonable detail any such objections or changes. If the
Executive does not notify the Company of any objections or changes thereto or if within twenty (20) days of the delivery
of an objection notice the Executive and the Company agree on the resolution of all objections or changes, then such
statements delivered by the Company, with such changes as are agreed upon, shall be final and binding. If the parties
shall fail to reach an agreement with respect to all objections or changes within such twenty (20)-day period, then all
disputed objections or changes shall, be subject to resolution in accordance with Section 11 above.
(k) 	Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as
if the signatures thereto and hereto were upon the same instrument.
(l) 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New
York, and consistent with the Company’s by-laws related to indemnification of Directors and Officers.
* 	* 	*
19

-- 67 of 155 --

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.
EXECUTIVE
/s/ Adena T. Friedman
Adena T. Friedman
NASDAQ, INC.
By: /s/ Michael R. Splinter
Name: Michael R. Splinter
Title: 	Lead Independent Director
20

-- 68 of 155 --

Exhibit A
NASDAQ CONTINUING OBLIGATIONS AGREEMENT
I, the undersigned, hereby enter into this agreement (the “Agreement”) with Nasdaq, Inc. as of the signature date below (the “Effective
Date”). Any reference in this Agreement to “I,” “me,” “my,” “mine,” or other like terms shall be deemed to refer to me. This
Agreement supersedes any prior Continuing Obligations Agreements signed by me during my employment with the Company (as
defined below).
During the course of my employment or engagement with Nasdaq, Inc. and/or its Affiliates (collectively, the “Company”) (hereinafter
referred to as my “Engagement”), I understand that I will have access to, be given access to, and/or receive Confidential Information
and Company Property. The Company regards the Confidential Information and Company Property as highly valued assets of the
Company. Any unauthorized disclosure or use of the Confidential Information or Company Property would cause grave harm to the
Company Parties. Therefore, to assure the confidentiality and proper use of Confidential Information and Company Property, and in
consideration of my Engagement, my access to Confidential Information and Company Property, and the compensation paid or to be
paid for my services during that Engagement, and pursuant to the mutual covenants and promises contained herein, I agree to the
following:
1. 	Confidentiality and Company Property
I agree that all Confidential Information and Company Property is owned by and for the Company Parties exclusively, and I agree that I
will use Confidential Information and Company Property solely for authorized, work-related purposes on behalf of the Company
Parties, and not for personal or other non-work-related purposes. I agree that Confidential Information is a valuable and unique asset of
the Company, and, except as provided in Section 6 of this Agreement, I covenant that I will not disclose any Confidential Information
to any Person (except as my duties for the Company may require or as required by law or in a judicial or administrative proceeding)
without the prior express written authorization of the Company.
Specifically, without limitation, I shall not, directly or indirectly, at any time during or after my Engagement, without prior express
written authorization from the Company: (a) divulge, disclose, transmit, reproduce, convey, summarize, quote, share, or make
accessible Confidential Information or non-public Company Property to any other Person; (b) use any Confidential Information or
Company Property for any purpose outside the course of performing the authorized duties of my Engagement; (c) remove Company
Property or Confidential Information from the Company Parties’ premises, except as expressly sanctioned by the Company provided
there are appropriate security measures in place; or (d) review or seek to access any Confidential Information or Company Property
except as required in connection with my work for the Company. Notwithstanding the above, I understand that I am not prohibited from
discussing the terms and conditions of my Engagement with coworkers, union representatives, or others, pursuant to Section 7 of the
NLRA, and nothing in this agreement prohibits me from responding to an inquiry from, or providing testimony before, the SEC,
FINRA, etc. or filing a charge regarding a possible securities law violation.
36

-- 69 of 155 --

Upon the termination of my Engagement for any reason, or if the Company so requests, I shall promptly deliver to the Company all
Confidential Information, Company Property, or Physical Embodiments of either of the foregoing (collectively, “Returnable Property”)
in my possession or under my control. If at any time after the termination of my Engagement I determine that I have any Returnable
Property in my possession or control, I shall immediately: (a) notify the Company of such determination, and (b) return to the Company
all such Returnable Property.
2. 	Non-Use of Other’s Confidential Information
During my Engagement, I will not (a) breach any agreement to keep in confidence any Confidential Information, knowledge, or data
acquired by me prior to or independent of my Engagement; or (b) disclose to the Company, or use or induce the Company to use, any
confidential or proprietary information or material belonging to any previous employer or to any other third party.
3. 	Non-Solicitation of Customers, Potential Customers and Employees
I agree that, for a period of twenty-four (24) months following the termination of my Engagement for any reason, I shall not, directly or
indirectly, without express written consent from the Company’s Office of General Counsel:
(i) 	Interfere with any customer relationship the Company has with any of its current customers or potential
customers that I had any involvement with, directly or indirectly, during the last twelve (12) months of my
Engagement;
(ii) 	Solicit, or induce to enter into, any business arrangement with, any employee or contractor of the Company with
whom I had any contact or a relationship with during the last twelve (12) months of my Engagement; or
(iii) 	Solicit, or induce to enter into, any business arrangement with, any employee or contractor of the Company’s
customers that I knew, or reasonably could be expected to know, was solicited by the Company for any
technology, operations, sales, or business role during the last twelve (12) months of my Engagement.
4. 	Non-Disparagement
I agree that I shall not, at any time during or after my Engagement, issue, circulate, publish, or utter any false or disparaging statements,
remarks, opinions, or rumors about the Company or its shareholders unless giving truthful testimony under subpoena or court order.
Notwithstanding the preceding sentence, I understand that I may provide truthful information to any governmental agency or self-
regulatory organization with or without subpoena or court order. With the exception of communications made in a private corporate
communication as an employee or consultant with regard to a listing decision of my employer or my consulting client, I agree that
public communications regarding a preference for listing a security on a market other than a market operated by the Company,
indicating that the quality of any of the Company’s securities markets as a securities market is in any way inferior to any other
securities market or exchange, and/or indicating that the regulatory efforts or programs of the Company are or have been lax in
36

-- 70 of 155 --

any way, are specifically defined as disparaging and will constitute a material breach of this Agreement. Nothing in this paragraph,
however, is intended to preclude or inhibit protected, concerted activity, nor shall it prevent me from making good faith, factual, and
truthful statements related to listing with the Company as long as my statements are not based on Confidential Information.
The Company agrees to instruct all executive officers and members of the Board of Directors of the Company to not issue, circulate,
publish, or utter any false or disparaging statements, remarks, opinions, or rumors about you to any third party unless giving truthful
testimony under subpoena or court order.
5. 	Cooperation with the Company in Connection with Legal Proceedings
Subject to the Company’s compliance with its indemnification obligations (including advancement), I agree to reasonably cooperate
with the Company in relation to any actual or threatened legal proceedings concerning Company-related matters about which I have
relevant knowledge, even after the termination of my Engagement. Upon presentation of appropriate documentation, the Company shall
pay or reimburse you for all reasonable out-of-pocket travel, delivery or similar expenses incurred by complying with this Section 5
(excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs.
Additionally, at any time during or after my Engagement, if I receive a subpoena or process from any Person (including, but not limited
to, any governmental agency) that may or will require me to disclose documents or information or provide testimony (in a deposition,
court proceeding, or otherwise) regarding, in whole or in part, any of the Company Parties, any Confidential Information, or any
Company Property (including any Nasdaq Inventions), I shall: (a) to the extent permissible by law, notify the Company’s Office of the
General Counsel of the subpoena or other process as soon as practicable and no later than three business days of receiving it; and (b) to
the maximum extent possible, not make any disclosure until the Company Parties have had a reasonable opportunity to contest the right
of the requesting Person to such disclosure, limit the scope or nature of such disclosure, and/or seek to participate in the proceeding or
matter in which the disclosure is sought.
6. 	Immunity for Disclosure of Trade Secrets in Certain Circumstances
I understand and acknowledge that, pursuant to 18 U.S.C. § 1833 (as defined in the Defend Trade Secrets Act of 2016) and
notwithstanding anything else in this Agreement, I am permitted to disclose trade secrets to third parties under certain circumstances.
The relevant portion of 18 U.S.C. § 1833 is reproduced as follows:
36

-- 71 of 155 --

(b) Immunity From Liability for Confidential Disclosure of a Trade Secret to the Government or in a Court Filing.
(1) Immunity - An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the
disclosure of a trade secret that—
(A) is made—
(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and
(ii) solely for the purpose of reporting or investigating a suspected violation of law; or
(B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
(2) Use of trade secret information in anti-retaliation lawsuit. An individual who files a lawsuit for retaliation by an employer for
reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret
information in the court proceeding, if the individual—
(A) files any document containing the trade secret under seal; and
(B) does not disclose the trade secret, except pursuant to court order.
I understand that nothing in this Agreement prohibits me from communicating with or reporting possible violations of law or regulation
to any federal, state, or local governmental office, official, agency or entity, and that notwithstanding my confidentiality obligations set
forth in Section 1 this Agreement, I will not be held civilly or criminally liable under any U.S. Federal or State trade secret law for
disclosure of a trade secret made in accordance with the provisions of 18 U.S.C. § 1833. I understand that if a disclosure of trade secrets
was not done in good faith pursuant to 18 U.S.C. § 1833, then I may be subject to criminal or civil liability, including, without
limitation, punitive and exemplary damages, and attorneys’ fees.
7. 	Inventions
(a) 	Ownership of Nasdaq Inventions by the Company
(i) 	As between me and the Company, all Nasdaq Inventions are owned by the Company. I hereby assign to Nasdaq,
Inc., without any further consideration, all right, title, and interest in and to the Nasdaq Inventions, including all
Intellectual Property Rights associated therewith. I agree that
I understand and acknowledge that the provisions of this Agreement related to the Company’s ownership of the Nasdaq Inventions do not apply to any
Invention that qualifies fully under the provisions of California Labor Code Section 2870, or which qualifies under any similar state law that may apply.
California Labor Code Section 2870 provides that “[a]ny provision in an employment agreement which provides that an employee shall assign, or offer to
assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own
time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) relate at the time of
conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the
employer; or (2) result from any work performed by the employee for the employer.”
1
1
36

-- 72 of 155 --

the foregoing assignment includes a present conveyance to Nasdaq, Inc. of ownership of Nasdaq Inventions that
are not yet in existence as of the Effective Date.
(ii) 	I hereby agree that, to the extent permitted under applicable law, the Nasdaq Inventions constitute “works made
for hire” and are deemed to be authored by Nasdaq, Inc.
(iii) 	To the extent, if any, that this Agreement does not provide Nasdaq, Inc. with full ownership, right, title and
interest in and to the Nasdaq Inventions, I hereby grant Nasdaq, Inc. an exclusive, perpetual, irrevocable, fully-
paid, royalty-free, worldwide license to use, exploit, reproduce, perform (publicly or otherwise), display
(publicly or otherwise), create derivative works from, modify, improve, develop, protect, distribute, import,
make, have made, sell, offer to sell or otherwise dispose of the Nasdaq Inventions, effective immediately on their
creation, with the right to sublicense each and every such right, including through multiple tiers, alone or in
combination. I intend that Nasdaq, Inc. has all substantial rights in the Nasdaq Inventions and associated
Intellectual Property Rights throughout the world. To the extent that any Moral Rights in the Nasdaq Inventions
cannot be assigned under applicable law, I hereby unconditionally and irrevocably waive and agree not to enforce
any and all Moral Rights, including any limitation on subsequent modification, to the extent permitted under
applicable law.
(iv) 	I agree to promptly make full disclosure to the Company of any and all Nasdaq Inventions. On request, such
disclosure shall be made in writing. During and after my Engagement and at the Company’s request and expense,
I will (1) assist the Company in every way necessary or desirable to establish or perfect the Company’s rights in
the Nasdaq Inventions and associated Intellectual Property Rights throughout the world, including by executing
in favor of the Company or its designee(s) any necessary or desirable documents, including patent and copyright
assignment documents, and (2) consent to or join in any action to enforce any Intellectual Property Right
associated with the Nasdaq Inventions. I agree that, if the Company is unable, because of my unavailability,
mental or physical incapacity, or for any other reason, to secure my signature with respect to the purposes set
forth in the preceding sentence, then I hereby irrevocably designate and appoint the Company and its duly
authorized officers and agents as my agent and attorney-in-fact, to act for and on my behalf to execute and file
any papers and oaths, and to do all other lawfully permitted acts with respect to such Nasdaq Inventions and
associated Intellectual Property Rights to further the prosecution, issuance, and enforcement of such Intellectual
Property Rights with the same legal force and effect as if executed by me. This power of attorney shall be
deemed coupled with an interest, and it is irrevocable.
(v) 	I agree to not challenge, dispute, or otherwise contest, or assist any Person in challenging, disputing, or otherwise
contesting, the validity, enforceability, or ownership of any Intellectual Property Rights (including those
associated with the Nasdaq Inventions) owned by or asserted to be owned by the Company or its designees. For
the avoidance of doubt, I agree to the foregoing without regard to whether any such challenge,
36

-- 73 of 155 --

dispute, or contest would make use of any Confidential Information or Company Property.
(vi) 	I agree to assist the Company in enforcing the Intellectual Property Rights associated with the Nasdaq
Inventions; though if I am requested by the Company to render such assistance after the termination of my
Engagement, I shall be entitled to: (1) if allowable under applicable law, a fair and reasonable rate of
compensation for such assistance; and (2) reimbursement of any reasonable expenses incurred at the request of
the Company relating to such assistance.
(b) 	Non-Use of My Personal Inventions
Without limiting any of my obligations under this Section 7, I agree that I will not integrate or incorporate any of My Personal
Inventions into any product, service, or other offering of the Company. Notwithstanding the foregoing prohibition, if I integrate or
incorporate, or allow the integration or incorporation of, any of My Personal Inventions into any product, service, or other offering of
the Company, I agree that I will make no claim against the Company with respect to such of My Personal Inventions. “My Personal
Inventions” means Inventions in which I personally possess any right, title, or interest. As examples, My Personal Inventions may
include Inventions that qualify as My Personal Inventions under the preceding definition and that I (i) developed prior to my
Engagement or (ii) develop during my Engagement but which do not qualify as owned by the Company pursuant to the terms of this
Section 7.
8. 	Injunctive Action; No Third-Party Beneficiaries; Duration of Obligations Extends Past Engagement
I acknowledge that all of the terms and provisions of this Agreement, along with all restrictions, prohibitions, and obligations created
thereunder (with such terms, provisions, restrictions, prohibitions, and obligations being, collectively, “Obligations”), are reasonable
and necessary for the protection of the Company Parties and their respective businesses. I agree that my breach of any of the
Obligations may result in irreparable injury to the Company Parties, that monetary relief alone may be inadequate to redress such a
breach, and further that the Company shall be entitled to seek an injunction to prevent and/or remedy such a breach (without first
having to post a bond).
In any proceeding for an injunction and upon any motion for a temporary or permanent injunction (“Injunctive Action”), the Company’s
right to receive monetary damages shall not be a bar or interposed as a defense to the granting of such injunction. The Company’s right
to an injunction is in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity,
including any remedy the Company may seek in any arbitration brought pursuant to Section 9 of this Agreement.
I hereby irrevocably submit to the jurisdiction of the courts of New York (or the jurisdiction in which I am assigned to work in at the
time of the issue under dispute) for any Injunctive Action and waive any claim or defense of inconvenient or improper forum or lack of
personal jurisdiction under any applicable law or decision, unless the Company has opted for another
36

-- 74 of 155 --

jurisdiction. Upon the issuance (or denial) of an injunction, the underlying merits of any such dispute shall be resolved in accordance
with Section 9 of this Agreement.
This Agreement is intended solely for the benefit of me, the Company, and our and respective permitted successors or assigns;
notwithstanding any provision of this Section 8, it is not the intention of the parties to confer, and this Agreement shall not confer, third-
party beneficiary rights upon any other Person other than me and the Company. I understand that the Company has the right to bring an
Injunctive Action or seek monetary damages or any other remedy for a breach of this Agreement that injures the Company’s customers
or prospective customers, but the Company is under no obligation to do so.
Unless explicitly set forth herein, none of the Obligations in this Agreement are limited in time; and all Obligations, unless
explicitly set forth herein, shall survive the termination of my Engagement, regardless of the reason for such termination.
9. 	Arbitration
Except as provided in Section 8 of this Agreement, any dispute arising between the Parties under this Agreement, under any statute,
regulation, or ordinance, under any other agreement between the Parties, and/or in way relating to my engagement by the Company
(other than sexual harassment or sexual assault claims, unless agreed to by all parties), shall be submitted to binding arbitration before
the American Arbitration Association (“AAA”) (or local arbitration body for disputes outside of the U.S.) for resolution.
The arbitration shall be conducted in accordance with the AAA’s Employment Arbitration Rules, as modified herein, including without
limitation the AAA Employment/Workplace Fee Schedule and Costs of Arbitration, as in effect from time-to-time (or the rules of the
local arbitration body for disputes outside of the U.S.). The arbitration shall be conducted in the state/jurisdiction where I work, unless
the parties mutually agree to another location. The arbitrator shall apply the applicable state/local jurisdiction law, depending on the
nature of the claim(s) at issue, including federal law as applied in such state where applicable.
The arbitration shall be conducted by a single arbitrator, who shall be an attorney who specializes in the field of employment law and
who shall have prior experience arbitrating employment disputes. However, if any disputes arising between the Parties under the
Agreement concern any Inventions or Intellectual Property Rights, the single arbitrator shall be an attorney who specializes in the field
of intellectual property law and who shall have prior experience arbitrating intellectual property disputes.
The award of the arbitrator shall be final and binding on the Parties, and judgment on the award may be confirmed and entered in any
state or federal court of the applicable jurisdiction. In the event of any court proceeding to challenge or enforce an arbitrator’s award,
the Parties hereby consent to the exclusive jurisdiction of the state and federal courts in the applicable jurisdiction and agree to venue in
that jurisdiction.
36

-- 75 of 155 --

To the fullest extent allowable under applicable, the arbitration shall be conducted on a strictly confidential basis. This means that I
shall not disclose the existence of a claim, the nature of a claim, any documents, exhibits, or information exchanged or presented in
connection with such a claim, or the result of any action (collectively, “Arbitration Materials”), to any third party, with the sole
exception of my legal counsel, who also shall be bound by these confidentiality terms. The Parties agree to take all steps necessary to
protect the confidentiality of the Arbitration Materials in connection with any such proceeding; agree to file all Confidential
Information (and documents containing Confidential Information) under seal; and agree to the entry of an appropriate protective order
encompassing the confidentiality terms of this Agreement, all to the extent allowable under the laws of that jurisdiction. The Company
shall pay the costs of the arbitration and the arbitrators.
10. 	Governing Law; Amendment; Waiver; Severability
Except as provided in Paragraph 9 regarding arbitration of disputes, this Agreement shall be construed in accordance with and shall be
governed by the laws of the State of New York (or the jurisdiction in which I am assigned to work in at the time of the issue under
dispute), excluding any choice of law principles. This Agreement constitutes the entire agreement between the Parties with respect to
the subject matter hereof, and may not be amended, discharged, or terminated, nor may any of its provisions be waived, except upon the
execution of a valid written instrument executed by me and the Company.
If any term or provision (or any portion thereof) of this Agreement is determined by an arbitrator or a court of competent jurisdiction to
be invalid, illegal, or incapable of being enforced, all other terms and provisions (and all other portions thereof) of this Agreement shall
nevertheless remain in full force and effect.
Upon a determination that any term or provision (or any portion thereof) of this Agreement is invalid, illegal, or incapable of being
enforced, the Company and I agree that an arbitrator or reviewing court shall have the authority to amend or modify this Agreement so
as to render it enforceable and effect the original intent of the Parties to the fullest extent permitted by applicable law.
11. 	Definitions
All capitalized terms used in this Agreement, along with their tenses, cases, and correlatives, shall have the defined meanings attributed
to them in this Section or in the other Sections where such defined meanings are provided.
“Affiliate” means, with respect to any entity, another entity that, directly or indirectly through one or more intermediaries, controls, is
controlled by or is under common control with, such entity. For purposes of this definition, “control” means the possession, direct or
indirect, of the power to direct or cause the direction of management and policies of the entity, whether through the ownership of voting
securities, by contract or otherwise.
“Company Parties” means the Company and Company’s customers or prospective customers.
36

-- 76 of 155 --

“Company Property” means all property and resources of the Company Parties, or any Company Party, including Confidential
Information, each Company Party’s products, each Company Party’s computer systems, and all software, e-mail, web pages, databases,
telephone, and facsimile services, and other administrative and/or support services provided by the Company Parties. I further agree
that Company Property shall include Nasdaq Inventions without regard to whether they also may be considered Confidential
Information as defined in this Agreement.
“Confidential Information” means any non-public, proprietary information regarding the Company Parties, in any Physical
Embodiment or format, including all personal information, financial data, commercial data, trade secrets, business plans, business
models, organizational structures and models, business strategies, pricing and advertising techniques and strategies, research and
development activities, software development, market development, exchange registration, studies, market penetration plans, listing
retention plans and strategies, marketing plans and strategies, communication and/or public relations products, plans, programs,
recruiting strategies, databases, processes, work product or inventions, financial formulas and methods relating to Company Parties’
business, computer software programs, accounting policies and practices, and all strategic plans or other matters, strategies, and
financial or operating information pertaining to current or potential customers or transactions (including information regarding each
Company Party’s current or prospective customers, customer names, and customer representatives), templates and agreements, and all
other information about or provided by the Company Parties, including information regarding any actual or prospective business
opportunities, employment opportunities, finances, investments, and other proprietary information and trade secrets. Confidential
Information also includes other information that is marked or otherwise identified as confidential or proprietary, or that would
otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is
known or used. Notwithstanding the above, Confidential Information shall not include any information that: (a) was known to me prior
to my Engagement as evidenced by written records in my possession prior to such disclosure; or (b) is generally and publicly available
and known to all Persons in the industries where the Company conducts business, other than because of any unauthorized disclosure by
me.
“Intellectual Property Rights” means all of the following, whether protected, created, or arising under the laws of the United States or
any other jurisdiction throughout the world, via statute, common law, equity, regulation, or other legal mechanism: (a) patents, patent
applications, and design rights (including industrial design rights); (b) rights in works of authorship, including copyrights, Moral
Rights, and mask work rights; (c) trademarks and service marks, and rights in trade names, trade dress, domain names, and any other
indicia of source or origin; (d) trade secrets and other rights in know-how and confidential or proprietary information; (e) any rights in,
to, or arising under any Invention; (f) any registrations or applications for registration for any of the foregoing (a)-(e), including any
provisionals, divisions, continuations, continuations-in-part, renewals, reissuances, rights subject to and/or arising out of post-grant
review (including re-examinations) and extensions (as applicable); (g) all contract and licensing rights and all claims and causes of
action of any kind with respect to any of the foregoing (a)-(f), including the right to sue and recover damages or other compensation
and/or obtain equitable relief for any past,
36

-- 77 of 155 --

present, or future infringement or misappropriation thereof; and (h) any right analogous to any right set forth above in (a)-(g).
“Inventions” means: (a) inventions, invention disclosures, discoveries, ideas, developments, improvements, technology, algorithms, and
designs (including industrial designs, user interface designs, user experience designs, and other types of designs); (b) original works of
authorship, copyrightable expression, research, computer software (including source code), computer programs, and mask works;
(c) trademarks, service marks, certification marks, logos, slogans, symbols, domain names, social media accounts, handles and
identifiers, and any other indicia of source or origin; (d) trade secrets, know-how, data, databases, information, formulas, patterns,
processes, technical information, business information, information regarding sales or potential sales and other commercial
relationships, business methods or processes, marketing plans, customer lists, vendor lists, and other types of proprietary or confidential
information; and (e) trading systems, trading strategies, and trading methodologies. The foregoing definition shall apply regardless of
whether or not the Inventions are subject to protection under patent, copyright, trade secret, industrial design, trademark, or other type
of intellectual property right, whether registered or unregistered.
“Moral Rights” means all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights
throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like.
“Nasdaq Inventions” means Inventions that are (a) made, conceived, expressed, developed, diligently worked on to reduce to practice,
or reduced to practice by me (solely or jointly with others) during or as a result of my Engagement or using Company Property and
(b) which relate in any manner to the Company, the business of the Company (including the services the Company provides to any of
the Company Parties), or my Engagement.
“Person” means a natural person, partnership, domestic or foreign limited partnership, domestic or foreign limited liability company,
trust, estate, association, corporation or any other legal entity or government authority.
“Physical Embodiments” means originals, copies, reproductions, documents, materials, records, papers, notebooks, files stored on or in
electronic or cloud-based media, and any other embodiment, in any format whatsoever, including in hard-copy formats, such as paper
and electronic or digital media, including, without limitation, computer-readable files, drives, disks, cloud-based information, and other
electronic media that may be developed in the future.
12. 	Miscellaneous
Other than any Contractor Agreement (as defined in Section 13), I agree that I am not currently a party, and will not become a party, to
any other agreement that is in conflict, or will prevent me from complying, with this Agreement.
This Agreement is binding upon, and shall inure to the benefit of, me and the Company and our respective heirs, executors,
administrators, successors, and assigns.
36

-- 78 of 155 --

I will not assign this Agreement or my obligations hereunder without the prior written consent of the Company, which consent must be
obtained from the Company’s Office of General Counsel, and which consent may be withheld in the Company’s sole discretion; and
any such purported assignment without consent shall be null and void from the beginning. I agree that the Company may freely assign
this Agreement, in whole or in part, to any Company entity, and I expressly consent to be bound by the provisions of this Agreement for
the benefit of any Company entity without the necessity that this Agreement be re-executed at the time of such transfer.
Without limiting the scope or generality of the terms of this Agreement in any way, I acknowledge and agree that the terms of this
Agreement and all discussions regarding this Agreement are confidential, and accordingly I agree not to disclose any such information
to any Person except to my attorney(s) or as otherwise may be required by law. I confirm that I may consult with an attorney regarding
the provisions of this Agreement, including the nonsolicit provisions as applicable to me, and that I have a fourteen (14)-day waivable
consideration period for these provisions. Notwithstanding the foregoing, I may disclose to any prospective employer the fact and
existence of this Agreement, and I may provide copies of this Agreement to such entity. The Company also has the right to apprise any
prospective employer of the terms of this Agreement and provide copies to any such prospective employer.
This Agreement shall be fairly interpreted in accordance with its terms and without any strict construction in favor of or against either
Party, notwithstanding which Party may have drafted it. The headings herein are included for reference only and are not intended to
affect the meaning or interpretation of the Agreement.
13. 	Other Terms of My Engagement
Nothing in this Agreement alters the at-will nature of my Engagement. I acknowledge and agree that my Engagement is at-will, which
means that both I and the Company shall have the right to terminate my Engagement at any time, for any lawful reason, with or without
cause and with or without prior notice, subject to the terms in that Employment Agreement dated March ____, 2025 between me and
the Company. If another agreement that establishes a third-party contractor relationship (or independent consultant relationship, or any
other similar non-employee relationship) between me and the Company (a “Contractor Agreement”) exists, the written terms of such
Contractor Agreement supersede any conflicting terms in this Agreement.
14. 	Signature
I hereby acknowledge and accept the terms of this Agreement as of the Effective Date, via my manual or electronic (e.g.,
DocuSign) signature, as reflected below.
Signature: /s/ Adena T. Friedman 	Date: March 11, 2025
Print Name: Adena T. Friedman
36

-- 79 of 155 --

Exhibit B
Release of Claims
GENERAL RELEASE
WHEREAS, Adena Friedman (hereinafter referred to as the “Executive”) and Nasdaq, Inc. (hereinafter referred to as
“Employer”) are parties to an Employment Agreement, dated March ____, 2025 (the “Employment Agreement”), which provided for
the Executive’s employment with Employer on the terms and conditions specified therein; and
WHEREAS, the Executive has agreed to execute a release of the type and nature set forth herein as a condition to her
entitlement to certain payments and benefits upon her termination of employment with Employer.
NOW, THEREFORE, in consideration of the premises and mutual promises herein contained and for other good and valuable
consideration received or to be received by the Executive in accordance with the terms of the Employment Agreement, it is agreed as
follows:
1. 	Excluding enforcement of the covenants, promises and/or rights reserved herein, the Executive hereby irrevocably and
unconditionally releases, acquits and forever discharges Employer and each of Employer’s owners, stockholders, predecessors,
successors, assigns, directors, officers, employees, divisions, subsidiaries, affiliates (and directors, officers and employees of
such companies, divisions, subsidiaries and affiliates) and all persons acting by, through, under or in concert with any of them
(collectively “Releasees”), or any of them, from any and all Claims (as defined below) through the date of this Release. You
agree not to file a lawsuit or arbitration to assert any such Claim. Further, you agree that should any other person, organization
or entity file a lawsuit or arbitration to assert any such Claim, you will not seek or accept any personal relief in such action.
(a) 	Definition of “Claims.” Except as stated below, “Claims” includes without limitation all actions or demands of any kind
that you may now have or have had or reasonably known you should have had (although you are not being asked to
waive Claims that may arise after the date of this Agreement). More specifically, Claims include rights, causes of action,
damages, penalties, losses, attorneys’ fees, costs, expenses, obligations, agreements, judgments and all other liabilities of
any kind or description whatsoever, either in law or in equity, whether known or unknown, suspected or unsuspected.
The nature of Claims covered by this release includes without limitation all actions or demands in any way based on
your employment with the Company, the terms and conditions of such employment, or your separation from
employment. More specifically, all of the following are among the types of Claims which are waived and barred by this
General Release of Claims to the extent allowable under applicable law and are considered illustrative but not
exhaustive:
• Contract Claims, whether express or implied;
• Tort Claims, such as for defamation or emotional distress;
36

-- 80 of 155 --

• Claims under federal, state and municipal laws, regulations, ordinance or court decisions of any kind;
• Claims of discrimination, harassment or retaliation, whether based on race, color, religion, gender, sex, age, sexual
orientation, handicap and/or disability, genetic information, national origin, or any other legally protected class;
• Claims under the AGE DISCRIMINATION IN EMPLOYMENT ACT, Title VII of the Civil Rights Act of 1964, as
amended, the Americans with Disabilities Act as amended, the Genetic Information Nondiscrimination Act, the Family and
Medical Leave Act, and similar state and local statutes, laws and ordinances, including, but not limited to, the New York
State Human Rights Law, the New York Labor Act, the New York Equal Pay Law, the New York Civil Rights Law, the New
York Rights of Persons With Disabilities Law, and the New York Equal Rights Law, all as amended;
• Claims under the Employee Retirement Income Security Act (other than rights to vested benefits), the Occupational Safety
and Health Act, the False Claims Act, and similar state and local statutes, laws and ordinances;
• Claims for wrongful discharge; and
• Claims for attorneys’ fees, including litigation expenses and/or costs;
provided, however, that this release shall not apply to any of the obligations of Employer or any other Releasee under the Employment
Agreement, or under any agreements, plans, contracts, documents or programs described or referenced in the Employment Agreement;
and provided, further, that this release shall not apply to any rights the Executive may have to obtain contribution, advancement or
indemnity against Employer or any other Releasee pursuant to contract, Employer’s certificate of incorporation and bylaws, coverage
under Employer’s directors and officers or similar liability insurance (which rights survive and are incorporated herein by reference) or
otherwise.
(b) 	Exclusions: Notwithstanding any other provision of this release, the following are not barred by the release: (a) Claims
relating to the validity of this General Release; (b) Claims by either party to enforce this General Release or the
Employment Agreement (including the Continuing Obligations Agreement); (c) Claims which are not legally waivable,
including SEC whistleblowing claims pursuant to Rule 21F-17. In addition, this General Release of Claims will not
operate to limit or bar your right to file an administrative charge of discrimination with the Equal Employment
Opportunity Commission (EEOC) or to testify, assist or participate in an investigation, hearing or proceeding conducted
by the EEOC. However, the Release does bar your right to recover any personal or monetary relief, including if you or
anyone on your behalf seeks to file a lawsuit or arbitration on the same basis as the charge of discrimination.
Additionally, nothing in this Release should have a chilling effect on your ability to engage in whistleblowing activity,
by prohibiting or restricting you (or your attorney) from initiating communications directly with, or responding to any
inquiry from, or providing testimony before, the SEC or FINRA regarding your employment at the Company, and
nothing prevents you from reporting to, communicating with, contacting, responding to an inquiry from, providing
relevant information to, participating or assisting in an investigation conducted by, or receiving a
36

-- 81 of 155 --

monetary award from the SEC or any other governmental enforcement agency related to such communication (except as
noted in Section 1(a) above).
2. 	The Executive expressly waives and relinquishes all rights and benefits afforded by California Civil Code Section 1542 and
does so understanding and acknowledging the significance of such specific waiver of Section 1542. Section 1542 states as
follows:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR
SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR.”
Thus, notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release and discharge of
the Releasees, the Executive expressly acknowledges that this Agreement is intended to include in its effect, without limitation, all
Claims that the Executive does not know or suspect to exist in the Executive’s favor at the time of execution hereof, and that this
Agreement contemplates the extinguishment of any such Claim or Claims.
3. 	The Executive understands that she has been given a period of twenty-one (21) days to review and consider this General Release
before signing it pursuant to the Age Discrimination In Employment Act of 1967, as amended. The Executive further
understands that she may use as much of this twenty-one (21)-day period as the Executive wishes prior to signing.
4. 	The Executive acknowledges and represents that she understands that she may revoke the waiver of her rights under the Age
Discrimination In Employment Act of 1967, as amended, effectuated in this Agreement within seven days of signing this
Agreement. Revocation can be made by delivering a written notice of revocation to Office of the General Counsel, Nasdaq, Inc.,
One Liberty Plaza, New York, New York 10006. For this revocation to be effective, written notice must be received by the
General Counsel no later than the close of business on the seventh day after the Executive signs this General Release. If the
Executive revokes the waiver of her rights under the Age Discrimination in Employment Act of 1967, as amended, Employer
shall have no obligations to the Executive under Section 8 (other than the Base Obligations) of the Employment Agreement.
5. 	The Executive and Employer respectively represent and acknowledge that in executing this Agreement neither of them is
relying upon, and has not relied upon, any representation or statement not set forth herein made by any of the agents,
representatives or attorneys of the Releasees with regard to the subject matter, basis or effect of this Agreement or otherwise.
6. 	This General Release shall not in any way be construed as an admission by any of the Releasees that any Releasee has acted
wrongfully or that the Executive has any rights whatsoever against any of the Releasees except as specifically set forth herein,
and each of the Releasees specifically disclaims any liability to any party for any wrongful acts. Further, this Agreement shall
not in any way be construed as an admission by the Executive that the Executive has acted wrongfully.
7. 	It is the desire and intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible
under law. Should there be any conflict
36

-- 82 of 155 --

between any provision hereof and any present or future law, such law will prevail, but the provisions affected thereby will be
curtailed and limited only to the extent necessary to bring them within the requirements of law, and the remaining provisions of
this Agreement will remain in full force and effect and be fully valid and enforceable.
8. 	The Executive represents and agrees (a) that the Executive has to the extent she desires discussed all aspects of this Agreement
with her attorney, (b) that the Executive has carefully read and fully understands all of the provisions of this Agreement, and
(c) that the Executive is voluntarily entering into this Agreement.
9. 	This General Release shall be governed by, and construed in accordance with, the laws of the State of New York, without giving
effect to the conflicts of laws principles thereof or to those of any other jurisdiction which, in either case, could cause the
application of the laws of any jurisdiction other than the State of New York. This General Release is binding on the successors
and assigns of, and sets forth the entire agreement between, the parties hereto; fully supersedes any and all prior agreements or
understandings between the parties hereto pertaining to the subject matter hereof; and may not be changed except by explicit
written agreement to that effect subscribed by the parties hereto.
PLEASE READ CAREFULLY. THIS GENERAL RELEASE INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN
CLAIMS.
This General Release is executed by the Executive and Employer as of the ___day of __________, 20__.
Adena Friedman
NASDAQ, INC.
By:
Name:
Title:
36

-- 83 of 155 --

Exhibit 10.2
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into on March 10, 2025 (the “Effective Date”), by and
between Nasdaq, Inc. (the “Company”) and Tal Cohen (the “Executive”).
In consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties hereby
agree as follows:
1. 	Term of Agreement. Subject to Section 8 below, the term of this Agreement shall commence on the Effective Date and end on
January 1, 2030 (the “Term”). The Term may be extended by mutual agreement of the parties. In the event of a Change in
Control (as defined in Section 8(g)), the Term shall automatically be extended until the end of the CIC Protection Period (as
defined in Section 8(g)) below if the Term would otherwise expire during such CIC Protection Period absent the extension.
2. 	Position.
(a) 	Duties. The Executive shall serve as the Company’s President and shall have such other duties as agreed to by the
Executive, the Chair and Chief Executive Officer (the “CEO”), and the Board of Directors of the Company (the
“Board”). In such position, the Executive shall have such duties and authority as shall be determined from time to time
by the CEO and the Board and as shall be consistent with the bylaws of the Company as in effect from time to time.
During the Term, the Executive shall devote his full time and best efforts to his duties hereunder. The Executive shall
report directly to the CEO. The scope, duties and responsibilities of the role will be evaluated at least annually and
increased, as appropriate, based on performance in the role.
(b) 	Company Code of Ethics. The Executive shall comply in all respects with the Company’s Code of Ethics and all
applicable corporate policies referenced in the Code of Ethics, as may be amended from time to time (the “Code of
Ethics”). The Executive may, in accordance with the Code of Ethics, (i) engage in personal activities involving
charitable, community, educational, religious or similar organizations, (ii) may engage in board service for an
organization that is not a Competitive Business (as defined below) with the CEO’s prior written consent (which shall not
be unreasonably withheld); provided that such board service does not unreasonably interfere with the performance of
Executive’s duties and responsibilities and (iii) manage his personal investments; provided, however, that, in each case,
such activities are in all respects consistent with applicable law, the Continuing Obligations Agreement attached as
Exhibit A (“Continuing Obligations Agreement”), and Section 9 below.
3. 	Base Salary. During the Term, the Company shall pay the Executive a base salary (the “Base Salary”) at an annual rate of not
less than $750,000. The Base Salary shall be payable in regular payroll installments in accordance with the Company’s payroll
practices as in effect from time to time (but no less frequently than monthly). The Management Compensation Committee of the
Board (the “Compensation Committee”) shall review the Base Salary at least annually and may (but shall be under no obligation
to) increase (but not decrease) the Base Salary on the basis of such review.
4. 	Annual Bonus.

-- 84 of 155 --

(a) 	Annual Bonus. For each calendar year during the Term, the Executive shall be eligible to participate in the Executive
Corporate Incentive Plan of the Company (the “Bonus Program”) in accordance with the terms and provisions of such
Bonus Program as established from time to time by the Compensation Committee and pursuant to which the Executive
will be eligible to earn an annual cash bonus (the “Annual Bonus”). Pursuant to the terms of the Bonus Program, the
Executive shall be eligible to earn, for each full calendar year during the Term, a target Annual Bonus of not less than
200% of Base Salary (the “Target Bonus”) based upon the achievement of one or more performance goals established for
such year by the CEO and the Compensation Committee. The Executive shall have the opportunity to make suggestions
to the CEO and the Compensation Committee prior to the determination of the performance goals for the Bonus Program
for each performance period, but the Compensation Committee will have final power and authority concerning the
establishment of such goals. The CEO and the Compensation Committee shall review the Target Bonus at least annually
and may (but shall be under no obligation to) increase (but shall not decrease) the Target Bonus on the basis of such
review. The Target Bonus for each year during the Term shall never be less than the Target Bonus for the immediately
preceding year.
(b) 	Timing of Annual Bonus. The Annual Bonus for each year shall be paid to the Executive as soon as reasonably
practicable following the end of such year, but in no event later than March 15 following the end of the calendar year to
which such Annual Bonus relates.
5. 	Equity Compensation.
(a) 	Annual Equity Award. Based on the Compensation Committee’s evaluation of the performance of the Company and
Executive, peer group market data, internal equity and consistent with past practices with respect to the combined
aggregate value of the grants of options, restricted share units and performance share units, the Executive shall be
eligible to receive an annual equity compensation award (an “Annual Equity Award”), in accordance with the terms and
provisions of the Company’s Equity Incentive Plan (the “Stock Plan”), which has been adopted by the Board and may
from time to time be amended. The applicable provisions of the Stock Plan and each equity award agreement to be
executed by the Executive and the Company (to the extent not inconsistent with this Agreement) shall govern the
treatment of the equity awards. The Executive shall receive an Annual Equity Award for 2025 with a target value at the
time of grant of not less than $6,000,000.
(b) 	One-Time Equity Award. Within thirty (30) days of the Effective Date of this Agreement, the Executive shall be granted
a one-time equity award with a target value at the time of grant of $7,000,000 (the “One-Time Equity Award”). The One-
Time Equity Award shall be comprised of 50% Restricted Stock Units (“RSUs”) and 50% Performance Share Units
(“PSUs”), as these terms are defined in the Stock Plan. The RSUs shall vest as to 33% on the first anniversary of the
grant date; 33% on the second anniversary of the grant date; and the remainder on the third anniversary of the grant date,
subject to the Executive’s continued employment on each vesting date (except as provided herein). The PSUs shall vest
on December 31, 2027, subject to the Executive’s continued employment on the vesting date and achievement of the
performance goals set forth in the applicable equity award agreement, except as set forth below. The applicable
provisions of the Stock Plan and of each equity award agreement to be executed
th
2

-- 85 of 155 --

by the Executive and the Company (to the extent not inconsistent with this Agreement) shall govern the treatment of this
equity award.
6. 	Employee Benefits. During the Term, and except as otherwise noted herein, the Company shall provide the Executive with
benefits on the same basis as benefits are generally made available to other senior executives of the Company, including,
without limitation, medical, dental, vision, disability and life insurance, financial and tax planning services and retirement
benefits.
7. 	Business and Other Expenses.
(a) 	Business Expenses. During the Term, the Company shall reimburse the Executive for reasonable business expenses
incurred by him in the performance of his duties hereunder in accordance with the policy established by the Company.
Upon presentation of appropriate documentation, the Company shall reimburse the Executive for up to $15,000 in
attorney fees relating to the negotiation and execution of this Agreement.
8. 	Termination. Notwithstanding any other provision of this Agreement, subject to the further provisions of this Section 8, the
Company may terminate the Executive’s employment or the Executive may resign such employment for any reason or no stated
reason at any time, subject to the notice and other provisions set forth below:
(a) 	Generally. In the event of the termination of the Executive’s employment for any reason, the Executive shall receive
payment of (i) any unpaid Base Salary through the Date of Termination (as defined below), to be paid in accordance with
Section 3 above and (ii) any earned but unpaid Annual Bonus with respect to the calendar year ended prior to the Date of
Termination, payable in accordance with Section 4(b) (the “Base Obligations”). In addition, in the event of the
Executive’s termination of employment, the applicable provisions of the Company’s Stock Plan or each equity award
agreement executed by the Executive and the Company shall govern the treatment of the equity awards.
For purposes of this Agreement, “Date of Termination” means (i) in the event of a termination of the Executive’s employment by the
Company for Cause or by the Executive for Good Reason, the date specified in a written notice of termination (or, if not specified
therein, the date of delivery of such notice), but in no event earlier than the expiration of the cure periods set forth in Section 8(b)(ii) or
8(b)(iii) below, respectively; (ii) in the event of a termination of the Executive’s employment by the Company without Cause, the date
specified in a written notice of termination (or if not specified therein, the date of delivery of such notice); (iii) in the event of a
termination of the Executive’s employment by the Executive without Good Reason, the date specified in a written notice of termination,
but in no event less than sixty (60) days following the date of delivery of such notice; (iv) in the event of a termination of the
Executive’s employment due to Permanent Disability (as defined below), the date the Company terminates the Executive’s employment
following the certification of the Executive’s Permanent Disability; (v) in the event of a termination of employment due to the
Executive’s death, the date of the Executive’s death; or (vi) in the event of a termination of Executive’s employment due to Retirement
(as defined below), the earlier to occur of (1) the last day of the Retirement Notice Period (as defined below) or (2) the date specified in
a written notice of termination by the Company, in each case pursuant to Section 8(c).
3

-- 86 of 155 --

(b) 	Termination by the Company Without Cause or by the Executive for Good Reason Other Than in Connection with
Change in Control.
(i) 	The Executive’s employment hereunder may be terminated by the Company without Cause or by the Executive
for Good Reason on or before the last day of the Term. Upon the termination of the Executive’s employment by
the Company without Cause or by the Executive for Good Reason pursuant to this Section 8(b), which occurs
more than six months prior to a Change in Control or at least two years after a Change in Control, the Executive
shall, subject to Section 8(i) below, be entitled to receive, in addition to the Base Obligations, the following
payments and benefits (the “Severance Benefits”):
(A) 	Severance Payment. The Company shall pay the Executive an amount (the “Severance Payment”)
equal to the sum of (I) one and one half (1.5) times the Base Salary paid to the Executive with
respect to the calendar year immediately preceding the Executive’s Date of Termination, (II) one
and one half (1.5) times the Target Bonus and (III) a pro rata Target Bonus with respect to the
calendar year in which the Date of Termination occurs, determined in accordance with the Pro-
Rata Target Bonus Calculation (the “Pro-Rata Target Bonus”).
“Pro-Rata Target Bonus Calculation” is determined by multiplying the Executive’s Target Bonus
under Section 4(a) for the fiscal year in which the Date of Termination occurs by a fraction, the
numerator of which is the number of days in the fiscal year in which the Date of Termination
occurs through the Date of Termination and the denominator of which is the total number of days
in the calendar year.
The Severance Payment (other than the Pro-Rata Target Bonus) is payable, subject to
Section 12(h), in substantially equal monthly installments for the twelve (12)-month period
following the Executive’s Date of Termination, with the first installment to be paid in the month
following the month in which the Release Effective Date occurs; provided, however, (consistent
with the requirements of Section 409A), that if the sixty (60)-day period described in Section 8(i)
below begins in one calendar year and ends in another, the first installment of the Severance
Payment shall be paid not earlier than January 1 of the calendar year following the Date of
Termination (the period during which the Severance Benefits are paid being the “Severance
Period”). The Pro-Rata Target Bonus shall be paid, subject to Section 12(h), in a lump sum within
thirty (30) days following the Release Effective Date (provided that if the
4

-- 87 of 155 --

sixty (60)-day period described in Section 8(i) below begins in one calendar year and ends in
another, the Pro-Rata Target Bonus shall be paid not earlier than January 1 of the calendar year
following the Date of Termination); and
(B) 	Equity Vesting. The Executive shall, subject to Section 8(i), be entitled to receive twelve (12)
months of continued vesting of outstanding PSUs, stock options and RSUs. Any performance-
based vesting will be based on actual performance goals during the respective performance
periods. Any stock options will remain exercisable for twenty-four (24) months after the Date of
Termination (but no later than its original scheduled expiration date).
(C) 	Health Care Coverage Payments. Provided that the Executive timely elects to continue coverage
under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), the Company agrees to
continue to pay the employer’s share of the medical, dental and vision premiums for the Executive
and his eligible dependents from the expiration date of the Executive’s coverage under the
Company plan (which is at the end of month in which the Executive’s Date of Termination
occurs), for eighteen (18) months (“COBRA Continuation Period”). The Executive will still be
responsible for paying the employee share of the premium as specified by the plan administrator.
If, during the COBRA Continuation Period, the Executive begins work with an employer who
provides health insurance benefits for which the Executive is eligible, the Company’s obligation
under this section shall forever cease upon the expiration of the waiting period (if any) for
entitlement to insurance coverage through the Executive’s new employer. The Executive agrees to
promptly notify the Company in writing within seven (7) days of the Executive’s commencement
of full-time employment during the COBRA Continuation Period. 	In any event, and
notwithstanding any provision to the contrary in this section, the Company shall have no
obligation to make any payments for COBRA premiums paid for health insurance coverage
beyond the expiration of the COBRA Continuation Period.
(D) 	Other Benefits. The Company will make a one-time cash payment to the Executive in the amount
of $45,000 to subsidize the cost of continuation of financial and tax services for a period of
twenty-four (24) months following the Date of Termination.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(b)
shall be determined in accordance with the plans, policies and
5

-- 88 of 155 --

practices of the Company; provided, however, that the Executive shall not participate in any
severance plan, policy or program of the Company. The Severance Benefits are payments and
benefits to which the Executive is not otherwise entitled, are given in consideration for the
Release (as described in Section 8(i) below) and are in lieu of any severance plan, policy or
program of the Company or any of its subsidiaries that may now or hereafter exist. The payments
and benefits to be provided pursuant to this Section 8(b)(i) shall constitute liquidated damages and
shall be deemed to satisfy and be in full and final settlement of all obligations of the Company to
the Executive under this Agreement. The Executive acknowledges and agrees that such amounts
are fair and reasonable, and are his sole and exclusive remedy, in lieu of all other remedies at law
or in equity, with respect to the termination of his employment hereunder. If, during the Severance
Period, the Executive breaches in any material respect any of his obligations under Section 9, or
the Continuing Obligations Agreement, the Company may, upon written notice to the Executive
(x) terminate the Severance Period and cease to make any further payments of the Severance
Payment and (y) cease any health care coverage payments, except in each case as required by
applicable law.
(ii) 	For purposes of this Agreement, “Cause” shall mean (A) the Executive’s conviction of, or pleading nolo
contendere to, any crime, whether a felony or misdemeanor, involving the purchase or sale of any security, mail
or wire fraud, theft, embezzlement, moral turpitude, or Company property (with the exception of minor traffic
violations or similar misdemeanors); (B) the Executive’s repeated neglect of his duties to the Company; or
(C) the Executive’s willful misconduct in connection with the performance of his duties or other material breach
by the Executive of this Agreement provided that the Company may not terminate the Executive’s employment
for Cause unless (x) the Company first gives the Executive written notice of its intention to terminate and of the
grounds for such termination within ninety (90) days following the date the Board is informed of such grounds at
a meeting of the Board and (y) the Executive has not, within thirty (30) days following receipt of such notice,
cured such Cause (if capable of cure) in a manner that is reasonably satisfactory to the Board.
(iii) 	For purposes of this Agreement, “Good Reason” shall mean the Company (A) reducing the Executive’s position,
duties, or authority, other than during the Retirement Notice Period; (B) failing to secure the agreement of any
successor entity to the Company that the Executive shall continue in his position without reduction in position,
duties or authority; (C) relocating the Executive’s principal work location beyond a fifty (50)-mile radius of his
work location as of the Effective Date (provided that this
6

-- 89 of 155 --

Clause (C) shall apply only to a relocation that occurs during the two-year period beginning upon a Change of
Control, as defined below, and ending two years thereafter); or (D) committing any other material breach of this
Agreement; provided, however, that the occurrence of a Change in Control, following which the Company
continues to have its common stock publicly traded and the Executive is offered continued employment as an
executive officer with substantially the same duties and authority as he has hereunder of such publicly traded
entity, shall not be deemed to give rise to an event or condition constituting Good Reason; and provided, further,
that no event or condition shall constitute Good Reason unless (x) the Executive gives the Company a Notice of
Termination specifying his objection to such event or condition within ninety (90) days following the occurrence
of such event or condition, (y) such event or condition is not corrected, in all material respects, by the Company
in a manner that is reasonably satisfactory to the Executive within thirty (30) days following the Company’s
receipt of such notice and (z) the Executive resigns from his employment with the Company not more than thirty
(30) days following the expiration of the thirty (30)-day period described in the foregoing clause (y).
(c) 	Retirement
(i) 	Once the Executive has reached the age of fifty-five (55) and completed at least ten years of service with the
Company, the Executive may terminate his employment without Good Reason and such termination of
employment shall be deemed a termination due to retirement (“Retirement”) by providing the Company with
twelve (12) months’ written notice (or such shorter period as may be approved by the Board) (the “Retirement
Notice Period”) of such termination pursuant to Section 12(f) of this Agreement; provided that the Executive
may not provide notice of Retirement any earlier than January 1, 2027; and provided, further, that the Executive’s
Retirement may not occur prior to January 1, 2028. The Term shall automatically be extended until the end of the
Retirement Notice Period, if notice is given less than one year prior to the end of the Term. In the event of a
termination due to Retirement, the Company may, it its sole and absolute discretion, by written notice pursuant to
Section 12(f) of this Agreement, accelerate the Date of Termination without changing the characterization of
such termination as a Retirement; and more specifically, such written notice and acceleration shall not constitute
a termination without Cause by the Company nor provide a basis for a claim of Good Reason. Upon the
termination of the Executive’s employment pursuant to this Section 8(c), the Executive shall, subject to
Section 8(i) below, be entitled to receive, in addition to the Base Obligations, the following payments and
benefits:
(A) 	Payments. The Executive shall be entitled to receive continued Base Salary through the end of the
Retirement Notice Period and a pro-rata Target Bonus, determined in accordance with the Pro-
Rata Retirement Target Bonus Calculation and payable, subject to Section 12(h), in a lump sum
within thirty (30) days following the Release Effective Date (provided that if the sixty (60)-day
period described in Section 8(i) below begins in one calendar year and ends in another, the pro
rata Target Bonus shall be paid not earlier
7

-- 90 of 155 --

than January 1 of the calendar year following the Date of Termination). For the avoidance of
doubt, the Executive shall also remain entitled to any Annual Bonus for a year that ends during the
Retirement Notice Period, the amount of which to be calculated in accordance with the Bonus
Program for such year and without any adjustment as a result of the Executive’s decision to elect
Retirement.
“Pro-Rata Retirement Target Bonus Calculation” is determined by multiplying the Executive’s
Target Bonus under Section 4(a) by a fraction, the numerator of which is the number of days in the
fiscal year in which the last day of the Retirement Notice Period occurs through the last day of the
Retirement Notice Period and the denominator of which is the total number of days in the calendar
year.
(B) 	Equity Vesting. The Executive shall be entitled to continued vesting of all outstanding forms of
equity compensation issued prior to the commencement of the Retirement Notice Period as though
the Executive were employed through the applicable vesting dates (“Continued Vesting Period for
Retirement”), with PSUs vesting based on actual performance goals during the respective
performance periods. Any vested stock options shall remain exercisable until the expiration date
specified in the applicable award agreement. Notwithstanding anything to the in the Stock Plan
and the equity award agreement, any forms of equity compensation granted during the Retirement
Notice Period shall be prorated based on the time elapsed between the vesting commencement
date and the last day of the Retirement Notice Period, with PSUs vesting based on actual
performance goals during the applicable performance period.
(C) 	Health Care Coverage Payments. Provided that the Executive timely elects to continue COBRA
coverage, the Company agrees to continue to pay the employer’s share of the medical, dental and
vision premiums for the Executive and his eligible dependents for the COBRA Continuation
Period. The Executive will still be responsible for paying the employee share of the premium as
specified by the plan administrator. If, during the COBRA Continuation Period, the Executive
begins work with an employer who provides health insurance benefits for which the Executive is
eligible, the Company’s obligation under this section shall forever cease upon the expiration of the
waiting period (if any) for entitlement to insurance coverage through the Executive’s new
employer. The Executive agrees to promptly notify the Company in writing within seven (7) days
of the Executive’s commencement of full-time employment during the COBRA Continuation
Period. In any event, and notwithstanding any provision to the
8

-- 91 of 155 --

contrary in this section, the Company shall have no obligation to make any payments for COBRA
premiums paid for health insurance coverage beyond the expiration of the COBRA Continuation
Period.
(D) 	Other Benefits. The Company will make a one-time cash payment to the Executive in the amount
of $45,000 to subsidize the cost of continuation of financial and tax services for a period of
twenty-four (24) months following the Date of Termination. Additionally, upon the Executive’s
request, at any time within eighteen (18) months following the Date of Termination, the Company
will provide third-party concierge advisory services, at the Company’s expense, to assist the
Executive with the procurement of private health care coverage.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(c) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The payments and benefits in this Section 8(c) to which the Executive is not otherwise entitled are
given in consideration for the Release (as described in Section 8(i) below) and are in lieu of any severance plan, policy or program of
the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant to this
Section 8(c) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all obligations of
the Company to the Executive under this Agreement.
The Executive acknowledges and agrees that such amounts are fair and reasonable, and are his sole and exclusive remedy, in lieu of all
other remedies at law or in equity, with respect to the termination of his employment hereunder. If, during the Continued Vesting Period
for Retirement, the Executive breaches in any material respect any of his obligations under Section 9, the Continuing Obligations
Agreement, or commences employment in an operating executive role at a for-profit operating company, either publicly listed or
privately owned (a “Disqualifying Operational Role”), the Company may, upon written notice to the Executive terminate the Continued
Vesting Period for Retirement and cease any benefits continuation coverage or payments, except in each case as required by applicable
law. For the avoidance of doubt, the following will not constitute a Disqualifying Operational Role: (i) an operating executive role in a
non-profit organization or in a government agency or other government position, (ii) a role as an investment management professional,
or advisor to a private equity firm or venture capital firm with respect to a portfolio company (provided that such role is not an
operating role within a portfolio company or at the General Partner itself), or (iii) a role as a Non-Executive Chair or on the board of
directors of any organization, including a for-profit operating company or a private equity or venture capital firm.
If, during the twelve (12)-month period following the Date of Termination due to Retirement, the Executive commences employment in
a Disqualifying Operational Role, then the Executive shall promptly repay to the Company all payments and benefits received pursuant
to this Section 8(c). Further, if during the period between twelve (12) and thirty-six (36) months following the Date
9

-- 92 of 155 --

of Termination due to Retirement, the Executive commences employment in a Disqualifying Operational Role, then all continued
vesting of equity awards pursuant to Section 8(c)(i)(B) shall immediately cease. If the Executive seeks to obtain a Disqualifying
Operational Role during such three-year period, the Executive may seek a waiver of this provision upon written request to the Board of
Directors and the Board shall reasonably consider such request in good faith. Any such waiver, if granted, must be in writing.
(d) 	Permanent Disability.
(i) 	The Executive’s employment hereunder shall terminate upon his Permanent Disability. Upon termination of the
Executive’s employment due to Permanent Disability, the Executive shall, subject to Section 8(i) below, be
entitled to receive, in addition to the Base Obligations, (A) the Pro-Rata Target Bonus paid, subject to
Section 12(h), in a lump sum within thirty (30) days following the Release Effective Date (provided that if the
sixty (60)-day period described in Section 8(i) below begins in one calendar year and ends in another, the Pro-
Rata Target Bonus shall be paid not earlier than January 1 of the calendar year following the Date of
Termination) and (B) accelerated vesting of all unvested equity compensation awarded to the Executive by the
Company, effective as of December 31 of the year of termination and, in accordance with Section 5, each equity
award agreement executed by the Executive and the Company shall describe the treatment of the equity awards
under this Section 8(d). Any performance-based vesting will be based on actual performance goals during any
complete performance period; vesting will be at target performance for grants vesting prior to the completion of a
performance cycle. All other benefits, if any, due the Executive following termination pursuant to this
Section 8(d) shall be determined in accordance with the plans, policies and practices of the Company; provided,
however, that the Executive shall not participate in any other severance plan, policy or program of the Company.
(ii) 	For purposes of this Agreement, “Permanent Disability” means either (A) the inability of the Executive to
engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment
that can be expected to result in death or can be expected to last for a continuous period of not less than twelve
(12) months or (B) the Executive is, by reason of any medically determinable physical or mental impairment that
can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12)
months, receiving income replacement benefits for a period of not less than three months under an accident and
health plan covering employees of the Company. The Executive shall be deemed Permanently Disabled if he is
determined to be (A) totally disabled by the Social Security Administration or (B) disabled in accordance with a
disability insurance program, provided such definition of disabled under the program complies with the
definition of Permanent Disability hereunder. Otherwise, such Permanent Disability shall be certified by a
physician chosen by the Company and reasonably acceptable to the Executive (unless he is then legally
incapacitated, in which case such physician shall be reasonably acceptable to the Executive’s authorized legal
representative).
st
10

-- 93 of 155 --

(e) 	Death. The Executive’s employment hereunder shall terminate due to his death. Upon termination of the Executive’s
employment hereunder due to death, the Executive’s estate shall, subject to Section 8(i) below, be entitled to receive, in
addition to the Base Obligations, (A) the Pro-Rata Target Bonus paid, subject to Section 12(h), in a lump sum within
thirty (30) days following the Release Effective Date (provided that if the sixty (60)-day period described in Section 8(i)
below begins in one calendar year and ends in another, the Pro-Rata Target Bonus shall be paid not earlier than January 1
of the calendar year following the Date of Termination) and (B) accelerated vesting of all unvested equity compensation
awarded to the Executive by the Company, effective as of December 31 of the year of termination and, in accordance
with Section 5, each equity award agreement executed by the Executive and the Company shall describe the treatment of
the equity awards under this Section 8(e). Any performance-based vesting will be based on actual performance goals
during any complete performance period; vesting will be at target performance for grants vesting prior to the completion
of a performance cycle. All other benefits, if any, due the Executive’s estate following termination pursuant to this
Section 8(e) shall be determined in accordance with the plans, policies and practices of the Company.
(f) 	For Cause by the Company or Without Good Reason by the Executive. The Executive’s employment hereunder may be
terminated by the Company for Cause or by the Executive without Good Reason (other than Retirement). Upon
termination of the Executive’s employment for Cause or without Good Reason (other than Retirement) pursuant to this
Section 8(f), the Executive shall have no further rights to any compensation (including any Annual Bonus) or any other
benefits under this Agreement other than the Base Obligations. All other benefits, if any, due the Executive following the
Executive’s termination of employment pursuant to this Section 8(f) shall be determined in accordance with the plans,
policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy, or program of the Company.
(g) 	Termination in Connection with Change in Control by the Company Without Cause or by the Executive for Good
Reason.
(i) 	If the Executive’s employment is terminated by the Company without Cause or by the Executive for Good
Reason during the CIC Protection Period (as defined herein below), the Executive shall, subject to Section 8(i)
below, be entitled to receive, in addition to the Base Obligations, the following payments and benefits (the “CIC
Severance Benefits”):
(A) 	CIC Severance Payment. The Company shall pay the Executive a lump sum cash payment equal
to (I) the sum of (x) two times the Base Salary paid to the Executive with respect to the calendar
year immediately preceding the Executive’s Date of Termination and (y) two times the Target
Bonus and (II) the Pro-Rata Target Bonus, which shall be paid, subject to Section 12(h), within
thirty (30) days following the Release Effective Date (provided that if the sixty (60)-day period
described in Section 8(i) below begins in one calendar year and ends in another, the cash payment
shall be paid not earlier than January 1 of the calendar year following the Date of Termination).
st
11

-- 94 of 155 --

If (i) any amounts payable to the Executive under this Agreement or otherwise are characterized as excess parachute payments pursuant
to Section 4999 of the Internal Revenue Code of 1986, as amended (the “Section 4999”), and (ii) the Executive thereby would be
subject to any United States federal excise tax due to that characterization, the Executive’s termination benefits hereunder will be
reduced to an amount so that none of the amounts payable constitute excess parachute amounts payments if this would result, after
taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, in Executive’s
receipt on an after-tax basis of the greatest amount of termination and other benefits. The determination of any reduction required
pursuant to this section (including the determination as to which specific payments shall be reduced) shall be made by a neutral party
designated by the Company and such determination shall be conclusive and binding upon the Company or any related corporation for
all purposes.
(B) 	Equity Vesting. The Executive shall, subject to Section 8(i), be entitled to receive accelerated
vesting of all outstanding, unvested equity awards. The schedule for acceleration of the various
equity awards will be governed by Section 12 (Change in Control) of the Stock Plan.
(C) 	Health and Welfare Benefits. The Company shall pay to Executive on a monthly basis during the
CIC Coverage Period a taxable monthly cash payment equal to the COBRA premium for the
highest level of coverage available under the Company’s group health plans, but reduced by the
monthly amount that Executive would pay for such coverage if the Executive was an active
employee. “CIC Coverage Period” shall mean the period (I) commencing on the first day of the
month following the Release Effective Date (provided that if the sixty (60)-day period described
in Section 8(i) below begins in one calendar year and ends in another, the CIC Coverage Period
shall commence not earlier than January 1 of the calendar year following the Date of Termination)
and (II) ending on the earlier of (x) the expiration of eighteen (18) months from the first day of the
CIC Coverage Period, and (y) the date that the Executive is eligible for coverage under the health
care plans of a subsequent employer. The payments provided by this Section shall be conditioned
upon the Executive being covered by the Company’s health care plans immediately prior to the
Date of Termination. The foregoing payments are not intended to limit or otherwise reduce any
entitlements that Executive may have under COBRA. In addition, the Company shall continue to
provide the Executive with the same level of accident (AD&D) and life insurance benefits upon
substantially the same terms and conditions (including contributions required by the Executive for
such benefits) as existed immediately prior to the Executive’s Date of Termination (or, if more
favorable to the Executive, as such benefits and terms and conditions existed immediately prior to
the Change in Control) for the same period for which the
12

-- 95 of 155 --

Company shall provide the Executive with continued health care coverage payments.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(g) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The payments and other benefits provided for in this Section 8(g) are payments and benefits to
which the Executive is not otherwise entitled, are given in consideration for the Release and are in lieu of any severance plan, policy or
program of the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant
to this Section 8(g)(i) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all
obligations of the Company to the Executive under this Agreement. The Executive acknowledges and agrees that such amounts are fair
and reasonable, and are his sole and exclusive remedy, in lieu of all other remedies at law or in equity, with respect to the termination of
his employment hereunder. If, during the CIC Coverage Period, the Executive breaches in any material respect any of his obligations
under Section 9 or the Continuing Obligations Agreement, the Company may, upon written notice to the Executive, (x) terminate the
CIC Coverage Period and cease to make any further payments of the CIC Severance Payment and (y) cease any health and welfare
benefits and payments, except in each case as required by applicable law.
(ii) 	For purposes of this Agreement “Change in Control” means the first to occur of any one of the following events:
(A) 	any “Person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of
1934 (the “Exchange Act”) (other than (1) the Company, (2) any Person who becomes the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act) of more than 50% of the
Company’s then outstanding securities eligible to vote in the election of the Board (“Voting
Securities”) as a result of a reduction in the number of Voting Securities outstanding due to the
repurchase of Voting Securities by the Company unless and until such Person, after becoming
aware that such Person has become the beneficial owner of more than 50% of the then outstanding
Voting Securities, acquires beneficial ownership of additional Voting Securities representing 1%
or more of the Voting Securities then outstanding, (3) any trustee or other fiduciary holding
securities under an employee benefit plan of the Company, and (4) any entity owned, directly or
indirectly, by the stockholders of the Company in substantially the same proportions as their
ownership of Voting Securities), is or becomes the beneficial owner, directly or indirectly, of more
than 50% of the Voting Securities (not including any securities acquired directly (or through an
underwriter) from the Company or the Companies);
(B) 	the date on which, within any twelve (12)-month period (beginning on or after the Effective Date),
a majority of the
13

-- 96 of 155 --

directors then serving on the Board are replaced by directors not endorsed by at least two-thirds
(2/3) of the members of the Board before the date of appointment or election;
(C) 	there is consummated a merger or consolidation of the Company with any other corporation or
entity or the Company issues Voting Securities in connection with a merger or consolidation of
any direct or indirect subsidiary of the Company with any other corporation, other than (1) a
merger or consolidation that would result in the Voting Securities outstanding immediately prior
thereto continuing to represent (either by remaining outstanding or by being converted into Voting
Securities of the surviving or parent entity) more than 50% of the Company’s then outstanding
Voting Securities or more than 50% of the combined voting power of such surviving or parent
entity outstanding immediately after such merger or consolidation or (2) a merger or consolidation
effected to implement a recapitalization of the Company (or similar transaction) in which no
Person, directly or indirectly, acquired more than 50% of the Company’s then outstanding Voting
Securities (not including any securities acquired directly (or through an underwriter) from the
Company or the Companies); or
(D) 	the consummation of an agreement for the sale or disposition by the Company of all or
substantially all of the Company’s assets (or any transaction having a similar effect); provided that
such agreement or transaction of similar effect shall in all events require the disposition, within
any twelve (12)-month period, of at least 40% of the gross fair market value of all of the
Company’s then assets; other than a sale or disposition by the Company of all or substantially all
of the Company’s assets to an entity, at least 50% of the combined voting power of the voting
securities of which are owned directly or indirectly by stockholders of the Company in
substantially the same proportions as their ownership of the Company immediately prior to such
sale.
Notwithstanding the foregoing, in no event shall a Change in Control be deemed to occur hereunder unless such event constitutes a
change in ownership of the Company, a change in effective control of the Company or a change in ownership of a substantial portion of
the Company’s assets within the meaning of Section 409A.
(iii) 	For purposes of this Agreement “CIC Protection Period” means the two (2) years following the occurrence of a
Change in Control; provided that, if the Executive’s employment is terminated by the Company without Cause or
by the Executive for Good Reason within six (6) months prior to a Change in Control, then the termination will
be treated for all purposes of this Agreement as having occurred immediately following the Change in Control
and during the CIC Protection Period (provided such protection will end if such agreement is terminated or the
transaction is abandoned).
14

-- 97 of 155 --

(h) 	Mitigation; Offset. Following the termination of his employment under any of the above clauses of this Section 8, the
Executive shall have no obligation or duty to seek subsequent employment or engagement as an employee (including
self-employment) or as a consultant or otherwise mitigate the Company’s obligations hereunder; nor shall the payments
provided by this Section 8 be reduced by the compensation earned by the Executive as an employee or consultant from
such subsequent employment or consultancy.
(i) 	Release. Notwithstanding anything to the contrary in this Agreement, receipt of the Severance Benefits and the CIC
Severance Benefits or other compensation or benefits under this Section 8 (other than the Base Obligations), if any, by
the Executive is subject to the Executive executing and delivering to the Company a general release of claims following
the Date of Termination, in substantially the form attached as Exhibit B (the “Release”), that, within sixty (60) days
following the Executive’s Date of Termination, has become irrevocable by the Executive (such date the Release becomes
irrevocable being the “Release Effective Date”). If the Executive dies or becomes legally incapacitated prior to the
Release Effective Date, then the Release requirements described in the preceding sentence shall apply with respect to the
Executive’s estate and the Release shall be modified as reasonably necessary to allow for execution and delivery by the
personal representative of the Executive’s estate or the Executive’s authorized legal representative, as applicable.
9. 	Non-Competition. The Executive acknowledges and recognizes the highly competitive nature of the businesses of the Company
and accordingly agrees as follows:
(a) 	Non-Competition. For a period of twelve (12) months following the Date of Termination (the “Restricted Period”),
regardless of the circumstances surrounding such termination of employment, the Executive will not, directly or
indirectly without prior “Written Permission” (as defined below) (i) engage in any “Competitive Business” (as defined
below) for the Executive’s own account while he is in self-employment or acting as a sole proprietor, (ii) enter the
employ of, or render any services to, any person engaged in a Competitive Business, (iii) acquire a financial interest in,
or otherwise become actively involved with, any person engaged in a Competitive Business, directly or indirectly, as an
individual, partner, shareholder, officer, director, principal, agent, trustee or consultant, or (iv) interfere with business
relationships (whether formed before or after the Effective Date) between the Company and customers or suppliers of
the Company. For the avoidance of doubt, the Restricted Period shall apply only if the Date of Termination occurs on or
before the last day of the Term, but if the Date of Termination occurs on or before the last day of the Term, the full
Restricted Period shall apply regardless of the time remaining in the Term on the Date of Termination. The Executive
may seek a waiver of all or part of his Restricted Period upon written request to the Chief Legal Officer, who shall
reasonably consider such request in good faith. Any such waiver, if granted, must be in writing, in advance of the
Executive accepting any offers of engagement from the applicable entity.
For purposes of this Agreement, “Competitive Business” shall mean (x) any national securities exchange registered with the Securities
and Exchange Commission, (y) any electronic communications network or (z) any other entity that engages in substantially the same
business as the Company, but only to the extent that (i) the Company’s most recent annual revenue for that similar business unit equals
or exceeds 5% of the Company’s revenues (less transaction-
15

-- 98 of 155 --

based contra-revenues (i.e., rebates)), as reported in the Company’s most recent Form 10-K, or (ii) the entity’s most recent annual
revenue for that similar business unit equals or exceeds 5% of the entity’s revenues (less transaction-based contra-revenues (i.e.,
rebates)) as reported in the entity’s most recent Form 10-K (if applicable) or other financial statements (if such entity does not file a
Form 10-K).
For purposes of this Agreement, “person” shall mean an individual, corporation, partnership, limited partnership, limited liability
company, syndicate, person (including, without limitation, a “person” as defined in Section 13(d)(3) of the Securities Exchange Act of
1934, as amended), trust or association. “Written Permission” shall mean any permission granted by the Company’s Chief Legal Officer
in writing, which shall apply a reasonable, good faith consideration of the request based on factors including, without limitation, the
role the Executive will occupy, the Company’s strategic plans, any potential competitive threats posed, and the size of revenue
associated with any competing products and services offered by the Competitive Business.
(b) 	Securities Ownership. Notwithstanding anything to the contrary in this Agreement, the Executive may, directly or
indirectly, own, solely as an investment, securities of any person engaged in the business of the Company which are
publicly traded on a national or regional stock exchange or on the over-the-counter market if the Executive (i) is not a
controlling person of, or a member of a group which controls, such person and (ii) does not, directly or indirectly, own
five percent or more of any class of securities of such person.
(c) 	Severability. It is expressly understood and agreed that, although the Executive and the Company consider the
restrictions contained in this Section 9 to be reasonable, if a final judicial determination is made by a court of competent
jurisdiction that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction
against the Executive, the provisions of this Agreement shall not be rendered void, but shall be deemed amended to
apply as to such maximum time and territory and to such maximum extent as such court may judicially determine or
indicate to be enforceable. Alternatively, in the event that any one or more of the provisions of this Agreement shall be
or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions of this Agreement shall not be affected thereby.
10. 	Specific Performance. The Executive acknowledges and agrees that the Company’s remedies at law for a breach or threatened
breach of Section 9 above would be inadequate and, in recognition of this fact, the Executive agrees that, in the event of such a
breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or
any other equitable remedy which may then be available.
11. 	Disputes. Except as provided in Section 10 above, any dispute arising between the parties under this Agreement, under any
statute, regulation, or ordinance, under any other agreement between the parties, and/or in way relating to the Executive’s
employment, shall be submitted to binding arbitration before the American Arbitration Association (“AAA”) for resolution. Such
arbitration shall be conducted in New York, New York, and the arbitrator will apply New York law, including federal law as
applied in New York courts. The arbitration shall be conducted in accordance with the AAA’s Employment
16

-- 99 of 155 --

Arbitration Rules as modified herein. The arbitration shall be conducted by a panel of three arbitrators that is mutually agreeable
to both the Executive and the Company, all in accordance with AAA’s Employment Arbitration Rules then in effect. If the
Executive and the Company cannot agree upon the panel of arbitrators, the arbitration shall be settled before a panel of three
arbitrators, one to be selected by the Company, one by the Executive, and the third to be selected by the two persons so selected,
all in accordance with AAA’s Employment Arbitration Rules. Each party shall pay their own costs and expenses, including,
without limitation, attorney’s fees and costs, except that the Company shall pay the cost of the arbitrators and the filing fees
charged to Executive by the AAA; provided that he has not brought a frivolous claim (as determined by the arbitrator). The
award of the arbitrators shall be final and binding on the parties, and judgment on the award may be confirmed and entered in
any state or federal court in the State and City of New York. The arbitration shall be conducted on a strictly confidential basis,
and Executive shall not disclose the existence of a claim, the nature of a claim, any documents, exhibits, or information
exchanged or presented in connection with such a claim, or the result of any action (collectively, “Arbitration Materials”), to
any third party, with the sole exception of the Executive’s legal counsel, who also shall be bound by confidentiality obligations
no less protective than the provisions set forth in the Continuing Obligations Agreement. In the event of any court proceeding to
challenge or enforce an arbitrators’ award, the parties hereby consent to the exclusive jurisdiction of the state and federal courts
in New York, New York and agree to venue in that jurisdiction. The parties agree to take all steps necessary to protect the
confidentiality of the Arbitration Materials in connection with any such proceeding, agree to file all Confidential Information, as
defined in the Continuing Obligations Agreement (and documents containing Confidential Information) under seal, subject to
court order and agree to the entry of an appropriate protective order encompassing the confidentiality terms of this Agreement.
Nothing contained in this Section 11 shall be construed to preclude the Company from exercising its rights under Section 10
above.
12. 	Miscellaneous.
(a) 	Acceptance. The Executive hereby represents and warrants, as a material inducement to the Company’s agreement to
enter into this Agreement, that there are no legal, contractual or other impediments precluding the Executive from
entering into this Agreement or from performing the services with the Company contemplated hereby. Any violation of
this representation and warranty by the Executive shall render all of the obligations of the Company under this
Agreement void ab initio and of no force and effect.
(b) 	Entire Agreement; Amendments. This Agreement, together with the equity award agreements between the Executive and
the Company contain the entire understanding of the parties with respect to the employment of the Executive by the
Company, and shall supersede any and all previous contracts, arrangements or understandings between the Company and
the Executive with respect to the subject matter set forth herein. There are no restrictions, agreements, promises,
warranties, or covenants by and between the Company and the Executive and undertakings between the parties with
respect to the subject matter herein other than those expressly set forth herein. This Agreement may not be altered,
modified or amended except by written instrument signed by the parties hereto.
(c) 	No Waiver. The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not
be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence
to that term or any other term of this Agreement.
17

-- 100 of 155 --

(d) 	Successor; Assignment. This Agreement is confidential and personal and neither of the parties hereto shall, without the
consent of the other, assign or transfer this Agreement or any rights or obligations hereunder. Without limiting the
foregoing, the Executive’s right to receive payments hereunder shall not be assignable or transferable whether by pledge,
creation of a security interest or otherwise, other than a transfer by the Executive’s will or by the laws of descent and
distribution. In the event of any attempted assignment or transfer contrary to this Section 12(d), the Company shall have
no liability to pay the assignee or transferee any amount so attempted to be assigned or transferred. The Company shall
cause this Agreement to be assumed by any entity that succeeds to all or substantially all of the Company’s business or
assets and this Agreement shall be binding upon any successor to all or substantially all of the Company’s business or
assets; provided, however, that no such assumption shall release the Company of its obligations hereunder, to the extent
not satisfied by such successor, without the Executive’s prior written consent.
(e) 	Confidentiality of Tax Treatment and Structure. Notwithstanding anything herein to the contrary, each party and its
representatives may consult any tax advisor regarding the tax treatment and tax structure of this Agreement and may
disclose to any person, without limitation of any kind, the tax treatment and tax structure of this Agreement and all
materials (including opinions or other tax analyses) that are provided relating to such treatment or structure.
(f) 	Notice. For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be
in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail,
return receipt requested, postage prepaid, addressed to the respective addresses set forth on the execution page of this
Agreement; provided that all notices to the Company shall be directed to the attention of the General Counsel or to such
other address as either party may have furnished to the other in writing in accordance herewith, except that notice of
change of address shall be effective only upon receipt:
if to the Company:
The Office of the General Counsel
Nasdaq, Inc.
151 W. 42 Street
New York, NY 10036
if to the Executive:
his address as shown in the records of the Company
(g) 	Withholding Taxes. The Company may withhold from any amounts payable under this Agreement such federal, state and
local taxes as may be required to be withheld pursuant to any applicable law or regulation.
(h) 	Section 409A. Notwithstanding any other provision of this Agreement, any payment, settlement or benefit triggered by
termination of the Executive’s employment with the Company shall not be made until six months and one day following
Date of Termination if such delay is necessary to avoid the imposition
nd
18

-- 101 of 155 --

of any tax, penalty or interest under Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”).
Any installment payments that are delayed pursuant to this Section 12(h) shall be accumulated and paid in a lump sum
on the day that is six months and one day following the Date of Termination (or, if earlier, upon the Executive’s death)
and the remaining installment payments shall begin on such date in accordance with the schedule provided in this
Agreement. For purposes of this Agreement, termination or severance of employment will be read to mean a “separation
from service” within the meaning of Section 409A where it is reasonably anticipated that no further services would be
performed after that date or that the level of services the Executive would perform after that date (whether as an
employee or independent contractor) would permanently decrease to no more than 20% of the average level of bona fide
services performed over the immediately preceding thirty-six (36) month period. Additionally, the amount of expenses
eligible for reimbursement or in-kind benefits to be provided during one calendar year may not affect the expenses
eligible for reimbursement or any in-kind benefits to be provided in any other calendar year and the right to
reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. All reimbursements shall
be made no later than the last day of the calendar year following the calendar year in which the Executive incurs the
reimbursable expense. This Agreement is intended to comply with the requirements of Section 409A (including the
exceptions thereto), to the extent applicable, and the Agreement shall be administered and interpreted in accordance with
such intent. If any provision contained in the Agreement conflicts with the requirements of Section 409A (or the
exemptions intended to apply under the Agreement), the Agreement shall be deemed to be reformed to comply with the
requirements of Section 409A (or the applicable exemptions thereto). The Company, after consulting with the Executive,
may amend this Agreement or the terms of any award provided for herein in any manner that the Company considers
necessary or advisable to ensure that cash compensation, equity awards or other benefits provided for herein are not
subject to United States federal income tax, state or local income tax or any equivalent taxes in territories outside the
United States prior to payment, exercise, vesting or settlement, as applicable, or any tax, interest or penalties pursuant to
Section 409A. Any such amendments shall be made in a manner that preserves to the maximum extent possible the
intended benefits to the Executive. This Section 12(h) does not create an obligation on the part of the Company to
modify this Agreement and does not guarantee that the amounts or benefits owed under the Agreement will not be
subject to interest and penalties under Section 409A. For purposes of this Agreement, all rights to payments and benefits
hereunder shall be treated as rights to receive a series of separate payments and benefits to the fullest extent allowed by
Section 409A.
(i) 	Clawback. The Executive agrees that compensation and benefits provided by the Company under this Agreement or
otherwise will be subject to recoupment or clawback by the Company under any applicable clawback or recoupment
policy of the Company that is generally applicable to the Company’s executives, as may be in effect from time-to-time,
or as required by applicable law.
(j) 	Audit Rights. Any and all equity compensation of any kind due hereunder to Executive after the Date of Termination
shall be accompanied by a detailed statement from the Company showing the calculation for such compensation for the
period being measured. Within thirty (30) days after the delivery of such statement, the Executive may notify the
Company of any objections or changes thereto, specifying in reasonable detail any such objections or changes. If the
19

-- 102 of 155 --

Executive does not notify the Company of any objections or changes thereto or if within twenty (20) days of the delivery
of an objection notice the Executive and the Company agree on the resolution of all objections or changes, then such
statements delivered by the Company, with such changes as are agreed upon, shall be final and binding. If the parties
shall fail to reach an agreement with respect to all objections or changes within such twenty (20)-day period, then all
disputed objections or changes shall, be subject to resolution in accordance with Section 11 above.
(k) 	Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as
if the signatures thereto and hereto were upon the same instrument.
(l) 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New
York, and consistent with the Company’s bylaws related to indemnification of Directors and Officers.
IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.
EXECUTIVE
/s/ Tal Cohen
Tal Cohen
NASDAQ, INC.
By: 	/s/ Bryan E. Smith
Name: Bryan E. Smith
Title: 	Executive Vice President and
Chief People Officer
20

-- 103 of 155 --

Exhibit A
NASDAQ CONTINUING OBLIGATIONS AGREEMENT
I, the undersigned, hereby enter into this agreement (the “Agreement”) with Nasdaq, Inc. as of the signature date below (the “Effective
Date”). Any reference in this Agreement to “I,” “me,” “my,” “mine,” or other like terms shall be deemed to refer to me. This
Agreement supersedes any prior Continuing Obligations Agreements signed by me during my employment with the Company (as
defined below).
During the course of my employment or engagement with Nasdaq, Inc. and/or its Affiliates (collectively, the “Company”) (hereinafter
referred to as my “Engagement”), I understand that I will have access to, be given access to, and/or receive Confidential Information
and Company Property. The Company regards the Confidential Information and Company Property as highly valued assets of the
Company. Any unauthorized disclosure or use of the Confidential Information or Company Property would cause grave harm to the
Company Parties. Therefore, to assure the confidentiality and proper use of Confidential Information and Company Property, and in
consideration of my Engagement, my access to Confidential Information and Company Property, and the compensation paid or to be
paid for my services during that Engagement, and pursuant to the mutual covenants and promises contained herein, I agree to the
following:
1. 	Confidentiality and Company Property
I agree that all Confidential Information and Company Property is owned by and for the Company Parties exclusively, and I agree that I
will use Confidential Information and Company Property solely for authorized, work-related purposes on behalf of the Company
Parties, and not for personal or other non-work-related purposes. I agree that Confidential Information is a valuable and unique asset of
the Company, and, except as provided in Section 6 of this Agreement, I covenant that I will not disclose any Confidential Information
to any Person (except as my duties for the Company may require or as required by law or in a judicial or administrative proceeding)
without the prior express written authorization of the Company.
Specifically, without limitation, I shall not, directly or indirectly, at any time during or after my Engagement, without prior express
written authorization from the Company: (a) divulge, disclose, transmit, reproduce, convey, summarize, quote, share, or make
accessible Confidential Information or non-public Company Property to any other Person; (b) use any Confidential Information or
Company Property for any purpose outside the course of performing the authorized duties of my Engagement; (c) remove Company
Property or Confidential Information from the Company Parties’ premises, except as expressly sanctioned by the Company provided
there are appropriate security measures in place; or (d) review or seek to access any Confidential Information or Company Property
except as required in connection with my work for the Company. Notwithstanding the above, I understand that I am not prohibited from
discussing the terms and conditions of my Engagement with coworkers, union representatives, or others, pursuant to Section 7 of the
NLRA, and nothing in this agreement prohibits me from responding to an inquiry from, or providing testimony before, the SEC,
FINRA, etc. or filing a charge regarding a possible securities law violation.
21

-- 104 of 155 --

Upon the termination of my Engagement for any reason, or if the Company so requests, I shall promptly deliver to the Company all
Confidential Information, Company Property, or Physical Embodiments of either of the foregoing (collectively, “Returnable Property”)
in my possession or under my control. If at any time after the termination of my Engagement I determine that I have any Returnable
Property in my possession or control, I shall immediately: (a) notify the Company of such determination, and (b) return to the Company
all such Returnable Property.
2. 	Non-Use of Other’s Confidential Information
During my Engagement, I will not (a) breach any agreement to keep in confidence any Confidential Information, knowledge, or data
acquired by me prior to or independent of my Engagement; or (b) disclose to the Company, or use or induce the Company to use, any
confidential or proprietary information or material belonging to any previous employer or to any other third party.
3. 	Non-Solicitation of Customers, Potential Customers and Employees
I agree that, for a period of twelve (12) months following the termination of my Engagement for any reason, I shall not, directly or
indirectly, without express written consent from the Company’s Office of General Counsel:
(i) 	Interfere with any customer relationship the Company has with any of its current customers or potential
customers that I had any involvement with, directly or indirectly, during the last twelve (12) months of my
Engagement;
(ii) 	Solicit, or induce to enter into, any business arrangement with, any employee or contractor of the Company with
whom I had any contact or a relationship with during the last twelve (12) months of my Engagement; or
(iii) 	Solicit, or induce to enter into, any business arrangement with, any employee or contractor of the Company’s
customers that I knew, or reasonably could be expected to know, was solicited by the Company for any
technology, operations, sales, or business role during the last twelve (12) months of my Engagement.
4. 	Non-Disparagement
I agree that I shall not, at any time during or after my Engagement, issue, circulate, publish, or utter any false or disparaging statements,
remarks, opinions, or rumors about the Company or its shareholders unless giving truthful testimony under subpoena or court order.
Notwithstanding the preceding sentence, I understand that I may provide truthful information to any governmental agency or self-
regulatory organization with or without subpoena or court order. With the exception of communications made in a private corporate
communication as an employee or consultant with regard to a listing decision of my employer or my consulting client, I agree that
public communications regarding a preference for listing a security on a market other than a market operated by the Company,
indicating that the quality of any of the Company’s securities markets as a securities market is in any way inferior to any other
securities market or exchange, and/or indicating that the regulatory efforts or programs of the Company are or have been lax in
22

-- 105 of 155 --

any way, are specifically defined as disparaging and will constitute a material breach of this Agreement. Nothing in this paragraph,
however, is intended to preclude or inhibit protected, concerted activity, nor shall it prevent me from making good faith, factual, and
truthful statements related to listing with the Company as long as my statements are not based on Confidential Information.
The Company agrees to instruct all executive officers and members of the Board of Directors of the Company to not issue, circulate,
publish, or utter any false or disparaging statements, remarks, opinions, or rumors about you to any third party unless giving truthful
testimony under subpoena or court order.
5. 	Cooperation with the Company in Connection with Legal Proceedings
Subject to the Company’s compliance with its indemnification obligations (including advancement), I agree to reasonably cooperate
with the Company in relation to any actual or threatened legal proceedings concerning Company-related matters about which I have
relevant knowledge, even after the termination of my Engagement. Upon presentation of appropriate documentation, the Company shall
pay or reimburse you for all reasonable out-of-pocket travel, delivery or similar expenses incurred by complying with this Section 5
(excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs.
Additionally, at any time during or after my Engagement, if I receive a subpoena or process from any Person (including, but not limited
to, any governmental agency) that may or will require me to disclose documents or information or provide testimony (in a deposition,
court proceeding, or otherwise) regarding, in whole or in part, any of the Company Parties, any Confidential Information, or any
Company Property (including any Nasdaq Inventions), I shall: (a) to the extent permissible by law, notify the Company’s Office of the
General Counsel of the subpoena or other process as soon as practicable and no later than three business days of receiving it; and (b) to
the maximum extent possible, not make any disclosure until the Company Parties have had a reasonable opportunity to contest the right
of the requesting Person to such disclosure, limit the scope or nature of such disclosure, and/or seek to participate in the proceeding or
matter in which the disclosure is sought.
6. 	Immunity for Disclosure of Trade Secrets in Certain Circumstances
I understand and acknowledge that, pursuant to 18 U.S.C. § 1833 (as defined in the Defend Trade Secrets Act of 2016) and
notwithstanding anything else in this Agreement, I am permitted to disclose trade secrets to third parties under certain circumstances.
The relevant portion of 18 U.S.C. § 1833 is reproduced as follows:
23

-- 106 of 155 --

(b) Immunity From Liability for Confidential Disclosure of a Trade Secret to the Government or in a Court Filing.
(1) Immunity - An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the
disclosure of a trade secret that -
(A) is made -
(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and
(ii) solely for the purpose of reporting or investigating a suspected violation of law; or
(B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
(2) Use of trade secret information in anti-retaliation lawsuit. An individual who files a lawsuit for retaliation by an employer for
reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret
information in the court proceeding, if the individual—
(A) files any document containing the trade secret under seal; and
(B) does not disclose the trade secret, except pursuant to court order.
I understand that nothing in this Agreement prohibits me from communicating with or reporting possible violations of law or regulation
to any federal, state, or local governmental office, official, agency or entity, and that notwithstanding my confidentiality obligations set
forth in Section 1 this Agreement, I will not be held civilly or criminally liable under any U.S. Federal or State trade secret law for
disclosure of a trade secret made in accordance with the provisions of 18 U.S.C. § 1833. I understand that if a disclosure of trade secrets
was not done in good faith pursuant to 18 U.S.C. § 1833, then I may be subject to criminal or civil liability, including, without
limitation, punitive and exemplary damages, and attorneys’ fees.
7. 	Inventions
(a) 	Ownership of Nasdaq Inventions by the Company
(i) 	As between me and the Company, all Nasdaq Inventions are owned by the Company. I hereby assign to Nasdaq,
Inc., without any further consideration, all right, title, and interest in and to the Nasdaq Inventions, including all
Intellectual Property Rights associated therewith. I agree that the foregoing assignment includes a present
conveyance to Nasdaq, Inc. of
I understand and acknowledge that the provisions of this Agreement related to the Company’s ownership of the Nasdaq Inventions do not apply to any
Invention that qualifies fully under the provisions of California Labor Code Section 2870, or which qualifies under any similar state law that may apply.
California Labor Code Section 2870 provides that “[a]ny provision in an employment agreement which provides that an employee shall assign, or offer to
assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own
time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) relate at the time of
conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the
employer; or (2) result from any work performed by the employee for the employer.”
1
1
24

-- 107 of 155 --

ownership of Nasdaq Inventions that are not yet in existence as of the Effective Date.
(ii) 	I hereby agree that, to the extent permitted under applicable law, the Nasdaq Inventions constitute “works made
for hire” and are deemed to be authored by Nasdaq, Inc.
(iii) 	To the extent, if any, that this Agreement does not provide Nasdaq, Inc. with full ownership, right, title and
interest in and to the Nasdaq Inventions, I hereby grant Nasdaq, Inc. an exclusive, perpetual, irrevocable, fully-
paid, royalty-free, worldwide license to use, exploit, reproduce, perform (publicly or otherwise), display
(publicly or otherwise), create derivative works from, modify, improve, develop, protect, distribute, import,
make, have made, sell, offer to sell or otherwise dispose of the Nasdaq Inventions, effective immediately on their
creation, with the right to sublicense each and every such right, including through multiple tiers, alone or in
combination. I intend that Nasdaq, Inc. has all substantial rights in the Nasdaq Inventions and associated
Intellectual Property Rights throughout the world. To the extent that any Moral Rights in the Nasdaq Inventions
cannot be assigned under applicable law, I hereby unconditionally and irrevocably waive and agree not to enforce
any and all Moral Rights, including any limitation on subsequent modification, to the extent permitted under
applicable law.
(iv) 	I agree to promptly make full disclosure to the Company of any and all Nasdaq Inventions. On request, such
disclosure shall be made in writing. During and after my Engagement and at the Company’s request and expense,
I will (1) assist the Company in every way necessary or desirable to establish or perfect the Company’s rights in
the Nasdaq Inventions and associated Intellectual Property Rights throughout the world, including by executing
in favor of the Company or its designee(s) any necessary or desirable documents, including patent and copyright
assignment documents, and (2) consent to or join in any action to enforce any Intellectual Property Right
associated with the Nasdaq Inventions. I agree that, if the Company is unable, because of my unavailability,
mental or physical incapacity, or for any other reason, to secure my signature with respect to the purposes set
forth in the preceding sentence, then I hereby irrevocably designate and appoint the Company and its duly
authorized officers and agents as my agent and attorney-in-fact, to act for and on my behalf to execute and file
any papers and oaths, and to do all other lawfully permitted acts with respect to such Nasdaq Inventions and
associated Intellectual Property Rights to further the prosecution, issuance, and enforcement of such Intellectual
Property Rights with the same legal force and effect as if executed by me. This power of attorney shall be
deemed coupled with an interest, and it is irrevocable.
(v) 	I agree to not challenge, dispute, or otherwise contest, or assist any Person in challenging, disputing, or otherwise
contesting, the validity, enforceability, or ownership of any Intellectual Property Rights (including those
associated with the Nasdaq Inventions) owned by or asserted to be owned by the Company or its designees. For
the avoidance of doubt, I agree to the foregoing without regard to whether any such challenge, dispute, or contest
would make use of any Confidential Information or Company Property.
25

-- 108 of 155 --

(vi) 	I agree to assist the Company in enforcing the Intellectual Property Rights associated with the Nasdaq
Inventions; though if I am requested by the Company to render such assistance after the termination of my
Engagement, I shall be entitled to: (1) if allowable under applicable law, a fair and reasonable rate of
compensation for such assistance; and (2) reimbursement of any reasonable expenses incurred at the request of
the Company relating to such assistance.
(b) 	Non-Use of My Personal Inventions
Without limiting any of my obligations under this Section 7, I agree that I will not integrate or incorporate any of My Personal
Inventions into any product, service, or other offering of the Company. Notwithstanding the foregoing prohibition, if I integrate or
incorporate, or allow the integration or incorporation of, any of My Personal Inventions into any product, service, or other offering of
the Company, I agree that I will make no claim against the Company with respect to such of My Personal Inventions. “My Personal
Inventions” means Inventions in which I personally possess any right, title, or interest. As examples, My Personal Inventions may
include Inventions that qualify as My Personal Inventions under the preceding definition and that I (i) developed prior to my
Engagement or (ii) develop during my Engagement but which do not qualify as owned by the Company pursuant to the terms of this
Section 7.
8. 	Injunctive Action; No Third-Party Beneficiaries; Duration of Obligations Extends Past Engagement
I acknowledge that all of the terms and provisions of this Agreement, along with all restrictions, prohibitions, and obligations created
thereunder (with such terms, provisions, restrictions, prohibitions, and obligations being, collectively, “Obligations”), are reasonable
and necessary for the protection of the Company Parties and their respective businesses. I agree that my breach of any of the
Obligations may result in irreparable injury to the Company Parties, that monetary relief alone may be inadequate to redress such a
breach, and further that the Company shall be entitled to seek an injunction to prevent and/or remedy such a breach (without first
having to post a bond).
In any proceeding for an injunction and upon any motion for a temporary or permanent injunction (“Injunctive Action”), the Company’s
right to receive monetary damages shall not be a bar or interposed as a defense to the granting of such injunction. The Company’s right
to an injunction is in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity,
including any remedy the Company may seek in any arbitration brought pursuant to Section 9 of this Agreement.
I hereby irrevocably submit to the jurisdiction of the courts of New York (or the jurisdiction in which I am assigned to work in at the
time of the issue under dispute) for any Injunctive Action and waive any claim or defense of inconvenient or improper forum or lack of
personal jurisdiction under any applicable law or decision, unless the Company has opted for another jurisdiction. Upon the issuance
(or denial) of an injunction, the underlying merits of any such dispute shall be resolved in accordance with Section 9 of this Agreement.
26

-- 109 of 155 --

This Agreement is intended solely for the benefit of me, the Company, and our and respective permitted successors or assigns;
notwithstanding any provision of this Section 8, it is not the intention of the parties to confer, and this Agreement shall not confer, third-
party beneficiary rights upon any other Person other than me and the Company. I understand that the Company has the right to bring an
Injunctive Action or seek monetary damages or any other remedy for a breach of this Agreement that injures the Company’s customers
or prospective customers, but the Company is under no obligation to do so.
Unless explicitly set forth herein, none of the Obligations in this Agreement are limited in time; and all Obligations, unless
explicitly set forth herein, shall survive the termination of my Engagement, regardless of the reason for such termination.
9. 	Arbitration
Except as provided in Section 8 of this Agreement, any dispute arising between the Parties under this Agreement, under any statute,
regulation, or ordinance, under any other agreement between the Parties, and/or in way relating to my engagement by the Company
(other than sexual harassment or sexual assault claims, unless agreed to by all parties), shall be submitted to binding arbitration before
the American Arbitration Association (“AAA”) (or local arbitration body for disputes outside of the U.S.) for resolution.
The arbitration shall be conducted in accordance with the AAA’s Employment Arbitration Rules, as modified herein, including, without
limitation, the AAA Employment/Workplace Fee Schedule and Costs of Arbitration, as in effect from time-to-time (or the rules of the
local arbitration body for disputes outside of the U.S.). The arbitration shall be conducted in the state/jurisdiction where I work, unless
the parties mutually agree to another location. The arbitrator shall apply the applicable state/local jurisdiction law, depending on the
nature of the claim(s) at issue, including federal law as applied in such state where applicable.
The arbitration shall be conducted by a single arbitrator, who shall be an attorney who specializes in the field of employment law and
who shall have prior experience arbitrating employment disputes. However, if any disputes arising between the Parties under the
Agreement concern any Inventions or Intellectual Property Rights, the single arbitrator shall be an attorney who specializes in the field
of intellectual property law and who shall have prior experience arbitrating intellectual property disputes.
The award of the arbitrator shall be final and binding on the Parties, and judgment on the award may be confirmed and entered in any
state or federal court of the applicable jurisdiction. In the event of any court proceeding to challenge or enforce an arbitrator’s award,
the Parties hereby consent to the exclusive jurisdiction of the state and federal courts in the applicable jurisdiction and agree to venue in
that jurisdiction.
To the fullest extent allowable under applicable, the arbitration shall be conducted on a strictly confidential basis. This means that I
shall not disclose the existence of a claim, the nature of a claim, any documents, exhibits, or information exchanged or presented in
connection with such a claim, or the result of any action (collectively, “Arbitration Materials”), to any third party, with
27

-- 110 of 155 --

the sole exception of my legal counsel, who also shall be bound by these confidentiality terms. The Parties agree to take all steps
necessary to protect the confidentiality of the Arbitration Materials in connection with any such proceeding; agree to file all
Confidential Information (and documents containing Confidential Information) under seal; and agree to the entry of an appropriate
protective order encompassing the confidentiality terms of this Agreement, all to the extent allowable under the laws of that
jurisdiction. The Company shall pay the costs of the arbitration and the arbitrators.
10. 	Governing Law; Amendment; Waiver; Severability
Except as provided in Paragraph 9 regarding arbitration of disputes, this Agreement shall be construed in accordance with and shall be
governed by the laws of the State of New York (or the jurisdiction in which I am assigned to work in at the time of the issue under
dispute), excluding any choice of law principles. This Agreement constitutes the entire agreement between the Parties with respect to
the subject matter hereof, and may not be amended, discharged, or terminated, nor may any of its provisions be waived, except upon the
execution of a valid written instrument executed by me and the Company.
If any term or provision (or any portion thereof) of this Agreement is determined by an arbitrator or a court of competent jurisdiction to
be invalid, illegal, or incapable of being enforced, all other terms and provisions (and all other portions thereof) of this Agreement shall
nevertheless remain in full force and effect.
Upon a determination that any term or provision (or any portion thereof) of this Agreement is invalid, illegal, or incapable of being
enforced, the Company and I agree that an arbitrator or reviewing court shall have the authority to amend or modify this Agreement so
as to render it enforceable and effect the original intent of the Parties to the fullest extent permitted by applicable law.
11. 	Definitions
All capitalized terms used in this Agreement, along with their tenses, cases, and correlatives, shall have the defined meanings attributed
to them in this Section or in the other Sections where such defined meanings are provided.
“Affiliate” means, with respect to any entity, another entity that, directly or indirectly through one or more intermediaries, controls, is
controlled by or is under common control with, such entity. For purposes of this definition, “control” means the possession, direct or
indirect, of the power to direct or cause the direction of management and policies of the entity, whether through the ownership of voting
securities, by contract or otherwise.
“Company Parties” means the Company and Company’s customers or prospective customers.
“Company Property” means all property and resources of the Company Parties, or any Company Party, including Confidential
Information, each Company Party’s products, each Company Party’s computer systems, and all software, e-mail, web pages, databases,
telephone, and facsimile services, and other administrative and/or support services provided by the Company
28

-- 111 of 155 --

Parties. I further agree that Company Property shall include Nasdaq Inventions without regard to whether they also may be considered
Confidential Information as defined in this Agreement.
“Confidential Information” means any non-public, proprietary information regarding the Company Parties, in any Physical
Embodiment or format, including all personal information, financial data, commercial data, trade secrets, business plans, business
models, organizational structures and models, business strategies, pricing and advertising techniques and strategies, research and
development activities, software development, market development, exchange registration, studies, market penetration plans, listing
retention plans and strategies, marketing plans and strategies, communication and/or public relations products, plans, programs,
recruiting strategies, databases, processes, work product or inventions, financial formulas and methods relating to Company Parties’
business, computer software programs, accounting policies and practices, and all strategic plans or other matters, strategies, and
financial or operating information pertaining to current or potential customers or transactions (including information regarding each
Company Party’s current or prospective customers, customer names, and customer representatives), templates and agreements, and all
other information about or provided by the Company Parties, including information regarding any actual or prospective business
opportunities, employment opportunities, finances, investments, and other proprietary information and trade secrets. Confidential
Information also includes other information that is marked or otherwise identified as confidential or proprietary, or that would
otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is
known or used. Notwithstanding the above, Confidential Information shall not include any information that: (a) was known to me prior
to my Engagement as evidenced by written records in my possession prior to such disclosure; or (b) is generally and publicly available
and known to all Persons in the industries where the Company conducts business, other than because of any unauthorized disclosure by
me.
“Intellectual Property Rights” means all of the following, whether protected, created, or arising under the laws of the United States or
any other jurisdiction throughout the world, via statute, common law, equity, regulation, or other legal mechanism: (a) patents, patent
applications, and design rights (including industrial design rights); (b) rights in works of authorship, including copyrights, Moral
Rights, and mask work rights; (c) trademarks and service marks, and rights in trade names, trade dress, domain names, and any other
indicia of source or origin; (d) trade secrets and other rights in know-how and confidential or proprietary information; (e) any rights in,
to, or arising under any Invention; (f) any registrations or applications for registration for any of the foregoing (a)-(e), including any
provisionals, divisions, continuations, continuations-in-part, renewals, reissuances, rights subject to and/or arising out of post-grant
review (including re-examinations) and extensions (as applicable); (g) all contract and licensing rights and all claims and causes of
action of any kind with respect to any of the foregoing (a)-(f), including the right to sue and recover damages or other compensation
and/or obtain equitable relief for any past, present, or future infringement or misappropriation thereof; and (h) any right analogous to
any right set forth above in (a)-(g).
“Inventions” means: (a) inventions, invention disclosures, discoveries, ideas, developments, improvements, technology, algorithms, and
designs (including industrial designs, user interface
29

-- 112 of 155 --

designs, user experience designs, and other types of designs); (b) original works of authorship, copyrightable expression, research,
computer software (including source code), computer programs, and mask works; (c) trademarks, service marks, certification marks,
logos, slogans, symbols, domain names, social media accounts, handles and identifiers, and any other indicia of source or origin;
(d) trade secrets, know-how, data, databases, information, formulas, patterns, processes, technical information, business information,
information regarding sales or potential sales and other commercial relationships, business methods or processes, marketing plans,
customer lists, vendor lists, and other types of proprietary or confidential information; and (e) trading systems, trading strategies, and
trading methodologies. The foregoing definition shall apply regardless of whether or not the Inventions are subject to protection under
patent, copyright, trade secret, industrial design, trademark, or other type of intellectual property right, whether registered or
unregistered.
“Moral Rights” means all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights
throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like.
“Nasdaq Inventions” means Inventions that are (a) made, conceived, expressed, developed, diligently worked on to reduce to practice,
or reduced to practice by me (solely or jointly with others) during or as a result of my Engagement or using Company Property and
(b) which relate in any manner to the Company, the business of the Company (including the services the Company provides to any of
the Company Parties), or my Engagement.
“Person” means a natural person, partnership, domestic or foreign limited partnership, domestic or foreign limited liability company,
trust, estate, association, corporation or any other legal entity or government authority.
“Physical Embodiments” means originals, copies, reproductions, documents, materials, records, papers, notebooks, files stored on or in
electronic or cloud-based media, and any other embodiment, in any format whatsoever, including in hard-copy formats, such as paper
and electronic or digital media, including, without limitation, computer-readable files, drives, disks, cloud-based information, and other
electronic media that may be developed in the future.
12. 	Miscellaneous
Other than any Contractor Agreement (as defined in Section 13), I agree that I am not currently a party, and will not become a party, to
any other agreement that is in conflict, or will prevent me from complying, with this Agreement.
This Agreement is binding upon, and shall inure to the benefit of, me and the Company and our respective heirs, executors,
administrators, successors, and assigns.
I will not assign this Agreement or my obligations hereunder without the prior written consent of the Company, which consent must be
obtained from the Company’s Office of General Counsel, and which consent may be withheld in the Company’s sole discretion; and
any such purported assignment without consent shall be null and void from the beginning. I agree that the Company
30

-- 113 of 155 --

may freely assign this Agreement, in whole or in part, to any Company entity, and I expressly consent to be bound by the provisions of
this Agreement for the benefit of any Company entity without the necessity that this Agreement be re-executed at the time of such
transfer.
Without limiting the scope or generality of the terms of this Agreement in any way, I acknowledge and agree that the terms of this
Agreement and all discussions regarding this Agreement are confidential, and accordingly I agree not to disclose any such information
to any Person except to my attorney(s) or as otherwise may be required by law. I confirm that I may consult with an attorney regarding
the provisions of this Agreement, including the nonsolicit provisions as applicable to me, and that I have a fourteen (14)-day waivable
consideration period for these provisions. Notwithstanding the foregoing, I may disclose to any prospective employer the fact and
existence of this Agreement, and I may provide copies of this Agreement to such entity. The Company also has the right to apprise any
prospective employer of the terms of this Agreement and provide copies to any such prospective employer.
This Agreement shall be fairly interpreted in accordance with its terms and without any strict construction in favor of or against either
Party, notwithstanding which Party may have drafted it. The headings herein are included for reference only and are not intended to
affect the meaning or interpretation of the Agreement.
13. 	Other Terms of My Engagement
Nothing in this Agreement alters the at-will nature of my Engagement. I acknowledge and agree that my Engagement is at-will, which
means that both I and the Company shall have the right to terminate my Engagement at any time, for any lawful reason, with or without
cause and with or without prior notice, subject to the terms in that Employment Agreement dated March ____, 2025 between me and
the Company. If another agreement that establishes a third-party contractor relationship (or independent consultant relationship, or any
other similar non-employee relationship) between me and the Company (a “Contractor Agreement”) exists, the written terms of such
Contractor Agreement supersede any conflicting terms in this Agreement.
14. 	Signature
I hereby acknowledge and accept the terms of this Agreement as of the Effective Date, via my manual or electronic (e.g.,
DocuSign) signature, as reflected below.
Signature: /s/ Tal Cohen 	Date: March 10, 2025
Print Name: Tal Cohen
31

-- 114 of 155 --

Exhibit B
Release of Claims
GENERAL RELEASE
WHEREAS, Tal Cohen (hereinafter referred to as the “Executive”) and Nasdaq, Inc. (hereinafter referred to as “Employer”) are
parties to an Employment Agreement, dated March ____, 2025 (the “Employment Agreement”), which provided for the Executive’s
employment with Employer on the terms and conditions specified therein; and
WHEREAS, the Executive has agreed to execute a release of the type and nature set forth herein as a condition to his
entitlement to certain payments and benefits upon his termination of employment with Employer.
NOW, THEREFORE, in consideration of the premises and mutual promises herein contained and for other good and valuable
consideration received or to be received by the Executive in accordance with the terms of the Employment Agreement, it is agreed as
follows:
1. 	Excluding enforcement of the covenants, promises and/or rights reserved herein, the Executive hereby irrevocably and
unconditionally releases, acquits and forever discharges Employer and each of Employer’s owners, stockholders, predecessors,
successors, assigns, directors, officers, employees, divisions, subsidiaries, affiliates (and directors, officers and employees of
such companies, divisions, subsidiaries and affiliates) and all persons acting by, through, under or in concert with any of them
(collectively “Releasees”), or any of them, from any and all Claims (as defined below) through the date of this Release. You
agree not to file a lawsuit or arbitration to assert any such Claim. Further, you agree that should any other person, organization
or entity file a lawsuit or arbitration to assert any such Claim, you will not seek or accept any personal relief in such action.
(a) 	Definition of “Claims.” Except as stated below, “Claims” includes without limitation all actions or demands of any kind
that you may now have or have had or reasonably known you should have had (although you are not being asked to
waive Claims that may arise after the date of this Agreement). More specifically, Claims include rights, causes of action,
damages, penalties, losses, attorneys’ fees, costs, expenses, obligations, agreements, judgments and all other liabilities of
any kind or description whatsoever, either in law or in equity, whether known or unknown, suspected or unsuspected.
The nature of Claims covered by this release includes without limitation all actions or demands in any way based on
your employment with the Company, the terms and conditions of such employment, or your separation from
employment. More specifically, all of the following are among the types of Claims which are waived and barred by this
General Release of Claims to the extent allowable under applicable law and are considered illustrative but not
exhaustive:
• Contract Claims, whether express or implied;
• Tort Claims, such as for defamation or emotional distress;
32

-- 115 of 155 --

• Claims under federal, state and municipal laws, regulations, ordinance or court decisions of any kind;
• Claims of discrimination, harassment or retaliation, whether based on race, color, religion, gender, sex, age, sexual
orientation, handicap and/or disability, genetic information, national origin, or any other legally protected class;
• Claims under the AGE DISCRIMINATION IN EMPLOYMENT ACT, Title VII of the Civil Rights Act of 1964, as
amended, the Americans with Disabilities Act as amended, the Genetic Information Nondiscrimination Act, the Family and
Medical Leave Act, and similar state and local statutes, laws and ordinances, including, but not limited to, the New York
State Human Rights Law, the New York Labor Act, the New York Equal Pay Law, the New York Civil Rights Law, the New
York Rights of Persons With Disabilities Law, and the New York Equal Rights Law, all as amended;
• Claims under the Employee Retirement Income Security Act (other than rights to vested benefits), the Occupational Safety
and Health Act, the False Claims Act, and similar state and local statutes, laws and ordinances;
• Claims for wrongful discharge; and
• Claims for attorneys’ fees, including litigation expenses and/or costs;
provided, however, that this release shall not apply to any of the obligations of Employer or any other Releasee under the Employment
Agreement, or under any agreements, plans, contracts, documents or programs described or referenced in the Employment Agreement;
and provided, further, that this release shall not apply to any rights the Executive may have to obtain contribution, advancement or
indemnity against Employer or any other Releasee pursuant to contract, Employer’s certificate of incorporation and bylaws, coverage
under Employer’s directors and officers or similar liability insurance (which rights survive and are incorporated herein by reference) or
otherwise.
(b) 	Exclusions: Notwithstanding any other provision of this release, the following are not barred by the release: (i) Claims
relating to the validity of this General Release; (ii) Claims by either party to enforce this General Release or the
Employment Agreement (including that Continuing Obligations Agreement dated March ____, 2025); (ii) Claims which
are not legally waivable, including SEC whistleblowing claims pursuant to Rule 21F-17. In addition, this General
Release of Claims will not operate to limit or bar your right to file an administrative charge of discrimination with the
Equal Employment Opportunity Commission (EEOC) or to testify, assist or participate in an investigation, hearing or
proceeding conducted by the EEOC. However, the Release does bar your right to recover any personal or monetary
relief, including if you or anyone on your behalf seeks to file a lawsuit or arbitration on the same basis as the charge of
discrimination. Additionally, nothing in this Release should have a chilling effect on your ability to engage in
whistleblowing activity, by prohibiting or restricting you (or your attorney) from initiating communications directly
with, or responding to any inquiry from, or providing testimony before, the SEC or FINRA regarding your employment
at the Company, and nothing prevents you from reporting to, communicating with, contacting, responding to an inquiry
from, providing relevant information to, participating or assisting in an investigation conducted by, or receiving a
monetary award from the SEC or any
33

-- 116 of 155 --

other governmental enforcement agency related to such communication (except as noted in Section 1(a) above).
2. 	The Executive expressly waives and relinquishes all rights and benefits afforded by California Civil Code Section 1542 and
does so understanding and acknowledging the significance of such specific waiver of Section 1542. Section 1542 states as
follows:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR
SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR.”
Thus, notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release and discharge of
the Releasees, the Executive expressly acknowledges that this Agreement is intended to include in its effect, without limitation, all
Claims that the Executive does not know or suspect to exist in the Executive’s favor at the time of execution hereof, and that this
Agreement contemplates the extinguishment of any such Claim or Claims.
3. 	The Executive understands that he has been given a period of twenty-one (21) days to review and consider this General Release
before signing it pursuant to the Age Discrimination In Employment Act of 1967, as amended. The Executive further
understands that he may use as much of this twenty-one (21)-day period as the Executive wishes prior to signing.
4. 	The Executive acknowledges and represents that he understands that he may revoke the waiver of his rights under the Age
Discrimination In Employment Act of 1967, as amended, effectuated in this Agreement within seven days of signing this
Agreement. Revocation can be made by delivering a written notice of revocation to Office of the General Counsel, Nasdaq, Inc.,
One Liberty Plaza, New York, New York 10006. For this revocation to be effective, written notice must be received by the
General Counsel no later than the close of business on the seventh day after the Executive signs this General Release. If the
Executive revokes the waiver of his rights under the Age Discrimination in Employment Act of 1967, as amended, Employer
shall have no obligations to the Executive under Section 8 (other than the Base Obligations) of the Employment Agreement.
5. 	The Executive and Employer respectively represent and acknowledge that in executing this Agreement neither of them is
relying upon, and has not relied upon, any representation or statement not set forth herein made by any of the agents,
representatives or attorneys of the Releasees with regard to the subject matter, basis or effect of this Agreement or otherwise.
6. 	This General Release shall not in any way be construed as an admission by any of the Releasees that any Releasee has acted
wrongfully or that the Executive has any rights whatsoever against any of the Releasees except as specifically set forth herein,
and each of the Releasees specifically disclaims any liability to any party for any wrongful acts. Further, this Agreement shall
not in any way be construed as an admission by the Executive that the Executive has acted wrongfully.
7. 	It is the desire and intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible
under law. Should there be any conflict
34

-- 117 of 155 --

between any provision hereof and any present or future law, such law will prevail, but the provisions affected thereby will be
curtailed and limited only to the extent necessary to bring them within the requirements of law, and the remaining provisions of
this Agreement will remain in full force and effect and be fully valid and enforceable.
8. 	The Executive represents and agrees (a) that the Executive has to the extent he desires discussed all aspects of this Agreement
with his attorney, (b) that the Executive has carefully read and fully understands all of the provisions of this Agreement, and
(c) that the Executive is voluntarily entering into this Agreement.
9. 	This General Release shall be governed by, and construed in accordance with, the laws of the State of New York, without giving
effect to the conflicts of laws principles thereof or to those of any other jurisdiction which, in either case, could cause the
application of the laws of any jurisdiction other than the State of New York. This General Release is binding on the successors
and assigns of, and sets forth the entire agreement between, the parties hereto; fully supersedes any and all prior agreements or
understandings between the parties hereto pertaining to the subject matter hereof; and may not be changed except by explicit
written agreement to that effect subscribed by the parties hereto.
PLEASE READ CAREFULLY. THIS GENERAL RELEASE INCLUDES A RELEASE OF This General Release is executed by the
Executive and Employer as of the ___day of __________, 20__.
Tal Cohen
NASDAQ, INC.
By:
Name:
Title:
35

-- 118 of 155 --

Exhibit 10.3
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into and effective as of March 10, 2025 (the “Effective
Date”), by and between Nasdaq, Inc. (the “Company”) and Bradley J. Peterson (the “Executive”), hereby superseding the terms of the
Executive’s prior employment agreement effective June 22, 2022.
In consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties hereby
agree as follows:
1. 	Term of Agreement. Subject to Section 8 below, the term of this Agreement shall commence on the Effective Date and end on
January 1, 2028 (the “Term”). The Term may be extended by mutual agreement of the parties. In the event of a Change in
Control (as defined in Section 8(g)), the Term shall automatically be extended until the end of the CIC Protection Period (as
defined in Section 8(g)) below, if the Term would otherwise expire during such period absent the extension.
2. 	Position.
(a) 	Duties. The Executive shall serve as the Company’s Executive Vice President and Chief Information and Chief
Technology Officer and shall have such other duties as agreed to by the Executive, the Chair and Chief Executive
Officer (the “CEO”), and the Board of Directors of the Company (the “Board”). In such position, the Executive shall
have such duties and authority as shall be determined from time to time by the CEO and the Board and as shall be
consistent with the bylaws of the Company as in effect from time to time. During the Term, the Executive shall devote
his full time and best efforts to his duties hereunder. The Executive shall report directly to the CEO. The scope, duties
and responsibilities of the role will be evaluated at least annually and increased, as appropriate, based on performance in
the role.
(b) 	Company Code of Ethics. The Executive shall comply in all respects with the Company’s Code of Ethics and all
applicable corporate policies referenced in the Code of Ethics, as may be amended from time to time (the “Code of
Ethics”). The Executive may, in accordance with the Code of Ethics, (i) engage in personal activities involving
charitable, community, educational, religious or similar organizations and (ii) manage his personal investments;
provided, however, that, in each case, such activities are in all respects consistent with applicable law, the Continuing
Obligations Agreement attached as Exhibit A (“Continuing Obligations Agreement”), and Section 9 below.
3. 	Base Salary. During the Term, the Company shall pay the Executive a base salary (the “Base Salary”) at an annual rate of not
less than $650,000. The Base Salary shall be payable in regular payroll installments in accordance with the Company’s payroll
practices as in effect from time to time (but no less frequently than monthly). The Management Compensation Committee of the
Board (the “Compensation Committee”) shall review the Base Salary at least annually and may (but shall be under no obligation
to) increase (but not decrease) the Base Salary on the basis of such review.

-- 119 of 155 --

4. 	Annual Bonus.
(a) 	Annual Bonus. For each calendar year during the Term, the Executive shall be eligible to participate in the Executive
Corporate Incentive Plan of the Company (the “Bonus Program”) in accordance with the terms and provisions of such
Bonus Program as established from time to time by the Compensation Committee and pursuant to which the Executive
will be eligible to earn an annual cash bonus (the “Annual Bonus”). Pursuant to the terms of the Bonus Program, the
Executive shall be eligible to earn, for each full calendar year during the Term, a target Annual Bonus of not less than
175% of Base Salary (the “Target Bonus”) based upon the achievement of one or more performance goals established for
such year by the CEO and the Compensation Committee. The Executive shall have the opportunity to make suggestions
to the CEO and the Compensation Committee prior to the determination of the performance goals for the Bonus Program
for each performance period, but the Compensation Committee will have final power and authority concerning the
establishment of such goals. The CEO and the Compensation Committee shall review the Target Bonus at least annually
and may (but shall be under no obligation to) increase (but shall not decrease) the Target Bonus on the basis of such
review. The Target Bonus for each year during the Term shall never be less than the Target Bonus for the immediately
preceding year.
(b) 	Timing of Annual Bonus. The Annual Bonus for each year shall be paid to the Executive as soon as reasonably
practicable following the end of such year, but in no event later than March 15 following the end of the calendar year to
which such Annual Bonus relates.
5. 	Equity Compensation. Based on the Compensation Committee’s evaluation of the performance of the Company and Executive,
peer group market data, internal equity and consistent with past practices with respect to the combined aggregate value of the
grants of options, restricted share units and performance share units, the Executive shall be eligible to receive an annual equity
compensation award (an “Annual Equity Award”), in accordance with the terms and provisions of the Company’s Equity
Incentive Plan (the “Stock Plan”), which has been adopted by the Board and may from time to time be amended. The applicable
provisions of the Stock Plan and each equity award agreement to be executed by the Executive and the Company (to the extent
not inconsistent with this Agreement) shall govern the treatment of the equity awards. The Executive shall receive an Annual
Equity Award for 2025 with a target value at the time of grant of not less than $3,200,000.
6. 	Employee Benefits. During the Term, and except as otherwise noted herein, the Company shall provide the Executive with
benefits on the same basis as benefits are generally made available to other senior executives of the Company, including,
without limitation, medical, dental, vision, disability and life insurance, financial and tax planning services and retirement
benefits.
7. 	Business and Other Expenses.
(a) 	Business Expenses. During the Term, the Company shall reimburse the Executive for reasonable business expenses
incurred by him in the performance of his duties hereunder in accordance with the policy established by the Company.
th
2

-- 120 of 155 --

8. 	Termination. Notwithstanding any other provision of this Agreement, subject to the further provisions of this Section 8, the
Company may terminate the Executive’s employment or the Executive may resign such employment for any reason or no stated
reason at any time, subject to the notice and other provisions set forth below:
(a) 	Generally. In the event of the termination of the Executive’s employment for any reason, the Executive shall receive
payment of (i) any unpaid Base Salary through the Date of Termination (as defined below), to be paid in accordance with
Section 3 above, and (ii) any earned but unpaid Annual Bonus with respect to the calendar year ended prior to the Date
of Termination, payable in accordance with Section 4(b) (the “Base Obligations”). In addition, in the event of the
Executive’s termination of employment, the applicable provisions of the Company’s Stock Plan or each equity award
agreement executed by the Executive and the Company shall govern the treatment of the equity awards.
For purposes of this Agreement, “Date of Termination” means (i) in the event of a termination of the Executive’s employment
by the Company for Cause or by the Executive for Good Reason, the date specified in a written notice of termination (or, if not
specified therein, the date of delivery of such notice), but in no event earlier than the expiration of the cure periods set forth in
Section 8(b)(ii) or 8(b)(iii) below, respectively; (ii) in the event of a termination of the Executive’s employment by the Company
without Cause, the date specified in a written notice of termination (or if not specified therein, the date of delivery of such notice);
(iii) in the event of a termination of the Executive’s employment by the Executive without Good Reason, the date specified in a written
notice of termination, but in no event less than sixty (60) days following the date of delivery of such notice; (iv) in the event of a
termination of the Executive’s employment due to Permanent Disability (as defined below), the date the Company terminates the
Executive’s employment following the certification of the Executive’s Permanent Disability; (v) in the event of a termination of
employment due to the Executive’s death, the date of the Executive’s death; or (vi) in the event of a termination of Executive’s
employment due to Retirement (as defined below), the earlier to occur of (1) the last day of the Retirement Notice Period (as defined
below) or (2) the date specified in a written notice of termination by the Company, in each case pursuant to Section 8(c).
(b) 	Termination by the Company Without Cause or Termination by the Executive for Good Reason (other than in Connection
with a Change in Control).
(i) 	The Executive’s employment hereunder may be terminated by the Company without Cause or by the Executive
for Good Reason on or before the last day of the Term. Upon the termination of the Executive’s employment by
the Company without Cause or by the Executive for Good Reason pursuant to this Section 8(b), which occurs
more than six months prior to a Change in Control or at least two years after a Change in Control, the Executive
shall, subject to Section 8(i) below, be entitled to receive, in addition to the Base Obligations, the following
payments and benefits (the “Severance Benefits”):
(A) 	Severance Payment. The Executive shall, subject to Section 8(i), be entitled to receive a pro-rata
Target Bonus with respect to the calendar year in which the Date of Termination occurs,
determined in accordance with the
3

-- 121 of 155 --

Pro-Rata Target Bonus Calculation (the “Pro-Rata Target Bonus”) and payable, subject to
Section 12(h), in a lump sum within thirty (30) days following the Release Effective Date
(provided that if the sixty (60)-day period described in Section 8(i) below begins in one calendar
year and ends in another, the Pro-Rata Target Bonus shall be paid not earlier than January 1 of the
calendar year following the Date of Termination).
“Pro-Rata Target Bonus Calculation” is determined by multiplying the Executive’s Target Bonus
under Section 4(a) for the fiscal year in which the Date of Termination occurs by a fraction, the
numerator of which is the number of days in the fiscal year in which the Date of Termination
occurs through the Date of Termination and the denominator of which is the total number of days
in the calendar year.
(B) 	Equity Vesting. The Executive shall, subject to Section 8(i), be entitled to continued vesting of all
outstanding forms of equity compensation issued prior to the Date of Termination as though the
Executive were employed through the applicable vesting dates (“Continued Vesting Period for
Retirement”), with any performance-based vesting based on actual performance goals during the
respective performance periods.
(C) 	Health Care Coverage Payments. Provided that the Executive timely elects to continue coverage
under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), the Company agrees to
continue to pay the employer’s share of the medical, dental and vision premiums for the Executive
and his eligible dependents from the expiration date of the Executive’s coverage under the
Company plan (which is at the end of month in which the Executive’s Date of Termination
occurs), for eighteen (18) months (“COBRA Continuation Period”). The Executive will still be
responsible for paying the employee share of the premium as specified by the plan administrator.
If, during the COBRA Continuation Period, the Executive begins work with an employer who
provides health insurance benefits for which the Executive is eligible, the Company’s obligation
under this section shall forever cease upon the expiration of the waiting period (if any) for
entitlement to insurance coverage through the Executive’s new employer. The Executive agrees to
promptly notify the Company in writing within seven (7) days of the Executive’s commencement
of full-time employment during the COBRA Continuation Period. 	In any event, and
notwithstanding any provision to the contrary in this section, the Company shall have no
obligation to make any payments for COBRA premiums paid for health insurance coverage
beyond the expiration of the COBRA Continuation Period.
4

-- 122 of 155 --

(D) 	Other Benefits. The Company will make a one-time cash payment to the Executive in the amount
of $45,000 to subsidize the cost of continuation of financial and tax services (currently provided
by Ayco) for a period of twenty-four (24) months following the Date of Termination.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(b) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The Severance Benefits are payments and benefits to which the Executive is not otherwise entitled,
are given in consideration for the Release (as described in Section 8(i) below) and are in lieu of any severance plan, policy or program
of the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant to this
Section 8(b)(i) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all obligations of
the Company to the Executive under this Agreement. The Executive acknowledges and agrees that such amounts are fair and
reasonable, and are his sole and exclusive remedy, in lieu of all other remedies at law or in equity, with respect to the termination of his
employment hereunder. If, during the Continued Vesting Period, the Executive breaches in any material respect any of his obligations
under Section 9, or the Continuing Obligations Agreement, the Company may, upon written notice to the Executive terminate the
Continued Vesting Period and cease any benefits continuation coverage or payments, except in each case as required by applicable law.
(ii) 	For purposes of this Agreement, “Cause” shall mean (A) the Executive’s conviction of, or pleading nolo
contendere to, any crime, whether a felony or misdemeanor, involving the purchase or sale of any security, mail
or wire fraud, theft, embezzlement, moral turpitude, or Company property (with the exception of minor traffic
violations or similar misdemeanors); (B) the Executive’s repeated neglect of his duties to the Company; or
(C) the Executive’s willful misconduct in connection with the performance of his duties or other material breach
by the Executive of this Agreement provided that the Company may not terminate the Executive’s employment
for Cause unless (x) the Company first gives the Executive written notice of its intention to terminate and of the
grounds for such termination within ninety (90) days following the date the Board is informed of such grounds at
a meeting of the Board and (y) the Executive has not, within thirty (30) days following receipt of such notice,
cured such Cause (if capable of cure) in a manner that is reasonably satisfactory to the Board.
(iii) 	For purposes of this Agreement, “Good Reason” shall mean the Company (A) reducing the Executive’s position,
duties, or authority, other than during the Retirement Notice Period; (B) failing to secure the agreement of any
successor entity to the Company that the Executive shall continue in his position without reduction in position,
duties or authority; (C) relocating the Executive’s principal work location, excluding working from home
remotely, beyond a fifty (50)-mile radius of his work location as of the Effective Date (provided that this
Clause (C) shall apply only to a relocation that occurs during the two-year period beginning upon a
5

-- 123 of 155 --

Change of Control, as defined below, and ending two years thereafter); or (D) committing any other material
breach of this Agreement; provided, however, that the occurrence of a Change in Control, following which the
Company continues to have its common stock publicly traded and the Executive is offered continued
employment as an executive officer with substantially the same duties and authority as he has hereunder of such
publicly traded entity, shall not be deemed to give rise to an event or condition constituting Good Reason; and
provided, further, that no event or condition shall constitute Good Reason unless (x) the Executive gives the
Company a Notice of Termination specifying his objection to such event or condition within ninety (90) days
following the occurrence of such event or condition, (y) such event or condition is not corrected, in all material
respects, by the Company in a manner that is reasonably satisfactory to the Executive within thirty (30) days
following the Company’s receipt of such notice and (z) the Executive resigns from his employment with the
Company not more than thirty (30) days following the expiration of the thirty (30)-day period described in the
foregoing clause (y).
(c) 	Retirement.
(i) 	The Executive may terminate his employment without Good Reason and such termination of employment shall
be deemed a termination due to retirement (“Retirement”) by providing the Company with twelve (12) months’
written notice (or such shorter period as may be approved by the Board) (the “Retirement Notice Period”) of such
termination pursuant to Section 12(f) of this Agreement; provided that the Executive may not provide notice of
Retirement any earlier than December 31, 2026 (or such earlier date as may be approved by the Board), and
provided, further, that if the Term expires during the Retirement Notice Period, the Executive’s Retirement shall
occur on the last day of the Term unless otherwise agreed to by the Company and the Executive. In the event of a
termination due to Retirement, the Company may, it its sole and absolute discretion, by written notice pursuant to
Section 12(f) of this Agreement, accelerate the Date of Termination without changing the characterization of
such termination as a Retirement; and more specifically, such written notice and acceleration shall not constitute
a termination without Cause by the Company, nor provide a basis for a claim of Good Reason. Upon the
termination of the Executive’s employment pursuant to this Section 8(c), the Executive shall, subject to
Section 8(i) below, be entitled to receive, in addition to the Base Obligations, the following payments and
benefits:
(A) 	Payments. The Executive shall be entitled to receive, continued Base Salary through the end of the
Term and Executive’s Target Bonus for 2027, without proration, payable when bonuses are
otherwise paid for fiscal year 2027 (but in any event, no later than March 15, 2028).
(B) 	Equity Vesting. The Executive shall be entitled to continued vesting of all outstanding forms of
equity compensation issued prior to the commencement of the Retirement Notice Period as though
the Executive were employed through the applicable vesting dates (“Continued Vesting Period for
Retirement”), with any performance-
6

-- 124 of 155 --

based vesting based on actual performance goals during the respective performance periods.
Notwithstanding anything to the in the Stock Plan and the equity award agreement, any forms of
equity compensation granted during the Retirement Notice Period shall be prorated based on the
time elapsed between the vesting commencement date and the last day of the Retirement Notice
Period, with PSUs vesting based on actual performance goals during the applicable performance
period.
(C) 	Health Care Coverage Payments. Provided that the Executive timely elects to continue COBRA
coverage, the Company agrees to continue to pay the employer’s share of the medical, dental and
vision premiums for the Executive and his eligible dependents for the COBRA Continuation
Period. The Executive will still be responsible for paying the employee share of the premium as
specified by the plan administrator. If, during the COBRA Continuation Period, the Executive
begins work with an employer who provides health insurance benefits for which the Executive is
eligible, the Company’s obligation under this section shall forever cease upon the expiration of the
waiting period (if any) for entitlement to insurance coverage through the Executive’s new
employer. The Executive agrees to promptly notify the Company in writing within seven (7) days
of the Executive’s commencement of full-time employment during the COBRA Continuation
Period. In any event, and notwithstanding any provision to the contrary in this section, the
Company shall have no obligation to make any payments for COBRA premiums paid for health
insurance coverage beyond the expiration of the COBRA Continuation Period.
(D) 	Other Benefits. The Company will make a one-time cash payment to the Executive in the amount
of $45,000 to subsidize the cost of continuation of financial and tax services (currently provided
by Ayco) for a period of twenty-four (24) months following the Date of Termination. Additionally,
upon the Executive’s request at any time within eighteen (18) months following the Date of
Termination, the Company will provide third-party concierge advisory services at the Company’s
expense, to assist the Executive with the procurement of private health care coverage.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(c) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The payments and benefits in this Section 8(c) to which the Executive is not otherwise entitled are
given in consideration for the Release (as described in Section 8(i) below) and are in lieu of any severance plan, policy or program of
the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant
7

-- 125 of 155 --

to this Section 8(c) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all
obligations of the Company to the Executive under this Agreement.
The Executive acknowledges and agrees that such amounts are fair and reasonable, and are his sole and exclusive remedy, in lieu of all
other remedies at law or in equity, with respect to the termination of his employment hereunder. If, during the Continued Vesting Period
for Retirement, the Executive breaches in any material respect any of his obligations under Section 9, the Continuing Obligations
Agreement, or commences employment in an operating executive role at a for-profit operating company, either publicly listed or
privately owned (a “Disqualifying Operational Role”), the Company may, upon written notice to the Executive terminate the Continued
Vesting Period for Retirement and cease any benefits continuation coverage or payments, except in each case as required by applicable
law. For the avoidance of doubt, the following will not constitute a Disqualifying Operational Role: (i) an operating executive role in a
non-profit organization or in a government agency or other government position, (ii) a role as an investment management professional,
or advisor to a private equity firm or venture capital firm with respect to a portfolio company (provided that such role is not an
operating role within a portfolio company or at the General Partner itself), or (iii) a role as a Non-Executive Chair or on the board of
directors of any organization, including a for-profit operating company or a private equity or venture capital firm.
If, during the twelve (12) month period following the Date of Termination due to Retirement, the Executive commences employment in
a Disqualifying Operational Role, then the Executive shall promptly repay to the Company all payments and benefits received pursuant
to this Section 8(c). Further, if during the period between twelve (12) and thirty-six (36) months following the Date of Termination due
to Retirement, the Executive commences employment in a Disqualifying Operational Role, then all continued vesting of equity awards
pursuant to Section 8(c)(i)(B) shall immediately cease. If the Executive seeks to obtain a Disqualifying Operational Role during such
three-year period, the Executive may seek a waiver of this provision upon written request to the CEO and the CEO shall reasonably
consider such request in good faith. Any such waiver, if granted, must be in writing.
(d) 	Permanent Disability.
(i) 	The Executive’s employment hereunder shall terminate upon his Permanent Disability. Upon termination of the
Executive’s employment due to Permanent Disability, the Executive shall, subject to Section 8(i) below, be
entitled to receive, in addition to the Base Obligations, (A) the Pro-Rata Target Bonus paid, subject to
Section 12(h), in a lump sum within thirty (30) days following the Release Effective Date (provided that if the
sixty (60)-day period described in Section 8(i) below begins in one calendar year and ends in another, the Pro-
Rata Target Bonus shall be paid not earlier than January 1 of the calendar year following the Date of
Termination) and (B) accelerated vesting of all unvested equity compensation awarded to the Executive by the
Company, effective as of December 31 of the year of termination and, in accordance with Section 5, each equity
award agreement executed by the Executive and the Company shall describe the treatment of the equity awards
under this
st
8

-- 126 of 155 --

Section 8(d). Any performance-based vesting will be based on actual performance goals during any complete
performance period; vesting will be at target performance for grants vesting prior to the completion of a
performance cycle. All other benefits, if any, due the Executive following termination pursuant to this
Section 8(d) shall be determined in accordance with the plans, policies and practices of the Company; provided,
however, that the Executive shall not participate in any other severance plan, policy or program of the Company.
(ii) 	For purposes of this Agreement, “Permanent Disability” means either (A) the inability of the Executive to
engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment
that can be expected to result in death or can be expected to last for a continuous period of not less than twelve
(12) months or (B) the Executive is, by reason of any medically determinable physical or mental impairment that
can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12)
months, receiving income replacement benefits for a period of not less than three months under an accident and
health plan covering employees of the Company. The Executive shall be deemed Permanently Disabled if he is
determined to be (A) totally disabled by the Social Security Administration or (B) disabled in accordance with a
disability insurance program; provided such definition of disabled under the program complies with the
definition of Permanent Disability hereunder. Otherwise, such Permanent Disability shall be certified by a
physician chosen by the Company and reasonably acceptable to the Executive (unless he is then legally
incapacitated, in which case such physician shall be reasonably acceptable to the Executive’s authorized legal
representative).
(e) 	Death. The Executive’s employment hereunder shall terminate due to his death. Upon termination of the Executive’s
employment hereunder due to death, the Executive’s estate shall, subject to Section 8(i) below, be entitled to receive, in
addition to the Base Obligations,(A) the Pro-Rata Target Bonus paid, subject to Section 12(h), in a lump sum within
thirty (30) days following the Release Effective Date (provided that if the sixty (60)-day period described in Section 8(i)
below begins in one calendar year and ends in another, the Pro-Rata Target Bonus shall be paid not earlier than January 1
of the calendar year following the Date of Termination) and (B) accelerated vesting of all unvested equity compensation
awarded to the Executive by the Company, effective as of December 31 of the year of termination and, in accordance
with Section 5, each equity award agreement executed by the Executive and the Company shall describe the treatment of
the equity awards under this Section 8(e). Any performance-based vesting will be based on actual performance goals
during any complete performance period; vesting will be at target performance for grants vesting prior to the completion
of a performance cycle. All other benefits, if any, due the Executive’s estate following termination pursuant to this
Section 8(e) shall be determined in accordance with the plans, policies and practices of the Company.
(f) 	For Cause by the Company or Without Good Reason, by the Executive. The Executive’s employment hereunder may be
terminated by the Company for Cause or by the Executive without Good Reason (other than Retirement). Upon
termination of the Executive’s employment for Cause or without Good Reason (other than Retirement), pursuant to this
Section 8(f), the Executive shall have no further rights to any compensation (including any Annual Bonus) or any other
st
9

-- 127 of 155 --

benefits under this Agreement other than the Base Obligations. All other benefits, if any, due the Executive following the
Executive’s termination of employment pursuant to this Section 8(f) shall be determined in accordance with the plans,
policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy, or program of the Company.
(g) 	Termination in Connection with Change in Control by the Company Without Cause or by the Executive for Good
Reason.
(i) 	If the Executive’s employment is terminated by the Company without Cause or by the Executive for Good
Reason during the CIC Protection Period (as defined herein below), the Executive shall, subject to Section 8(i)
below, be entitled to receive, in addition to the Base Obligations, the following payments and benefits (the “CIC
Severance Benefits”):
(A) 	CIC Severance Payment. The Company shall pay the Executive a lump sum cash payment equal
to (I) the sum of (x) two times the Base Salary paid to the Executive with respect to the calendar
year immediately preceding the Executive’s Date of Termination and (y) the Target Bonus and
(II) the Pro-Rata Target Bonus, which shall be paid, subject to Section 12(h), within thirty (30)
days following the Release Effective Date (provided that if the sixty (60)-day period described in
Section 8(i) below begins in one calendar year and ends in another, the cash payment shall be paid
not earlier than January 1 of the calendar year following the Date of Termination).
If (i) any amounts payable to the Executive under this Agreement or otherwise are characterized as excess parachute payments pursuant
to Section 4999 of the Internal Revenue Code of 1986, as amended (the “Section 4999”), and (ii) the Executive thereby would be
subject to any United States federal excise tax due to that characterization, the Executive’s termination benefits hereunder will be
reduced to an amount so that none of the amounts payable constitute excess parachute amounts payments if this would result, after
taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, in Executive’s
receipt on an after-tax basis of the greatest amount of termination and other benefits. The determination of any reduction required
pursuant to this section (including the determination as to which specific payments shall be reduced) shall be made by a neutral party
designated by the Company and such determination shall be conclusive and binding upon the Company or any related corporation for
all purposes.
(B) 	Equity Vesting. The Executive shall, subject to Section 8(i), be entitled to receive accelerated
vesting of all outstanding, unvested equity awards. The schedule for acceleration of the various
equity awards will be governed by Section 12 (Change in Control) of the Stock Plan.
(C) 	Health and Welfare Benefits. The Company shall pay to Executive on a monthly basis during the
CIC Coverage Period a taxable monthly cash payment equal to the
10

-- 128 of 155 --

COBRA premium for the highest level of coverage available under the Company’s group health
plans, but reduced by the monthly amount that Executive would pay for such coverage if the
Executive was an active employee. “CIC Coverage Period” shall mean the period (I) commencing
on the first day of the month following the Release Effective Date (provided that if the sixty (60)-
day period described in Section 8(i) below begins in one calendar year and ends in another, the
CIC Coverage Period shall commence not earlier than January 1 of the calendar year following
the Date of Termination) and (II) ending on the earlier of (x) the expiration of eighteen (18)
months from the first day of the CIC Coverage Period, and (y) the date that the Executive is
eligible for coverage under the health care plans of a subsequent employer. The payments
provided by this Section shall be conditioned upon the Executive being covered by the Company’s
health care plans immediately prior to the Date of Termination. The foregoing payments are not
intended to limit or otherwise reduce any entitlements that Executive may have under COBRA. In
addition, the Company shall continue to provide the Executive with the same level of accident
(AD&D) and life insurance benefits upon substantially the same terms and conditions (including
contributions required by the Executive for such benefits) as existed immediately prior to the
Executive’s Date of Termination (or, if more favorable to the Executive, as such benefits and
terms and conditions existed immediately prior to the Change in Control) for the same period for
which the Company shall provide the Executive with continued health care coverage payments.
All other benefits, if any, due the Executive following termination pursuant to this Section 8(g) shall be determined in accordance with
the plans, policies and practices of the Company; provided, however, that the Executive shall not participate in any severance plan,
policy or program of the Company. The payments and other benefits provided for in this Section 8(g) are payments and benefits to
which the Executive is not otherwise entitled, are given in consideration for the Release and are in lieu of any severance plan, policy or
program of the Company or any of its subsidiaries that may now or hereafter exist. The payments and benefits to be provided pursuant
to this Section 8(g)(i) shall constitute liquidated damages and shall be deemed to satisfy and be in full and final settlement of all
obligations of the Company to the Executive under this Agreement. The Executive acknowledges and agrees that such amounts are fair
and reasonable, and are his sole and exclusive remedy, in lieu of all other remedies at law or in equity, with respect to the termination of
his employment hereunder. If, during the CIC Coverage Period, the Executive breaches in any material respect any of his obligations
under Section 9 or the Continuing Obligations Agreement, the Company may, upon written notice to the Executive, (x) terminate the
CIC Coverage Period and cease to make any further payments of the CIC Severance Payment and (y) cease any health and welfare
benefits and payments, except in each case as required by applicable law.
11

-- 129 of 155 --

(ii) 	For purposes of this Agreement “Change in Control” means the first to occur of any one of the following events:
(A) 	any “Person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of
1934 (the “Exchange Act”) (other than (1) the Company, (2) any Person who becomes the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act) of more than 50% of the
Company’s then outstanding securities eligible to vote in the election of the Board (“Voting
Securities”) as a result of a reduction in the number of Voting Securities outstanding due to the
repurchase of Voting Securities by the Company unless and until such Person, after becoming
aware that such Person has become the beneficial owner of more than 50% of the then outstanding
Voting Securities, acquires beneficial ownership of additional Voting Securities representing 1%
or more of the Voting Securities then outstanding, (3) any trustee or other fiduciary holding
securities under an employee benefit plan of the Company, and (4) any entity owned, directly or
indirectly, by the stockholders of the Company in substantially the same proportions as their
ownership of Voting Securities), is or becomes the beneficial owner, directly or indirectly, of more
than 50% of the Voting Securities (not including any securities acquired directly (or through an
underwriter) from the Company or the Companies);
(B) 	the date on which, within any twelve (12)-month period (beginning on or after the Effective Date),
a majority of the directors then serving on the Board are replaced by directors not endorsed by at
least two-thirds (2/3) of the members of the Board before the date of appointment or election;
(C) 	there is consummated a merger or consolidation of the Company with any other corporation or
entity or the Company issues Voting Securities in connection with a merger or consolidation of
any direct or indirect subsidiary of the Company with any other corporation, other than (1) a
merger or consolidation that would result in the Voting Securities outstanding immediately prior
thereto continuing to represent (either by remaining outstanding or by being converted into Voting
Securities of the surviving or parent entity) more than 50% of the Company’s then outstanding
Voting Securities or more than 50% of the combined voting power of such surviving or parent
entity outstanding immediately after such merger or consolidation or (2) a merger or consolidation
effected to implement a recapitalization of the Company (or similar transaction) in which no
Person, directly or indirectly, acquired more than 50% of the Company’s then outstanding Voting
Securities (not including any securities acquired directly (or through an underwriter) from the
Company or the Companies); or
12

-- 130 of 155 --

(D) 	the consummation of an agreement for the sale or disposition by the Company of all or
substantially all of the Company’s assets (or any transaction having a similar effect); provided that
such agreement or transaction of similar effect shall in all events require the disposition, within
any twelve (12)-month period, of at least 40% of the gross fair market value of all of the
Company’s then assets; other than a sale or disposition by the Company of all or substantially all
of the Company’s assets to an entity, at least 50% of the combined voting power of the voting
securities of which are owned directly or indirectly by stockholders of the Company in
substantially the same proportions as their ownership of the Company immediately prior to such
sale.
Notwithstanding the foregoing, in no event shall a Change in Control be deemed to occur hereunder unless such event constitutes a
change in ownership of the Company, a change in effective control of the Company or a change in ownership of a substantial portion of
the Company’s assets within the meaning of Section 409A.
(iii) 	For purposes of this Agreement “CIC Protection Period” means the two (2) years following the occurrence of a
Change in Control; provided that, if the Executive’s employment is terminated by the Company without Cause or
by the Executive for Good Reason within six (6) months prior to a Change in Control, then the termination will
be treated for all purposes of this Agreement as having occurred immediately following the Change in Control
and during the CIC Protection Period (provided such protection will end if such agreement is terminated or the
transaction is abandoned).
(h) 	Mitigation; Offset. Following the termination of his employment under any of the above clauses of this Section 8, the
Executive shall have no obligation or duty to seek subsequent employment or engagement as an employee (including
self-employment) or as a consultant or otherwise mitigate the Company’s obligations hereunder; nor shall the payments
provided by this Section 8 be reduced by the compensation earned by the Executive as an employee or consultant from
such subsequent employment or consultancy.
(i) 	Release. Notwithstanding anything to the contrary in this Agreement, receipt of the Severance Benefits and the
CIC Severance Benefits or other compensation or benefits under this Section 8 (other than the Base Obligations),
if any, by the Executive is subject to the Executive executing and delivering to the Company a general release of
claims following the Date of Termination, in substantially the form attached as Exhibit B (the “Release”), that,
within sixty (60) days following the Executive’s Date of Termination, has become irrevocable by the Executive
(such date the Release becomes irrevocable being the “Release Effective Date”). If the Executive dies or becomes
legally incapacitated prior to the Release Effective Date, then the Release requirements described in the
preceding sentence shall apply with respect to the Executive’s estate and the Release shall be modified as
reasonably necessary to allow for execution and delivery by the personal representative of the Executive’s estate
or the Executive’s authorized legal representative, as applicable.
13

-- 131 of 155 --

9. 	Non-Competition. The Executive acknowledges and recognizes the highly competitive nature of the businesses of the Company
and accordingly agrees as follows:
(a) 	Non-Competition. For a period of two years following the Date of Termination (the “Restricted Period”), regardless of
the circumstances surrounding such termination of employment, the Executive will not, directly or indirectly without
prior “Written Permission” (as defined below), (i) engage in any “Competitive Business” (as defined below) for the
Executive’s own account while he is in self-employment or acting as a sole proprietor, (ii) enter the employ of, or render
any services to, any person engaged in a Competitive Business, (iii) acquire a financial interest in, or otherwise become
actively involved with, any person engaged in a Competitive Business, directly or indirectly, as an individual, partner,
shareholder, officer, director, principal, agent, trustee or consultant, or (iv) interfere with business relationships (whether
formed before or after the Effective Date) between the Company and customers or suppliers of the Company. For the
avoidance of doubt, the Restricted Period shall apply only if the Date of Termination occurs on or before the last day of
the Term, but if the Date of Termination occurs on or before the last day of the Term, the full Restricted Period shall
apply regardless of the time remaining in the Term on the Date of Termination. The Executive may seek a waiver of all
or part of his Restricted Period upon written request to the Board, shall consider such request in good faith. Any such
waiver, if granted, must be in writing, in advance of the Executive accepting any offers of engagement from the
applicable entity.
For purposes of this Agreement, “Competitive Business” shall mean (x) any national securities exchange registered with the Securities
and Exchange Commission, (y) any electronic communications network or (z) any other entity that engages in substantially the same
business as the Company, but only to the extent that (i) the Company’s most recent annual revenue for that similar business unit equals
or exceeds 5% of the Company’s revenues (less transaction-based contra-revenues (i.e., rebates)), as reported in the Company’s most
recent Form 10-K, or (ii) the entity’s most recent annual revenue for that similar business unit equals or exceeds 5% of the entity’s
revenues (less transaction-based contra-revenues (i.e., rebates)) as reported in the entity’s most recent Form 10-K (if applicable) or
other financial statements (if such entity does not file a Form 10-K). For purposes of this Agreement, “person” shall mean an
individual, corporation, partnership, limited partnership, limited liability company, syndicate, person (including, without limitation, a
“person” as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended), trust, or association. “Written
Permission” shall mean any permission granted by the Company’s Board of Directors in writing, which shall apply a reasonable, good
faith consideration of the request based on factors including, without limitation, the role the Executive will occupy, the Company’s
strategic plans, any potential competitive threats posed, and the size of revenue associated with any competing products and services
offered by the Competitive Business.
(b) 	Securities Ownership. Notwithstanding anything to the contrary in this Agreement, the Executive may, directly or
indirectly, own, solely as an investment, securities of any person engaged in the business of the Company which are
publicly traded on a national or regional stock exchange or on the over-the-counter market if the Executive (i) is not a
controlling person of, or a member of a group which controls, such person and (ii) does not, directly or indirectly, own
5% or more of any class of securities of such person.
14

-- 132 of 155 --

(c) 	Severability. It is expressly understood and agreed that, although the Executive and the Company consider the
restrictions contained in this Section 9 to be reasonable, if a final judicial determination is made by a court of competent
jurisdiction that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction
against the Executive, the provisions of this Agreement shall not be rendered void, but shall be deemed amended to
apply as to such maximum time and territory and to such maximum extent as such court may judicially determine or
indicate to be enforceable. Alternatively, in the event that any one or more of the provisions of this Agreement shall be
or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions of this Agreement shall not be affected thereby.
10. 	Specific Performance. The Executive acknowledges and agrees that the Company’s remedies at law for a breach or threatened
breach of Section 9 above would be inadequate and, in recognition of this fact, the Executive agrees that, in the event of such a
breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or
any other equitable remedy which may then be available.
11. 	Disputes. Except as provided in Section 10 above, any dispute arising between the parties under this Agreement, under any
statute, regulation, or ordinance, under any other agreement between the parties, and/or in way relating to the Executive’s
employment, shall be submitted to binding arbitration before the American Arbitration Association (“AAA”) for resolution. Such
arbitration shall be conducted in New York, New York, and the arbitrator will apply New York law, including federal law as
applied in New York courts. The arbitration shall be conducted in accordance with the AAA’s Employment Arbitration Rules as
modified herein. The arbitration shall be conducted by a panel of three arbitrators that is mutually agreeable to both the
Executive and the Company, all in accordance with AAA’s Employment Arbitration Rules then in effect. If the Executive and
the Company cannot agree upon the panel of arbitrators, the arbitration shall be settled before a panel of three arbitrators, one to
be selected by the Company, one by the Executive, and the third to be selected by the two persons so selected, all in accordance
with AAA’s Employment Arbitration Rules. Each party shall pay their own costs and expenses, including, without limitation,
attorney’s fees and costs, except that the Company shall pay the cost of the arbitrators and the filing fees charged to Executive
by the AAA; provided that he has not brought a frivolous claim (as determined by the arbitrator). The award of the arbitrators
shall be final and binding on the parties, and judgment on the award may be confirmed and entered in any state or federal court
in the State and City of New York. The arbitration shall be conducted on a strictly confidential basis, and Executive shall not
disclose the existence of a claim, the nature of a claim, any documents, exhibits, or information exchanged or presented in
connection with such a claim, or the result of any action (collectively, “Arbitration Materials”), to any third party, with the sole
exception of the Executive’s legal counsel, who also shall be bound by confidentiality obligations no less protective than the
provisions set forth in the Continuing Obligations Agreement. In the event of any court proceeding to challenge or enforce an
arbitrators’ award, the parties hereby consent to the exclusive jurisdiction of the state and federal courts in New York, New York
and agree to venue in that jurisdiction. The parties agree to take all steps necessary to protect the confidentiality of the
Arbitration Materials in connection with any such proceeding, agree to file all Confidential Information, as defined in the
Continuing Obligations Agreement (and documents containing Confidential Information) under seal, subject to court order and
agree to the entry of an appropriate protective order encompassing the confidentiality
15

-- 133 of 155 --

terms of this Agreement. Nothing contained in this Section 11 shall be construed to preclude the Company from exercising its
rights under Section 10 above.
12. 	Miscellaneous.
(a) 	Acceptance. The Executive hereby represents and warrants, as a material inducement to the Company’s agreement to
enter into this Agreement, that there are no legal, contractual or other impediments precluding the Executive from
entering into this Agreement or from performing the services with the Company contemplated hereby. Any violation of
this representation and warranty by the Executive shall render all of the obligations of the Company under this
Agreement void ab initio and of no force and effect.
(b) 	Entire Agreement; Amendments. This Agreement, together with the equity award agreements between the Executive and
the Company contain the entire understanding of the parties with respect to the employment of the Executive by the
Company, and shall supersede any and all previous contracts, arrangements or understandings between the Company and
the Executive with respect to the subject matter set forth herein. For the avoidance of doubt, this Agreement supersedes
and replaces, in its entirety, the employment agreement by and between the Company and the Executive dated June 22,
2022. There are no restrictions, agreements, promises, warranties, or covenants by and between the Company and the
Executive and undertakings between the parties with respect to the subject matter herein other than those expressly set
forth herein. This Agreement may not be altered, modified or amended except by written instrument signed by the
parties hereto.
(c) 	No Waiver. The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not
be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence
to that term or any other term of this Agreement.
(d) 	Successor; Assignment. This Agreement is confidential and personal and neither of the parties hereto shall, without the
consent of the other, assign or transfer this Agreement or any rights or obligations hereunder. Without limiting the
foregoing, the Executive’s right to receive payments hereunder shall not be assignable or transferable whether by pledge,
creation of a security interest or otherwise, other than a transfer by the Executive’s will or by the laws of descent and
distribution. In the event of any attempted assignment or transfer contrary to this Section 12(d), the Company shall have
no liability to pay the assignee or transferee any amount so attempted to be assigned or transferred. The Company shall
cause this Agreement to be assumed by any entity that succeeds to all or substantially all of the Company’s business or
assets and this Agreement shall be binding upon any successor to all or substantially all of the Company’s business or
assets; provided, however, that no such assumption shall release the Company of its obligations hereunder, to the extent
not satisfied by such successor, without the Executive’s prior written consent.
(e) 	Confidentiality of Tax Treatment and Structure. Notwithstanding anything herein to the contrary, each party and its
representatives may consult any tax advisor regarding the tax treatment and tax structure of this Agreement and may
disclose to any person, without limitation of any kind, the tax treatment and tax structure of this Agreement and all
materials (including opinions or other tax analyses) that are provided relating to such treatment or structure.
16

-- 134 of 155 --

(f) 	Notice. For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be
in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail,
return receipt requested, postage prepaid, addressed to the respective addresses set forth on the execution page of this
Agreement; provided that all notices to the Company shall be directed to the attention of the General Counsel or to such
other address as either party may have furnished to the other in writing in accordance herewith, except that notice of
change of address shall be effective only upon receipt:
if to the Company:
The Office of the General Counsel
Nasdaq, Inc.
151 West 42 Street
New York, NY 10036
Email: ogc@nasdaq.com
if to the Executive:
his address as shown in the records of the Company
(g) 	Withholding Taxes. The Company may withhold from any amounts payable under this Agreement such federal, state and
local taxes as may be required to be withheld pursuant to any applicable law or regulation.
(h) 	Section 409A. Notwithstanding any other provision of this Agreement, any payment, settlement or benefit triggered by
termination of the Executive’s employment with the Company shall not be made until six months and one day following
Date of Termination if such delay is necessary to avoid the imposition of any tax, penalty or interest under Section 409A
of the Internal Revenue Code of 1986, as amended (Section “409A”). Any installment payments that are delayed
pursuant to this Section 12(h) shall be accumulated and paid in a lump sum on the day that is six months and one day
following the Date of Termination (or, if earlier, upon the Executive’s death) and the remaining installment payments
shall begin on such date in accordance with the schedule provided in this Agreement. For purposes of this Agreement,
termination or severance of employment will be read to mean a “separation from service” within the meaning of
Section 409A where it is reasonably anticipated that no further services would be performed after that date or that the
level of services the Executive would perform after that date (whether as an employee or independent contractor) would
permanently decrease to no more than 20% of the average level of bona fide services performed over the immediately
preceding thirty-six (36) month period. Additionally, the amount of expenses eligible for reimbursement or in-kind
benefits to be provided during one calendar year may not affect the expenses eligible for reimbursement or any in-kind
benefits to be provided in any other calendar year and the right to reimbursement or in-kind benefits is not subject to
liquidation or exchange for another benefit. All reimbursements shall be made no later than the last day of the calendar
year following the calendar year in which the Executive incurs the reimbursable expense. This Agreement is intended to
comply with the requirements of Section 409A (including the exceptions thereto), to the extent applicable, and the
Agreement shall be administered and interpreted
nd
17

-- 135 of 155 --

in accordance with such intent. If any provision contained in the Agreement conflicts with the requirements of
Section 409A (or the exemptions intended to apply under the Agreement), the Agreement shall be deemed to be
reformed to comply with the requirements of Section 409A (or the applicable exemptions thereto). The Company, after
consulting with the Executive, may amend this Agreement or the terms of any award provided for herein in any manner
that the Company considers necessary or advisable to ensure that cash compensation, equity awards or other benefits
provided for herein are not subject to United States federal income tax, state or local income tax or any equivalent taxes
in territories outside the United States prior to payment, exercise, vesting or settlement, as applicable, or any tax, interest
or penalties pursuant to Section 409A. Any such amendments shall be made in a manner that preserves to the maximum
extent possible the intended benefits to the Executive. This Section 12(h) does not create an obligation on the part of the
Company to modify this Agreement and does not guarantee that the amounts or benefits owed under the Agreement will
not be subject to interest and penalties under Section 409A. For purposes of this Agreement, all rights to payments and
benefits hereunder shall be treated as rights to receive a series of separate payments and benefits to the fullest extent
allowed by Section 409A.
(i) 	Clawback. The Executive agrees that compensation and benefits provided by the Company under this Agreement or
otherwise will be subject to recoupment or clawback by the Company under any applicable clawback or recoupment
policy of the Company that is generally applicable to the Company’s executives, as may be in effect from time-to-time,
or as required by applicable law.
(j) 	Audit Rights. Any and all equity compensation of any kind due hereunder to Executive after the Date of Termination
shall be accompanied by a detailed statement from the Company showing the calculation for such compensation for the
period being measured. Within thirty (30) days after the delivery of such statement, the Executive may notify the
Company of any objections or changes thereto, specifying in reasonable detail any such objections or changes. If the
Executive does not notify the Company of any objections or changes thereto or if within twenty (20) days of the delivery
of an objection notice the Executive and the Company agree on the resolution of all objections or changes, then such
statements delivered by the Company, with such changes as are agreed upon, shall be final and binding. If the parties
shall fail to reach an agreement with respect to all objections or changes within such twenty (20)-day period, then all
disputed objections or changes shall, be subject to resolution in accordance with Section 11 above.
(k) 	Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as
if the signatures thereto and hereto were upon the same instrument.
(l) 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New
York.
* 	* 	*
18

-- 136 of 155 --

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.
EXECUTIVE
/s/ Bradley J. Peterson
Bradley J. Peterson
NASDAQ, INC.
By: 	/s/ Bryan E. Smith
Name: Bryan E. Smith
Title: 	Executive Vice President and
Chief People Officer
19

-- 137 of 155 --

Exhibit A
NASDAQ CONTINUING OBLIGATIONS AGREEMENT
I, the undersigned, hereby enter into this agreement (the “Agreement”) with Nasdaq, Inc. as of the signature date below (the “Effective
Date”). Any reference in this Agreement to “I,” “me,” “my,” “mine,” or other like terms shall be deemed to refer to me. This
Agreement supersedes any prior Continuing Obligations Agreements signed by me during my employment with the Company (as
defined below).
During the course of my employment or engagement with Nasdaq, Inc. and/or its Affiliates (collectively, the “Company”) (hereinafter
referred to as my “Engagement”), I understand that I will have access to, be given access to, and/or receive Confidential Information
and Company Property. The Company regards the Confidential Information and Company Property as highly valued assets of the
Company. Any unauthorized disclosure or use of the Confidential Information or Company Property would cause grave harm to the
Company Parties. Therefore, to assure the confidentiality and proper use of Confidential Information and Company Property, and in
consideration of my Engagement, my access to Confidential Information and Company Property, and the compensation paid or to be
paid for my services during that Engagement, and pursuant to the mutual covenants and promises contained herein, I agree to the
following:
1. 	Confidentiality and Company Property
I agree that all Confidential Information and Company Property is owned by and for the Company Parties exclusively, and I agree that I
will use Confidential Information and Company Property solely for authorized, work-related purposes on behalf of the Company
Parties, and not for personal or other non-work-related purposes. I agree that Confidential Information is a valuable and unique asset of
the Company, and, except as provided in Section 6 of this Agreement, I covenant that I will not disclose any Confidential Information
to any Person (except as my duties for the Company may require or as required by law or in a judicial or administrative proceeding)
without the prior express written authorization of the Company.
Specifically, without limitation, I shall not, directly or indirectly, at any time during or after my Engagement, without prior express
written authorization from the Company: (a) divulge, disclose, transmit, reproduce, convey, summarize, quote, share, or make
accessible Confidential Information or non-public Company Property to any other Person; (b) use any Confidential Information or
Company Property for any purpose outside the course of performing the authorized duties of my Engagement; (c) remove Company
Property or Confidential Information from the Company Parties’ premises, except as expressly sanctioned by the Company provided
there are appropriate security measures in place; or (d) review or seek to access any Confidential Information or Company Property
except as required in connection with my work for the Company. Notwithstanding the above, I understand that I am not prohibited from
discussing the terms and conditions of my Engagement with coworkers, union representatives, or others, pursuant to Section 7 of the
NLRA, and nothing in this agreement prohibits me from responding to an inquiry from, or providing testimony before, the SEC,
FINRA, etc. or filing a charge regarding a possible securities law violation.
20

-- 138 of 155 --

Upon the termination of my Engagement for any reason, or if the Company so requests, I shall promptly deliver to the Company all
Confidential Information, Company Property, or Physical Embodiments of either of the foregoing (collectively, “Returnable Property”)
in my possession or under my control. If at any time after the termination of my Engagement I determine that I have any Returnable
Property in my possession or control, I shall immediately: (a) notify the Company of such determination, and (b) return to the Company
all such Returnable Property.
2. 	Non-Use of Other’s Confidential Information
During my Engagement, I will not (a) breach any agreement to keep in confidence any Confidential Information, knowledge, or data
acquired by me prior to or independent of my Engagement; or (b) disclose to the Company, or use or induce the Company to use, any
confidential or proprietary information or material belonging to any previous employer or to any other third party.
3. 	Non-Solicitation of Customers, Potential Customers and Employees
I agree that, for a period of twenty-four (24) months following the termination of my Engagement for any reason, I shall not, directly or
indirectly, without express written consent from the Company’s Office of General Counsel:
(i) 	Interfere with any customer relationship the Company has with any of its current customers or potential
customers that I had any involvement with, directly or indirectly, during the last twelve (12) months of my
Engagement;
(ii) 	Solicit, or induce to enter into, any business arrangement with, any employee or contractor of the Company with
whom I had any contact or a relationship with during the last twelve (12) months of my Engagement; or
(iii) 	Solicit, or induce to enter into, any business arrangement with, any employee or contractor of the Company’s
customers that I knew, or reasonably could be expected to know, was solicited by the Company for any
technology, operations, sales, or business role during the last twelve (12) months of my Engagement.
4. 	Non-Disparagement
I agree that I shall not, at any time during or after my Engagement, issue, circulate, publish, or utter any false or disparaging statements,
remarks, opinions, or rumors about the Company or its shareholders unless giving truthful testimony under subpoena or court order.
Notwithstanding the preceding sentence, I understand that I may provide truthful information to any governmental agency or self-
regulatory organization with or without subpoena or court order. With the exception of communications made in a private corporate
communication as an employee or consultant with regard to a listing decision of my employer or my consulting client, I agree that
public communications regarding a preference for listing a security on a market other than a market operated by the Company,
indicating that the quality of any of the Company’s securities markets as a securities market is in any way inferior to any other
securities market or exchange, and/or indicating that the regulatory efforts or programs of the Company are or have been lax in
21

-- 139 of 155 --

any way, are specifically defined as disparaging and will constitute a material breach of this Agreement. Nothing in this paragraph,
however, is intended to preclude or inhibit protected, concerted activity, nor shall it prevent me from making good faith, factual, and
truthful statements related to listing with the Company as long as my statements are not based on Confidential Information.
The Company agrees to instruct all executive officers and members of the Board of Directors of the Company to not issue, circulate,
publish, or utter any false or disparaging statements, remarks, opinions, or rumors about you to any third party unless giving truthful
testimony under subpoena or court order.
5. 	Cooperation with the Company in Connection with Legal Proceedings
Subject to the Company’s compliance with its indemnification obligations (including advancement), I agree to reasonably cooperate
with the Company in relation to any actual or threatened legal proceedings concerning Company-related matters about which I have
relevant knowledge, even after the termination of my Engagement. Upon presentation of appropriate documentation, the Company shall
pay or reimburse you for all reasonable out-of-pocket travel, delivery or similar expenses incurred by complying with this Section 5
(excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs.
Additionally, at any time during or after my Engagement, if I receive a subpoena or process from any Person (including, but not limited
to, any governmental agency) that may or will require me to disclose documents or information or provide testimony (in a deposition,
court proceeding, or otherwise) regarding, in whole or in part, any of the Company Parties, any Confidential Information, or any
Company Property (including any Nasdaq Inventions), I shall: (a) to the extent permissible by law, notify the Company’s Office of the
General Counsel of the subpoena or other process as soon as practicable and no later than three business days of receiving it; and (b) to
the maximum extent possible, not make any disclosure until the Company Parties have had a reasonable opportunity to contest the right
of the requesting Person to such disclosure, limit the scope or nature of such disclosure, and/or seek to participate in the proceeding or
matter in which the disclosure is sought.
6. 	Immunity for Disclosure of Trade Secrets in Certain Circumstances
I understand and acknowledge that, pursuant to 18 U.S.C. §1833 (as defined in the Defend Trade Secrets Act of 2016) and
notwithstanding anything else in this Agreement, I am permitted to disclose trade secrets to third parties under certain circumstances.
The relevant portion of 18 U.S.C. § 1833 is reproduced as follows:
22

-- 140 of 155 --

(b) Immunity From Liability for Confidential Disclosure of a Trade Secret to the Government or in a Court Filing.
(1) Immunity - An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the
disclosure of a trade secret that -
(A) is made -
(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and
(ii) solely for the purpose of reporting or investigating a suspected violation of law; or
(B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
(2) Use of trade secret information in anti-retaliation lawsuit. An individual who files a lawsuit for retaliation by an employer for
reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret
information in the court proceeding, if the individual—
(A) files any document containing the trade secret under seal; and
(B) does not disclose the trade secret, except pursuant to court order.
I understand that nothing in this Agreement prohibits me from communicating with or reporting possible violations of law or regulation
to any federal, state, or local governmental office, official, agency or entity, and that notwithstanding my confidentiality obligations set
forth in Section 1 this Agreement, I will not be held civilly or criminally liable under any U.S. Federal or State trade secret law for
disclosure of a trade secret made in accordance with the provisions of 18 U.S.C. § 1833. I understand that if a disclosure of trade secrets
was not done in good faith pursuant to 18 U.S.C. § 1833, then I may be subject to criminal or civil liability, including, without
limitation, punitive and exemplary damages, and attorneys’ fees.
7. 	Inventions
(a) 	Ownership of Nasdaq Inventions by the Company
(i) 	As between me and the Company, all Nasdaq Inventions are owned by the Company. I hereby assign to Nasdaq,
Inc., without any further consideration, all right, title, and interest in and to the Nasdaq Inventions, including all
Intellectual Property Rights associated therewith. I agree that the foregoing assignment includes a present
conveyance to Nasdaq, Inc. of
I understand and acknowledge that the provisions of this Agreement related to the Company’s ownership of the Nasdaq Inventions do not apply to any
Invention that qualifies fully under the provisions of California Labor Code Section 2870, or which qualifies under any similar state law that may apply.
California Labor Code Section 2870 provides that “[a]ny provision in an employment agreement which provides that an employee shall assign, or offer to
assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own
time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) relate at the time of
conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the
employer; or (2) result from any work performed by the employee for the employer.”
1
1
23

-- 141 of 155 --

ownership of Nasdaq Inventions that are not yet in existence as of the Effective Date.
(ii) 	I hereby agree that, to the extent permitted under applicable law, the Nasdaq Inventions constitute “works made
for hire” and are deemed to be authored by Nasdaq, Inc.
(iii) 	To the extent, if any, that this Agreement does not provide Nasdaq, Inc. with full ownership, right, title and
interest in and to the Nasdaq Inventions, I hereby grant Nasdaq, Inc. an exclusive, perpetual, irrevocable, fully-
paid, royalty-free, worldwide license to use, exploit, reproduce, perform (publicly or otherwise), display
(publicly or otherwise), create derivative works from, modify, improve, develop, protect, distribute, import,
make, have made, sell, offer to sell or otherwise dispose of the Nasdaq Inventions, effective immediately on their
creation, with the right to sublicense each and every such right, including through multiple tiers, alone or in
combination. I intend that Nasdaq, Inc. has all substantial rights in the Nasdaq Inventions and associated
Intellectual Property Rights throughout the world. To the extent that any Moral Rights in the Nasdaq Inventions
cannot be assigned under applicable law, I hereby unconditionally and irrevocably waive and agree not to enforce
any and all Moral Rights, including any limitation on subsequent modification, to the extent permitted under
applicable law.
(iv) 	I agree to promptly make full disclosure to the Company of any and all Nasdaq Inventions. On request, such
disclosure shall be made in writing. During and after my Engagement and at the Company’s request and expense,
I will (1) assist the Company in every way necessary or desirable to establish or perfect the Company’s rights in
the Nasdaq Inventions and associated Intellectual Property Rights throughout the world, including by executing
in favor of the Company or its designee(s) any necessary or desirable documents, including patent and copyright
assignment documents, and (2) consent to or join in any action to enforce any Intellectual Property Right
associated with the Nasdaq Inventions. I agree that, if the Company is unable, because of my unavailability,
mental or physical incapacity, or for any other reason, to secure my signature with respect to the purposes set
forth in the preceding sentence, then I hereby irrevocably designate and appoint the Company and its duly
authorized officers and agents as my agent and attorney-in-fact, to act for and on my behalf to execute and file
any papers and oaths, and to do all other lawfully permitted acts with respect to such Nasdaq Inventions and
associated Intellectual Property Rights to further the prosecution, issuance, and enforcement of such Intellectual
Property Rights with the same legal force and effect as if executed by me. This power of attorney shall be
deemed coupled with an interest, and it is irrevocable.
(v) 	I agree to not challenge, dispute, or otherwise contest, or assist any Person in challenging, disputing, or otherwise
contesting, the validity, enforceability, or ownership of any Intellectual Property Rights (including those
associated with the Nasdaq Inventions) owned by or asserted to be owned by the Company or its designees. For
the avoidance of doubt, I agree to the foregoing without regard to whether any such challenge, dispute, or contest
would make use of any Confidential Information or Company Property.
24

-- 142 of 155 --

(vi) 	I agree to assist the Company in enforcing the Intellectual Property Rights associated with the Nasdaq
Inventions; though if I am requested by the Company to render such assistance after the termination of my
Engagement, I shall be entitled to: (1) if allowable under applicable law, a fair and reasonable rate of
compensation for such assistance; and (2) reimbursement of any reasonable expenses incurred at the request of
the Company relating to such assistance.
(b) 	Non-Use of My Personal Inventions
Without limiting any of my obligations under this Section 7, I agree that I will not integrate or incorporate any of My Personal
Inventions into any product, service, or other offering of the Company. Notwithstanding the foregoing prohibition, if I integrate or
incorporate, or allow the integration or incorporation of, any of My Personal Inventions into any product, service, or other offering of
the Company, I agree that I will make no claim against the Company with respect to such of My Personal Inventions. “My Personal
Inventions” means Inventions in which I personally possess any right, title, or interest. As examples, My Personal Inventions may
include Inventions that qualify as My Personal Inventions under the preceding definition and that I (i) developed prior to my
Engagement or (ii) develop during my Engagement but which do not qualify as owned by the Company pursuant to the terms of this
Section 7.
8. 	Injunctive Action; No Third-Party Beneficiaries; Duration of Obligations Extends Past Engagement
I acknowledge that all of the terms and provisions of this Agreement, along with all restrictions, prohibitions, and obligations created
thereunder (with such terms, provisions, restrictions, prohibitions, and obligations being, collectively, “Obligations”), are reasonable
and necessary for the protection of the Company Parties and their respective businesses. I agree that my breach of any of the
Obligations may result in irreparable injury to the Company Parties, that monetary relief alone may be inadequate to redress such a
breach, and further that the Company shall be entitled to seek an injunction to prevent and/or remedy such a breach (without first
having to post a bond).
In any proceeding for an injunction and upon any motion for a temporary or permanent injunction (“Injunctive Action”), the Company’s
right to receive monetary damages shall not be a bar or interposed as a defense to the granting of such injunction. The Company’s right
to an injunction is in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity,
including any remedy the Company may seek in any arbitration brought pursuant to Section 9 of this Agreement.
I hereby irrevocably submit to the jurisdiction of the courts of New York (or the jurisdiction in which I am assigned to work in at the
time of the issue under dispute) for any Injunctive Action and waive any claim or defense of inconvenient or improper forum or lack of
personal jurisdiction under any applicable law or decision, unless the Company has opted for another jurisdiction. Upon the issuance
(or denial) of an injunction, the underlying merits of any such dispute shall be resolved in accordance with Section 9 of this Agreement.
25

-- 143 of 155 --

This Agreement is intended solely for the benefit of me, the Company, and our and respective permitted successors or assigns;
notwithstanding any provision of this Section 8, it is not the intention of the parties to confer, and this Agreement shall not confer, third-
party beneficiary rights upon any other Person other than me and the Company. I understand that the Company has the right to bring an
Injunctive Action or seek monetary damages or any other remedy for a breach of this Agreement that injures the Company’s customers
or prospective customers, but the Company is under no obligation to do so.
Unless explicitly set forth herein, none of the Obligations in this Agreement are limited in time; and all Obligations, unless
explicitly set forth herein, shall survive the termination of my Engagement, regardless of the reason for such termination.
9. 	Arbitration
Except as provided in Section 8 of this Agreement, any dispute arising between the Parties under this Agreement, under any statute,
regulation, or ordinance, under any other agreement between the Parties, and/or in way relating to my engagement by the Company
(other than sexual harassment or sexual assault claims, unless agreed to by all parties), shall be submitted to binding arbitration before
the American Arbitration Association (“AAA”) (or local arbitration body for disputes outside of the U.S.) for resolution.
The arbitration shall be conducted in accordance with the AAA’s Employment Arbitration Rules, as modified herein, including, without
limitation, the AAA Employment/Workplace Fee Schedule and Costs of Arbitration, as in effect from time-to-time (or the rules of the
local arbitration body for disputes outside of the U.S.). The arbitration shall be conducted in the state/jurisdiction where I work, unless
the parties mutually agree to another location. The arbitrator shall apply the applicable state/local jurisdiction law, depending on the
nature of the claim(s) at issue, including federal law as applied in such state where applicable.
The arbitration shall be conducted by a single arbitrator, who shall be an attorney who specializes in the field of employment law and
who shall have prior experience arbitrating employment disputes. However, if any disputes arising between the Parties under the
Agreement concern any Inventions or Intellectual Property Rights, the single arbitrator shall be an attorney who specializes in the field
of intellectual property law and who shall have prior experience arbitrating intellectual property disputes.
The award of the arbitrator shall be final and binding on the Parties, and judgment on the award may be confirmed and entered in any
state or federal court of the applicable jurisdiction. In the event of any court proceeding to challenge or enforce an arbitrator’s award,
the Parties hereby consent to the exclusive jurisdiction of the state and federal courts in the applicable jurisdiction and agree to venue in
that jurisdiction.
To the fullest extent allowable under applicable, the arbitration shall be conducted on a strictly confidential basis. This means that I
shall not disclose the existence of a claim, the nature of a claim, any documents, exhibits, or information exchanged or presented in
connection with such a claim, or the result of any action (collectively, “Arbitration Materials”), to any third party, with
26

-- 144 of 155 --

the sole exception of my legal counsel, who also shall be bound by these confidentiality terms. The Parties agree to take all steps
necessary to protect the confidentiality of the Arbitration Materials in connection with any such proceeding; agree to file all
Confidential Information (and documents containing Confidential Information) under seal; and agree to the entry of an appropriate
protective order encompassing the confidentiality terms of this Agreement, all to the extent allowable under the laws of that
jurisdiction. The Company shall pay the costs of the arbitration and the arbitrators.
10. 	Governing Law; Amendment; Waiver; Severability
Except as provided in Paragraph 9 regarding arbitration of disputes, this Agreement shall be construed in accordance with and shall be
governed by the laws of the State of New York (or the jurisdiction in which I am assigned to work in at the time of the issue under
dispute), excluding any choice of law principles. This Agreement constitutes the entire agreement between the Parties with respect to
the subject matter hereof, and may not be amended, discharged, or terminated, nor may any of its provisions be waived, except upon the
execution of a valid written instrument executed by me and the Company.
If any term or provision (or any portion thereof) of this Agreement is determined by an arbitrator or a court of competent jurisdiction to
be invalid, illegal, or incapable of being enforced, all other terms and provisions (and all other portions thereof) of this Agreement shall
nevertheless remain in full force and effect.
Upon a determination that any term or provision (or any portion thereof) of this Agreement is invalid, illegal, or incapable of being
enforced, the Company and I agree that an arbitrator or reviewing court shall have the authority to amend or modify this Agreement so
as to render it enforceable and effect the original intent of the Parties to the fullest extent permitted by applicable law.
11. 	Definitions
All capitalized terms used in this Agreement, along with their tenses, cases, and correlatives, shall have the defined meanings attributed
to them in this Section or in the other Sections where such defined meanings are provided.
“Affiliate” means, with respect to any entity, another entity that, directly or indirectly through one or more intermediaries, controls, is
controlled by or is under common control with, such entity. For purposes of this definition, “control” means the possession, direct or
indirect, of the power to direct or cause the direction of management and policies of the entity, whether through the ownership of voting
securities, by contract or otherwise.
“Company Parties” means the Company and Company’s customers or prospective customers.
“Company Property” means all property and resources of the Company Parties, or any Company Party, including Confidential
Information, each Company Party’s products, each Company Party’s computer systems, and all software, e-mail, web pages, databases,
telephone, and facsimile services, and other administrative and/or support services provided by the Company
27

-- 145 of 155 --

Parties. I further agree that Company Property shall include Nasdaq Inventions without regard to whether they also may be considered
Confidential Information as defined in this Agreement.
“Confidential Information” means any non-public, proprietary information regarding the Company Parties, in any Physical
Embodiment or format, including all personal information, financial data, commercial data, trade secrets, business plans, business
models, organizational structures and models, business strategies, pricing and advertising techniques and strategies, research and
development activities, software development, market development, exchange registration, studies, market penetration plans, listing
retention plans and strategies, marketing plans and strategies, communication and/or public relations products, plans, programs,
recruiting strategies, databases, processes, work product or inventions, financial formulas and methods relating to Company Parties’
business, computer software programs, accounting policies and practices, and all strategic plans or other matters, strategies, and
financial or operating information pertaining to current or potential customers or transactions (including information regarding each
Company Party’s current or prospective customers, customer names, and customer representatives), templates and agreements, and all
other information about or provided by the Company Parties, including information regarding any actual or prospective business
opportunities, employment opportunities, finances, investments, and other proprietary information and trade secrets. Confidential
Information also includes other information that is marked or otherwise identified as confidential or proprietary, or that would
otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is
known or used. Notwithstanding the above, Confidential Information shall not include any information that: (a) was known to me prior
to my Engagement as evidenced by written records in my possession prior to such disclosure; or (b) is generally and publicly available
and known to all Persons in the industries where the Company conducts business, other than because of any unauthorized disclosure by
me.
“Intellectual Property Rights” means all of the following, whether protected, created, or arising under the laws of the United States or
any other jurisdiction throughout the world, via statute, common law, equity, regulation, or other legal mechanism: (a) patents, patent
applications, and design rights (including industrial design rights); (b) rights in works of authorship, including copyrights, Moral
Rights, and mask work rights; (c) trademarks and service marks, and rights in trade names, trade dress, domain names, and any other
indicia of source or origin, (d) trade secrets and other rights in know-how and confidential or proprietary information; (e) any rights in,
to, or arising under any Invention; (f) any registrations or applications for registration for any of the foregoing (a)-(e), including any
provisionals, divisions, continuations, continuations-in-part, renewals, reissuances, rights subject to and/or arising out of post-grant
review (including re-examinations) and extensions (as applicable); (g) all contract and licensing rights and all claims and causes of
action of any kind with respect to any of the foregoing (a)-(f), including the right to sue and recover damages or other compensation
and/or obtain equitable relief for any past, present, or future infringement or misappropriation thereof; and (h) any right analogous to
any right set forth above in (a)-(g).
“Inventions” means: (a) inventions, invention disclosures, discoveries, ideas, developments, improvements, technology, algorithms, and
designs (including industrial designs, user interface
28

-- 146 of 155 --

designs, user experience designs, and other types of designs); (b) original works of authorship, copyrightable expression, research,
computer software (including source code), computer programs, and mask works; (c) trademarks, service marks, certification marks,
logos, slogans, symbols, domain names, social media accounts, handles and identifiers, and any other indicia of source or origin;
(d) trade secrets, know-how, data, databases, information, formulas, patterns, processes, technical information, business information,
information regarding sales or potential sales and other commercial relationships, business methods or processes, marketing plans,
customer lists, vendor lists, and other types of proprietary or confidential information; and (e) trading systems, trading strategies, and
trading methodologies. The foregoing definition shall apply regardless of whether or not the Inventions are subject to protection under
patent, copyright, trade secret, industrial design, trademark, or other type of intellectual property right, whether registered or
unregistered.
“Moral Rights” means all rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights
throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like.
“Nasdaq Inventions” means Inventions that are (a) made, conceived, expressed, developed, diligently worked on to reduce to practice,
or reduced to practice by me (solely or jointly with others) during or as a result of my Engagement or using Company Property and
(b) which relate in any manner to the Company, the business of the Company (including the services the Company provides to any of
the Company Parties), or my Engagement.
“Person” means a natural person, partnership, domestic or foreign limited partnership, domestic or foreign limited liability company,
trust, estate, association, corporation or any other legal entity or government authority.
“Physical Embodiments” means originals, copies, reproductions, documents, materials, records, papers, notebooks, files stored on or in
electronic or cloud-based media, and any other embodiment, in any format whatsoever, including in hard-copy formats, such as paper
and electronic or digital media, including, without limitation, computer-readable files, drives, disks, cloud-based information, and other
electronic media that may be developed in the future.
12. 	Miscellaneous
Other than any Contractor Agreement (as defined in Section 13), I agree that I am not currently a party, and will not become a party, to
any other agreement that is in conflict, or will prevent me from complying, with this Agreement.
This Agreement is binding upon, and shall inure to the benefit of, me and the Company and our respective heirs, executors,
administrators, successors, and assigns.
I will not assign this Agreement or my obligations hereunder without the prior written consent of the Company, which consent must be
obtained from the Company’s Office of General Counsel, and which consent may be withheld in the Company’s sole discretion; and
any such purported assignment without consent shall be null and void from the beginning. I agree that the Company
29

-- 147 of 155 --

may freely assign this Agreement, in whole or in part, to any Company entity, and I expressly consent to be bound by the provisions of
this Agreement for the benefit of any Company entity without the necessity that this Agreement be re-executed at the time of such
transfer.
Without limiting the scope or generality of the terms of this Agreement in any way, I acknowledge and agree that the terms of this
Agreement and all discussions regarding this Agreement are confidential, and accordingly I agree not to disclose any such information
to any Person except to my attorney(s) or as otherwise may be required by law. I confirm that I may consult with an attorney regarding
the provisions of this Agreement, including the nonsolicit provisions as applicable to me, and that I have a fourteen (14)-day waivable
consideration period for these provisions. Notwithstanding the foregoing, I may disclose to any prospective employer the fact and
existence of this Agreement, and I may provide copies of this Agreement to such entity. The Company also has the right to apprise any
prospective employer of the terms of this Agreement and provide copies to any such prospective employer.
This Agreement shall be fairly interpreted in accordance with its terms and without any strict construction in favor of or against either
Party, notwithstanding which Party may have drafted it. The headings herein are included for reference only and are not intended to
affect the meaning or interpretation of the Agreement.
13. 	Other Terms of My Engagement
Nothing in this Agreement alters the at-will nature of my Engagement. I acknowledge and agree that my Engagement is at-will, which
means that both I and the Company shall have the right to terminate my Engagement at any time, for any lawful reason, with or without
cause and with or without prior notice, subject to the terms in that Employment Agreement dated March ___, 2025 between me and the
Company. If another agreement that establishes a third-party contractor relationship (or independent consultant relationship, or any
other similar non-employee relationship) between me and the Company (a “Contractor Agreement”) exists, the written terms of such
Contractor Agreement supersede any conflicting terms in this Agreement.
14. 	Signature
I hereby acknowledge and accept the terms of this Agreement as of the Effective Date, via my manual or electronic (e.g.,
DocuSign) signature, as reflected below.
Signature: /s/ Bradley J. Peterson 	Date: March 10, 2025
Print Name: Bradley J. Peterson
30

-- 148 of 155 --

Exhibit B
Release of Claims
GENERAL RELEASE
WHEREAS, Bradley J. Peterson (hereinafter referred to as the “Executive”) and Nasdaq, Inc. (hereinafter referred to as
“Employer”) are parties to an Employment Agreement, dated March ____, 2025 (the “Employment Agreement”), which provided for
the Executive’s employment with Employer on the terms and conditions specified therein; and
WHEREAS, the Executive has agreed to execute a release of the type and nature set forth herein as a condition to his
entitlement to certain payments and benefits upon his termination of employment with Employer.
NOW, THEREFORE, in consideration of the premises and mutual promises herein contained and for other good and valuable
consideration received or to be received by the Executive in accordance with the terms of the Employment Agreement, it is agreed as
follows:
1. 	Excluding enforcement of the covenants, promises and/or rights reserved herein, the Executive hereby irrevocably and
unconditionally releases, acquits and forever discharges Employer and each of Employer’s owners, stockholders, predecessors,
successors, assigns, directors, officers, employees, divisions, subsidiaries, affiliates (and directors, officers and employees of
such companies, divisions, subsidiaries and affiliates) and all persons acting by, through, under or in concert with any of them
(collectively “Releasees”), or any of them, from any and all Claims (as defined below) through the date of this Release. You
agree not to file a lawsuit or arbitration to assert any such Claim. Further, you agree that should any other person, organization
or entity file a lawsuit or arbitration to assert any such Claim, you will not seek or accept any personal relief in such action.
(a) 	Definition of “Claims.” Except as stated below, “Claims” includes without limitation all actions or demands of any kind
that you may now have or have had or reasonably known you should have had (although you are not being asked to
waive Claims that may arise after the date of this Agreement). More specifically, Claims include rights, causes of action,
damages, penalties, losses, attorneys’ fees, costs, expenses, obligations, agreements, judgments and all other liabilities of
any kind or description whatsoever, either in law or in equity, whether known or unknown, suspected or unsuspected.
The nature of Claims covered by this release includes without limitation all actions or demands in any way based on
your employment with the Company, the terms and conditions of such employment, or your separation from
employment. More specifically, all of the following are among the types of Claims which are waived and barred by this
General Release of Claims to the extent allowable under applicable law and are considered illustrative but not
exhaustive:
• Contract Claims, whether express or implied;
• Tort Claims, such as for defamation or emotional distress;
31

-- 149 of 155 --

• Claims under federal, state and municipal laws, regulations, ordinance or court decisions of any kind;
• Claims of discrimination, harassment or retaliation, whether based on race, color, religion, gender, sex, age, sexual
orientation, handicap and/or disability, genetic information, national origin, or any other legally protected class;
• Claims under the AGE DISCRIMINATION IN EMPLOYMENT ACT, Title VII of the Civil Rights Act of 1964, as
amended, the Americans with Disabilities Act as amended, the Genetic Information Nondiscrimination Act, the Family and
Medical Leave Act, and similar state and local statutes, laws and ordinances, including, but not limited to, the New York
State Human Rights Law, the New York Labor Act, the New York Equal Pay Law, the New York Civil Rights Law, the New
York Rights of Persons With Disabilities Law, and the New York Equal Rights Law, all as amended;
• Claims under the Employee Retirement Income Security Act (other than rights to vested benefits), the Occupational Safety
and Health Act, the False Claims Act, and similar state and local statutes, laws and ordinances;
• Claims for wrongful discharge; and
• Claims for attorneys’ fees, including litigation expenses and/or costs;
provided, however, that this release shall not apply to any of the obligations of Employer or any other Releasee under the Employment
Agreement, or under any agreements, plans, contracts, documents or programs described or referenced in the Employment Agreement;
and provided, further, that this release shall not apply to any rights the Executive may have to obtain contribution, advancement or
indemnity against Employer or any other Releasee pursuant to contract, Employer’s certificate of incorporation and bylaws, coverage
under Employer’s directors and officers or similar liability insurance (which rights survive and are incorporated herein by reference) or
otherwise.
(b) 	Exclusions: Notwithstanding any other provision of this release, the following are not barred by the release: (i) Claims
relating to the validity of this General Release; (ii) Claims by either party to enforce this General Release or the
Employment Agreement (including the Continuing Obligations Agreement); (iii) Claims which are not legally waivable,
including SEC whistleblowing claims pursuant to Rule 21F-17. In addition, this General Release of Claims will not
operate to limit or bar your right to file an administrative charge of discrimination with the Equal Employment
Opportunity Commission (EEOC) or to testify, assist or participate in an investigation, hearing or proceeding conducted
by the EEOC. However, the Release does bar your right to recover any personal or monetary relief, including if you or
anyone on your behalf seeks to file a lawsuit or arbitration on the same basis as the charge of discrimination.
Additionally, nothing in this Release should have a chilling effect on your ability to engage in whistleblowing activity,
by prohibiting or restricting you (or your attorney) from initiating communications directly with, or responding to any
inquiry from, or providing testimony before, the SEC or FINRA regarding your employment at the Company, and
nothing prevents you from reporting to, communicating with, contacting, responding to an inquiry from, providing
relevant information to, participating or assisting in an investigation conducted by, or receiving a
32

-- 150 of 155 --

monetary award from the SEC or any other governmental enforcement agency related to such communication (except as
noted in Section 3(b) above).
2. 	The Executive expressly waives and relinquishes all rights and benefits afforded by California Civil Code Section 1542 and
does so understanding and acknowledging the significance of such specific waiver of Section 1542. Section 1542 states as
follows:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR
SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR.”
Thus, notwithstanding the provisions of Section 1542, and for the purpose of implementing a full and complete release and discharge of
the Releasees, the Executive expressly acknowledges that this Agreement is intended to include in its effect, without limitation, all
Claims that the Executive does not know or suspect to exist in the Executive’s favor at the time of execution hereof, and that this
Agreement contemplates the extinguishment of any such Claim or Claims.
3. 	The Executive understands that he has been given a period of twenty-one (21) days to review and consider this General Release
before signing it pursuant to the Age Discrimination In Employment Act of 1967, as amended. The Executive further
understands that he may use as much of this twenty-one (21)-day period as the Executive wishes prior to signing.
4. 	The Executive acknowledges and represents that he understands that he may revoke the waiver of his rights under the Age
Discrimination In Employment Act of 1967, as amended, effectuated in this Agreement within seven days of signing this
Agreement. Revocation can be made by delivering a written notice of revocation to Office of the General Counsel, Nasdaq, Inc.,
One Liberty Plaza, New York, New York 10006. For this revocation to be effective, written notice must be received by the
General Counsel no later than the close of business on the seventh day after the Executive signs this General Release. If the
Executive revokes the waiver of his rights under the Age Discrimination in Employment Act of 1967, as amended, Employer
shall have no obligations to the Executive under Section 8 (other than the Base Obligations) of the Employment Agreement.
5. 	The Executive and Employer respectively represent and acknowledge that in executing this Agreement neither of them is
relying upon, and has not relied upon, any representation or statement not set forth herein made by any of the agents,
representatives or attorneys of the Releasees with regard to the subject matter, basis or effect of this Agreement or otherwise.
6. 	This General Release shall not in any way be construed as an admission by any of the Releasees that any Releasee has acted
wrongfully or that the Executive has any rights whatsoever against any of the Releasees except as specifically set forth herein,
and each of the Releasees specifically disclaims any liability to any party for any wrongful acts. Further, this Agreement shall
not in any way be construed as an admission by the Executive that the Executive has acted wrongfully.
7. 	It is the desire and intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible
under law. Should there be any conflict
33

-- 151 of 155 --

between any provision hereof and any present or future law, such law will prevail, but the provisions affected thereby will be
curtailed and limited only to the extent necessary to bring them within the requirements of law, and the remaining provisions of
this Agreement will remain in full force and effect and be fully valid and enforceable.
8. 	The Executive represents and agrees (a) that the Executive has to the extent he desires discussed all aspects of this Agreement
with his attorney, (b) that the Executive has carefully read and fully understands all of the provisions of this Agreement, and
(c) that the Executive is voluntarily entering into this Agreement.
9. 	This General Release shall be governed by, and construed in accordance with, the laws of the State of New York, without giving
effect to the conflicts of laws principles thereof or to those of any other jurisdiction which, in either case, could cause the
application of the laws of any jurisdiction other than the State of New York. This General Release is binding on the successors
and assigns of, and sets forth the entire agreement between, the parties hereto; fully supersedes any and all prior agreements or
understandings between the parties hereto pertaining to the subject matter hereof; and may not be changed except by explicit
written agreement to that effect subscribed by the parties hereto.
PLEASE READ CAREFULLY. THIS GENERAL RELEASE INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN
CLAIMS.
This General Release is executed by the Executive and Employer as of the ___day of __________, 20__.
Bradley J. Peterson
NASDAQ, INC.
By:
Name:
Title:
34

-- 152 of 155 --

Exhibit 31.1
CERTIFICATION
I, Adena T. Friedman, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Nasdaq, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
/s/ Adena T. Friedman
Name: 	Adena T. Friedman
Title: 	Chief Executive Officer
Date: April 28, 2025

-- 153 of 155 --

Exhibit 31.2
CERTIFICATION
I, Sarah Youngwood, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Nasdaq, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
/s/ Sarah Youngwood
Name: 	Sarah Youngwood
Title: 	Executive Vice President and Chief Financial Officer
Date: April 28, 2025

-- 154 of 155 --

Exhibit 32.1
Certification of CEO and CFO Pursuant to
18 U.S.C. Section 1350
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Nasdaq, Inc. (the “Company”) for the period ended March 31, 2025 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), Adena T. Friedman, as Chief Executive Officer of the Company, and Sarah Youngwood, as
Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that, to the best of her knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the
Company.
/s/ Adena T. Friedman
Name: 	Adena T. Friedman
Title: 	Chief Executive Officer
Date: 	April 28, 2025
/s/ Sarah Youngwood
Name: 	Sarah Youngwood
Title: 	Executive Vice President and Chief Financial Officer
Date: 	April 28, 2025
This certification accompanies the Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley
Act of 2002, be deemed filed by the Company for purposes of § 18 of the Securities Exchange Act of 1934, as amended.

-- 155 of 155 --